









Development of Rift Valley fever virus candidate vaccines and reagents 
produced in Nicotiana benthamiana 
By 
Sandiswa Mbewana 
Thesis presented for the degree of 
DOCTOR of PHILOSOPHY 
In the Department of Molecular and Cell Biology, 
Faculty of Science, University of Cape Town 
January 2017 
Supervisor: Professor Edward Rybicki 









wnThe copyright of this thesis vests in the author. No
quotation from it or information derived from it is to be
published without full acknowledgement of the source.
The thesis is to be used for private study or non-
commercial research purposes only.
Published by the University of Cape Town (UCT) in terms
of the non-exclusive license granted to UCT by the author.
ii 
Declaration 
I, Sandiswa Mbewana, hereby declare that the work on which this thesis is based is 
my original work (except where acknowledgements indicate otherwise) and that 
neither the whole work nor any part of it has been or is being submitted for another 
degree in this or any other university.  I authorise the university to reproduce for the 







Development of Rift Valley fever virus candidate vaccines and reagents 




Biopharming Research Unit 
Department of Molecular and Cell Biology, Faculty of Science 
University of Cape Town, South Africa 
 
Rift Valley fever (RVF) is a haemorrhagic fever agent caused by an infection with an 
enveloped negative-stranded RNA Rift Valley fever virus (RVFV).  It belongs to the 
genus Phlebovirus in the family Bunyaviridae.  The virus is spread by infected 
mosquitoes and affects ruminants and humans, causing high numbers of neonatal 
fatalities in animals and occasional fatalities in humans.  It is endemic to parts of Africa 
and the Arabian Peninsula, but is described as an emerging virus due to the wide 
range of mosquitoes that could spread the disease into non-endemic areas, posing 
serious health and agricultural problems.  The disease can be prevented by 
vaccination, but there is currently no Food and Drug Administration-approved RVFV 
vaccine that can be used outside endemic areas, while there are two live attenuated 
vaccines available for use in endemic areas.  These vaccines have the potential for 
reversion, and are therefore not recommended for use in countries where RVFV is not 
endemic.  This indicates the need for more RVFV vaccine research and development.  
This work focused on the development of a RVFV vaccine candidate that would allow 




A readily available wild type Egyptian ZH548 RVFV GnGc polyprotein-encoding gene 
sequence was initially used for developing the candidate vaccines.  The GnGc genes 
were cloned into various plant expression vectors with and without a histidine tag.  
Initial strategies and efforts made to express GnGc protein resulted in a lack of 
recombinant protein detection.  Thus, a different GnGc DNA sequence representing a 
South African isolate M35/74 was selected to make putative vaccine candidates; this 
gene was Nicotiana sp.- and human-codon optimised and both were synthesised.  
Both genes were modified for various cloning strategies into different plant expression 
vectors.  Gene expression was conducted by transient expression of recombinant 
constructs in Nicotiana benthamiana via Agrobacterium tumefaciens-mediated gene 
transfer.  Protein expression analysis was verified by western blotting of crude leaf 
extracts separated using SDS-PAGE.  Protein expression could not be detected from 
the full length GnGc glycoprotein gene.   
 
The lack of recombinant protein expression from the full length GnGc lead to the RVFV 
Gn gene being used for further studies.  Gn was modified by truncation of its 
transmembrane domain and cytoplasmic tail (TMD-CT) and substituting its native 
signal peptide with two heterologous signal peptides, namely protein disulphide 
isomerase (PDI) and murine mAB24 heavy chain (LPH), to make a soluble 
recombinant protein vaccine candidates (PDI-∆tGn and LPH-∆tGn).  Virus-like 
particles are known to be more immunogenic than recombinant proteins alone 
because they display authentic conformation of the virus, thus displaying their 
immunogenic epitopes.  In addition to the recombinant protein vaccine, a second type 
of vaccine candidate was designed to form chimaeric VLPs by fusing the LPH-∆tGn to 
the influenza hemagglutinin TMD-CT (LPH-∆tGnHA).   
 
Gene expression was conducted by transient expression of recombinant constructs in 
N. benthamiana via A. tumefaciens-mediated gene transfer.  Protein expression 
analysis was verified by western blotting of crude leaf extracts separated using SDS-
PAGE.  Unfortunately, no recombinant protein expression was detected using the PDI-
∆tGn vaccine candidate.  Expression was successfully detected using the modified 
RVFV LPH-∆tGn and LPH-∆tGnHA vaccine candidate crude leaf extracts.  Production 
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of these recombinant vaccine candidates was scaled up and protocols for their 
purification were developed.  The soluble LPH-∆tGn was initially partially purified by 
ammonium sulphate precipitation and then by affinity chromatography.  The protein 
yields were calculated to be ~ 56.81 mg/kg fresh weight.  The chimaeric particulate 
LPH-∆tGnHA candidate was purified by differential centrifugation.  The protein yields 
were calculated to be ~ 59 mg/kg fresh weight.  Protein was characterised by 
transmission electron microscopy (TEM).  TEM showed chimaeric Gn particles of ~49 
– 60 nm.  Preliminary immunogenicity studies of both modified RVFV Gn candidate 
vaccines was carried out in BALB/c mice.  The vaccine candidates were found to be 
immunogenic in mice. 
 
The second focus of this research was on the development of a diagnostic reagent.  
Diagnosis of RVFV is carried out by various methods including ELISA, using the 
nucleocapsid protein (N-protein) as a diagnostic agent.  N-protein is the most 
abundant non-structural protein in the virion.  It has been used as a diagnostic reagent 
for other viruses in the Bunyaviridae family.  N-protein is currently produced from live 
virus preparations which involve high levels of biosafety, high production costs and 
have restricted use outside of RVF endemic areas due to potential escape of the virus 
in non-endemic areas.  This work describes the production of a cost-effective and safer 
diagnostic N-protein antigen using plants as an expression system. 
 
The South African isolate M35/74 RVF N-protein was human-codon optimised and 
synthesised.  Recombinant protein expression was successfully detected in plants 
when fused with a histidine tag.  Purification by affinity chromatography yielded high 
amounts of protein ranging from 500 - 558 mg/kg fresh weight.  TEM of purified 
preparations showed that the protein forms ring shaped structures of ~10 nm.  
Preliminary data carried out using purified protein showed that the N-protein is stable 
after at least 8 months when stored at both 4 and - 80 ˚C.  Preliminary ELISAs carried 
out revealed that plant-produced N-protein was functional as it could successfully 
differentiate between serum isolated from infected and non-infected animals, thus 
indicating it has potential use as a diagnostic reagent. 
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In conclusion, this research demonstrates the potential of LPH-∆tGn and LPH-∆tGnHA 
vaccine candidates.  They both elicited anti-Gn immune responses in vaccinated mice 
without the use of adjuvant.  These result show that these vaccine candidates have 
potential as RVFV candidate vaccines and their development should be further 
investigated.  The plant-produced N-protein detected IgG antibodies against RVFV-
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Chapter 1: General Introduction and project aims 
 
1.1 General Introduction 
 
Rift Valley fever (RVF) is a zoonotic infectious disease which primarily affects 
ruminants, and is caused by the enveloped Rift Valley fever virus (RVFV) with a three-
component single-stranded RNA genome, in the genus Phlebovirus of the family 
Bunyaviridae.  It is predominantly spread by mosquitoes (Moutailler et al., 2008).  
Infections in animals occur predominantly as a result of bites from mosquitoes carrying 
the virus but can also be spread by direct contact with infected animal tissues and 
fluids, which is the main route by which humans are infected (Morrill et al., 1997b; 
Moutailler et al., 2008).  Symptoms of infection in ruminants vary between different 
animal species, but include the occurrence of near simultaneous abortions in pregnant 
animals, high neonatal mortality rates, hepatic damage and deformed young.  Case 
fatality rates vary between 20 – 70% (Chevalier et al., 2010; Gerdes, 2004).  Infection 
of humans is often asymptomatic, but after an incubation period of 2 to 6 days 
symptoms can manifest as headaches, muscular pain, photophobia, weakness or 
onset of fever (McIntosh et al., 1980a).  Most patients recover from the disease 
completely after several weeks, but those more susceptible can develop retinal 
macular change which causes defective vision for a while.  Less than 1% of those 
infected develop complications which can lead to haemorrhagic fever or encephalitis, 
with a case fatality rate of about 45% (LaBeaud et al., 2008; McIntosh et al., 1980b).  
 
RVFV poses a great economic threat to the Agricultural and Health sectors, and is 
thus of interest in the One Health paradigm.  The World Organization for Animal Health 
(Office for International des Epizooties (OIE)) has classified this virus as a high-
consequence pathogen with the potential for international spread (OIE - List A) (Bird 
et al., 2009).  The lack of efficient prophylactic and therapeutic measures make 
infection with this virus a serious public concern not only in endemic, developing 
countries, but also in many non-endemic, developed countries.  The spread of RVFV 
can be prevented by vaccination of animals and humans, but there are currently no 
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licensed RVFV vaccines for use in animals and humans (Ikegami and Makino, 2009; 
Ly et al., 2016). 
 
Currently available animal vaccines are available as live attenuated RVF virus which 
is effective, but is also expensive due to the requirement for high biosafety levels 
during production (Muller et al., 1995; Smithburn, 1949).  An inactivated RVFV vaccine 
has also been used on animals: however, this is not as effective, requires booster 
inoculations and also has high biosafety level requirements for production (Randall et 
al., 1962).  For humans, there is no commercially available vaccine.  However, a killed 
vaccine which is made under stringent safety restrictions is used to immunise 
individuals who work in regions with high risk of infections (army workers and 
laboratory workers).  This vaccine requires several booster administrations to maintain 
complete immunity (Eddy and Peters, 1980; Niklasson, 1982). 
 
The envelope glycoproteins of RVFV (Gc and Gn), found on the outermost surface of 
the virions, are the most exposed parts of the virus.  They show a high degree of 
sequence conservation, and there is effectively only one serotype of the virus - 
therefore, a single vaccine should be able to provide protective immunity against 
currently circulating RVFV strains (Ikegami, 2012).  Recombinant Gn and Gc 
glycoproteins have been produced in bacterial, mammalian and insect cell expression 
systems and have been shown to elicit virus neutralising antibodies (de Boer et al., 
2010; El Salam, 2014; Habjan et al., 2009; Schmaljohn et al., 1989).  These 
neutralising antibodies (nAbs) have been shown to protect against the disease.  
Further, some research has shown that sufficient neutralising antibodies are induced 
by Gn protein alone to protect mice and sheep against RVFV challenge.  However, all 
the above production systems are costly, not easy to scale up, they do not produce 
glycosylated proteins, contaminating endotoxins are difficult to remove and 
recombinant proteins often form inclusion bodies.  As an alternative to the above-
mentioned systems, is the use of the plant-production system.  an attempt was 
recently made to develop a RVFV candidate vaccine using transgenic Arabidopsis 
thaliana (Kalbina et al., 2016).  The vaccine candidate was orally immunised and was 




Detection of the virus using traditional culture methods is time-consuming, and 
requires biosafety level 3 or 4 facilities.  This has led to the development of enzyme-
linked immunosorbent assays (ELISA) as a highly sensitive and rapid diagnostic tool 
(Paweska et al., 1995).  This is based on use of an inactivated antigen which binds to 
RVFV antibodies, production of which also requires biosafety containment facilities, 
and which binds poorly to the ELISA plates (Jansen van Vuren et al., 2007).  In 
addition, such antigen does not allow for distinguishing between infected and 
vaccinated animal or human serum. 
 
There is therefore a need for a cheap, safe and reliable vaccine, and for antigens for 
diagnostic use which allow for detecting RVFV antibodies in animal and human sera. 
Plants offer a viable alternative to the above-mentioned conventional expression 
systems.  Production can be rapidly scaled up, and yields may be high, resulting in 
potential for significantly reducing costs of raw material (Lomonossoff and D'Aoust, 
2016; Marsian and Lomonossoff, 2016; Rybicki, 2009; Rybicki, 2010).  The plant 
production system is more economical than the convensional expression sytems, as 
plants do not need expensive materials for growth and maintenance, and their use 
reduces concerns over human pathogen contamination of vaccine and reagent 
preparations. 
 
1.2 Project Aims 
 
The main objective of my study was to produce a Rift Valley fever candidate vaccine 
in Nicotiana benthamiana, as well as a diagnostic reagent for differentiating between 
infected and vaccinated animals.  In order to achieve this, the specific aims of the 
study were four-fold. 
1. To identify Rift Valley fever genes suitable for development of plant-made 
candidate vaccines 
Objectives: 
a. To clone RVFV GnGc glycoprotein genes into plant expression vectors  
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b. To assess recombinant GnGc levels in plants after infiltration on a small 
scale, and to scale up production if successful  
c. To purify and characterise the selected candidate vaccine protein(s) by 
chromatography and transmission electron microscopy 
 
2. To use the results obtained from Aim 1 to produce one or more candidate 
RVFV vaccines by fusing Gn with an Influenza virus HA transmembrane 
domain and co-expression with influenza M1 and RVFV nucleocapsid 
protein (N-protein) 
Objectives: 
a. To clone constructs derived from the relevant genes into plant 
expression vectors and do protein expression analysis to pick the best-
expressing constructs for further analysis 
b. To purify proteins and putative virus-like particles and characterize 
extracts by ultracentrifugation and electron microscopy  
 
3.  To test the immunogenicity of candidate plant-produced vaccines in mice  
Objectives: 
a. To analyse the immunogenicity of the plant-produced candidate 
vaccines in BALB/c mice 
 
4. To develop a diagnostic reagent for detection of RVFV in animal serum 
using the N-protein  
Objectives: 
a. To clone the N gene into plant expression vectors and do protein 
expression analysis to select the best expressing plasmid for further 
analysis 
b. To purify the N-protein and characterise by chromatography and 
electron microscopy 
c.  To test the functionality of the purified N-protein in ELISA tests using 
sera from animals previously shown to be infected or not infected with 




Chapter 2: Literature review 
 
2.1 Rift Valley Fever 
Rift Valley fever (RVF) is a mosquito-transmitted viral zoonotic disease which affects 
animals primarily, as well as humans.  RVF was first identified in the Rift Valley in 
Kenya in 1931 when it caused an outbreak of disease in sheep (Daubney et al., 1931).  
The causative agent of RVF is the Rift Valley fever virus (RVFV), which belongs to the 
Phlebovirus genus in the Bunyaviridae family (Elliott, 1997).  RVFV infects and is 
transmitted by more than 30 mosquito species which belong to seven genera, of which 
Aedes. sp and Culex. sp are considered the most significant.  RVFV persists for a long 
time in the mosquito population.  This virus can also be harboured by other vectors 
such as ticks and sand-flies. 
 
No antigenic differences have been reported between viral isolates involved in the 
different outbreaks in African countries; however, there is some evidence that there 
may be differences in virulence of certain isolates.  Infections in animals occur 
predominantly as a result of bites from mosquitoes carrying the virus (Moutailler et al., 
2008).  The main route of transmission to humans, however, is by direct contact with 
infected animal tissues and fluids, generally during the preparation of meat.  (Morrill et 
al., 1997b; Wilson, 1994).  They can also be infected by mosquito bites (Davies and 
Martin, 2006) during periods of high vector population levels, such as during rainy 
seasons.  No human to human transmission has been reported to date.  
 
2.2 Viral structure  
RVFV is a glycoprotein-enveloped virus with a tri-segmented single-stranded RNA 
genome, with genes mostly translated in the negative sense.  The genome is 
composed of a large segment (L), a medium segment (M), and a third small (S) 
segment which is ambisense in terms of having ORFs in both (+) and (-) senses.  Each 
segment is enclosed in a separate helical nucleocapsid protein (N-protein) within the 
same virion (Garcia et al., 2001).  The L segment encodes the viral RNA polymerase 
(~6.4 kb) which is used for replication and mRNA transcription.  The M (~3.8 kb) 
segment encodes a polyprotein consisting of an amino terminal glycoprotein (Gn) and 
a carboxy-terminal glycoprotein (Gc) as well as two non-structural proteins, NSm1 (78 
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kDa) and NSm2 (14 kDa), which play an important role in RVFV infection and 
pathogenesis (Freiberg et al., 2008; Gerrard et al., 2007; Won et al., 2006)  (Figure 
2.1).   
 
 
Figure 2.1:  The illustration of the Rift Valley fever virus genome.  A) The three genomic large segments 
(L), medium (M) and small (S) and proteins encoded by them.  B) The mRNA transcribed from the M 
segment contains five in-frame start codons which give rise to the NSm1 and NSm2 proteins, as well 
as some minor products (Bouloy and Flick, 2009).   
 
RVFV particles consist of an enveloped virion measuring 90 - 100 nm in diameter 
(Figure 2.2) (Ellis et al., 1979).  The envelope is composed of a lipid bilayer containing 
the Gn and the Gc glycoprotein surface subunits which are 5 – 8 nm in length.  These 
are regularly arranged on its surface forming an icosahedral shell of 122 capsomers 
(Huiskonen et al., 2009), similar to those reported for the related Uukuniemi 
Phlebovirus (Pettersson and von Bonsdorff, 1975).  Within the inner envelope of the 
virion, ribonucleoprotein (RNP) complexes composed of the three genomic segments 
associated with the nucleoprotein and the RNA-dependent RNA polymerase are 
packed proximal to the inner envelope, suggesting a possible interaction between the 







Figure 2.2: Illustration of the Rift Valley fever virus virion adapted from Pepin et al. (Pepin et al., 2010). 
 
2.3 Viral entry and transcription 
RVFV binds to unidentified cellular receptors, then enters the cells using a class II 
fusion mechanism which is activated by low pH following endocytosis of the virion.  
Viral transcription and replication take place in cytoplasm of the infected cells (de Boer 
et al., 2012; Filone et al., 2006).  The L segment allows RNA replication and viral RNA 
transcription.  The M (~3.8 kDa) segment contains four nested protein genes in a 
single open reading frame (ORF): these are the two structural glycoproteins Gn (55 
kDa) and Gc (58 kDa) and two non-structural proteins, the 14 kDa NSm and the 78 
kDa NSm-Gn fusion protein (Lagerqvist et al., 2009; Suzich et al., 1990).  The NSm1 
and NSm2 proteins are produced by alternative use of the first and second of the 5 in-
frame AUG codons, respectively, which are present at the 5’ end of the M mRNA 
upstream of the Gn.  They function as virus virulence factors and determinants for host 
pathogenesis.  NSm is dispensable for efficient RVF virus growth in both interferon-
competent and interferon-deficient cell cultures (Bird et al., 2007; Gerrard et al., 2007; 

















Figure 2.3:  A model showing the RVFV replication cycle 
 
The Gn and Gc polyproteins are produced when translation initiates at the second, 
fourth or fifth of the 5 in-frame AUG codons (Gerrard and Nichol, 2002).  They are 
inserted in the virus lipid envelope and are responsible for cell tropism and membrane 
fusion.  When Gn is expressed on its own, it is transported to the Golgi apparatus due 
to the specific Golgi localization signal at the C-terminus, whereas Gc is localized in 
the endoplasmic reticulum (ER) due to the presence of an ER retention signal (Gerrard 
and Nichol, 2002).  The RVFV GnGc polyprotein localizes to the Golgi apparatus.  The 
Gc moves to the Golgi apparatus due its physical association with Gn (Wasmoen et 
al., 1988); the remaining structural proteins and the genome are recruited by the 
glycoproteins, followed by viral budding.  The mature virions are released from the cell 
through fusion of virion-filled Golgi elements with the plasma membrane (Elliott, 1997; 
Gerrard and Nichol, 2002).  The endodomain of Gn interacts with the N-protein and 
this interaction is important for genome packaging into infectious virus particles. 
 
The S segment (~1.6 kb) encodes the viral N-protein (27 kDa) in its antisense 
orientation, while the complementary orientation encodes the non-structural protein 
NSs (Gerrard et al., 2007; Struthers et al., 1984).  After viral uncoating, viral 
ribonucleocapsids (RNP) composed of genomic RNA segments and N-protein are 
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released into the cytoplasm.  The NSs is a filamentous nuclear protein that functions 
as a virus virulent factor, by the inhibition of the host’s RNA polymerase II activity 
indirectly disrupting the host cell antiviral response and assembles in the cytoplasm of 
the infected cell, thus, plays an important role in pathogenesis (Bird et al., 2007; Vialat 
et al., 2000; Won et al., 2006). 
 
2.4 RVFV outbreaks 
Outbreaks of RVFV are often associated with abnormal heavy rains resulting in an 
accumulation of surface water in dams and depressions.  These are ideal conditions 
for hatching mosquito eggs, which can survive in dry mud for a number of seasons 
(Davies et al., 1985; Linthicum et al., 1985).  The virus is mainly detectable when 
weather conditions allow for a sufficient number of mosquitoes to breed.  RVFV is 
transmitted transovarially in mosquitoes, which provide a reservoir of infection during 
epizootics.  During an outbreak, mosquitoes feed on livestock such as cattle, sheep 
and goats.  Infection with the virus results in significant losses of livestock and results 
in abortion storms and death of new-borns and young animals. 
 
Table 2.1 lists the major RVFV outbreaks occurring from 1974 to 2010.  The RVF 
epidemic that occurred in Saudi Arabia between 2000 and 2001 had a 13% human 
fatality rate (Control and Prevention, 2000).  However, statistics from recent outbreaks 
that occurred in 2006 - 2007 in East Africa, Somalia and Tanzania revealed that the 
case fatality rate was significantly increased, to about 45% for those with complications 
(Bouloy and Flick, 2009; LaBeaud et al., 2008), when more than 300 patients died 
(2007a; 2007b).  The biggest outbreak in South Africa occurred in 1974 – 1976 when 
more than 10 000 infections were reported.  The most recent outbreak occurred from 
February to September in 2010, with 242 human RVF cases, of which 25 were deaths 








Table 2.1:  Major Rift valley fever outbreaks from 1974 - 2010 
Year Country (human infections) Reference 
1974 - 1974 South Africa (10 000 – 
20 000) 
(McIntosh et al., 1980b) 
1977 - 1978 Egypt (200 000, 594 deaths) (El-Akkad, 1978; Meegan, 1979; Meegan et al., 1979) 
1987 Mauritania, Senegal (8900, 
220 deaths) 
(Digoutte et al., 1989; Jouan et al., 1989) 
1997 - 1998 Kenya (89 000, 478 deaths) (Woods et al., 2002) 
2000 - 2001 Saudi Arabia, Yemen (2000, 
245 deaths) 
(Control and Prevention, 2000) 
2006 - 2007 Somalia, Kenya, Tanzania 
(1 062, 315 deaths) 
(2007a; 2007b) 
2010 South Africa (242, 25 deaths) (Métras et al., 2012) 
2012 Mauritania (36, 18 deaths) http://www.who.int/mediacentre/factsheets/fs207/en/ 
2016 Niger (348, 33 deaths) http://www.who.int/mediacentre/factsheets/fs207/en/ 
 
The virus was restricted to sub-Saharan Africa prior to the middle 1970s, but has now 
become endemic to parts of North Africa and the Arabian Peninsula.  Recently, large 
outbreaks have been reported in Kenya, South Africa, Senegal, Mauritania, Egypt and 
Madagascar (Control and Prevention, 2000).  For the first time in 2000, RVFV cases 
were reported in Saudi Arabia and Yemen.  These cases of the disease outside the 
African continent raise concerns that the virus could extend to other parts of Asia and 
Europe (Control and Prevention, 2000 ).  Due to the large number of mosquitoes that 





2.5 Clinical Symptoms 
2.5.1 RVFV in animals 
Symptoms of infection in ruminants vary between different animal species but include 
the occurrence of near simultaneous abortions in pregnant animals in the same herd, 
high neonatal mortality rates, hepatic damage and deformed young (Arishi et al., 
2006).  Clinical manifestations vary depending on the age of the animal.  In sheep, a 
fever of 41 - 42 °C is observed after a short incubation period.  Newborn lambs usually 
die within 36 to 40 h after the onset of symptoms, with mortality rates reaching 95%.  
Older animals either die or develop mild infection.  In pregnant ewes, abortions are 
frequent, ranging from 5 – 100%.  Twenty percent of aborting ewes die.  These animals 
may also experience fever with depression, haemorrhagic diarrhoea, blood staining 
muco-purulent nasal discharge and icterus.  Case fatality rates vary between 20 – 
30% (Gerdes, 2004).  In cows, calves often develop acute illness, with fever, diarrhoea 
and dyspnoea and mortality rates vary from 10 – 70% (Chevalier et al., 2010). 
 
2.5.2 RVFV in humans 
Infection of humans yields no symptoms until after an incubation period of 2 to 6 days.  
The high-risk individuals are herders, farmers, slaughterhouse workers and 
veterinarians.  Most people develop inapparent infections, with some having moderate 
to severe non-fatal flu-like symptoms characterized by fever, headache, light 
sensitivity, muscle and joint pain.  Some people develop neck stiffness, sensitivity to 
light, loss of appetite and vomiting.  Complete recovery usually occurs in two weeks 
(Ma et al., 2015; McIntosh et al., 1980a; McIntosh et al., 1980b). 
 
In severe cases, however, people infected can develop ocular lesions (0.5 – 2%) 
resulting in blurred vision which may resolve with time, but detachment of the retina 
may occur in a few cases causing permanent blindness.  Less than 1% of people 
infected develop severe haemorrhagic syndrome or meningoencephalitis, which may 
be fatal.  These symptoms usually occur within four weeks of infection.  Clinical 
features of encephalitis include intense headache, loss of memory, hallucinations, 
confusion, disorientation, vertigo, convulsions, lethargy and coma.  Neurological 
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complications can appear at later stages.  Haemorrhagic fever begins with the 
evidence of severe liver impairment, such as jaundice.  This is subsequently followed 
by signs of haemorrhage such as vomiting blood, blood in the faeces, a purplish 
discolouration of the skin or subcutaneous spots of blood, bleeding from the nose or 
gum, menorrhagia and bleeding from venepuncture sites.  Death usually occurs three 
to six days after the onset of symptoms (Bird et al., 2009; Chevalier et al., 2010; Flick 
and Bouloy, 2005; Gerdes, 2004; Le May et al., 2004; Magurano and Nicoletti, 1999; 
McIntosh et al., 1980b). 
 
2.6 Bioterrorism concerns 
The global spread of RVFV presents a serious bioterrorism or biosecurity concern due 
to movement of a wide range of mosquitoes, humans and animals into different 
countries: this can easily introduce the virus into non-endemic countries, resulting in 
serious health and agricultural problems (Chevalier et al., 2010; Gubler, 2002; House 
et al., 1992).  More so, since RVFV was reportedly weaponised by the US offensive 
biological weapons program, illustrating the real threat and utility of RVFV as a 
bioweapon.  The lack of treatment or no Food and Drug Administration (FDA) or U.S 
Department of Agriculture (USDA) approved RVFV vaccine for human or animal use 
makes infection with the virus a major concern and a need for more RVFV vaccine 
research and development (Bird et al., 2009; McElroy et al., 2009).  Handling of RVFV 
requires high containment facilities, including biosafety level 3 enhanced (BSL-3E) or 
BSL 4 laboratories (Mandell et al., 2010a; Mandell et al., 2010b). 
 
RVFV is classed as a RNA viral haemorrhagic fever agent: the OIE has classified 
RVFV as a high-consequence pathogen with the potential for international spread (List 
A).  In the United States of America, RVFV is number 3 on the list of the 17 most 
dangerous animal threats, behind only highly pathogenic avian influenza virus and 
Foot-and-Mouth disease virus (FMDV).  Therefore it is classified as a Category A 
agent by the Centers for Diseases Control and Prevention (CDC) and the USDA (Bird 
et al., 2009; Ikegami and Makino, 2009).  In Europe, the constraints are the same as 
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for Foot-and-Mouth disease and other epizootic diseases.  They were instituted in 
1972 (directive 72/462/CEE, which has been modified recently to be more stringent). 
 
2.7 Diagnosis 
RVF can be diagnosed using various methods, with serological test results being 
combined with clinical observation and epidemiological history.  The virus can be 
detected in blood during early phases of illness, or in post-mortem tissue using various 
techniques, including virus propagation, antigen detection and RT-PCR (Wilson et al., 
2014).  RT-PCR for detection of RVFV have been described (Drosten et al., 2002; 
Garcia et al., 2001; Sall et al., 2002) and shown to be valuable in mobile diagnosis 
(Njenga et al., 2009) as well as detection of the virus in serum samples (Chengula et 
al., 2014; Odendaal et al., 2014).  There are three main diagnostic methods for 
detecting antibodies against RVFV in serum.  The traditional methods for detection of 
antibodies to RVFV are hemagglutination inhibition (HI), virus neutralization (VN) and 
immunofluorescence assays (IFA).  Disadvantages of these tests include the high 
health risk to laboratory workers that handle the live virus, and that their use is 
restricted outside RVF endemic areas.  This has led to the development of an enzyme-
linked immunosorbent assay (ELISA), which is a rapid and reliable diagnostic tool.  N-
protein is the most abundant viral protein, and has been successfully used for the 
detection of antibodies for many viruses in the family Bunyaviridae (Fischer et al., 
2015; Schwarz et al., 1996; Swanepoel et al., 1986a).  A highly sensitive and specific 
indirect ELISA based on the use of β-propiolactone-inactivated or gamma irradiated, 
sucrose-acetone extracted antigens derived from tissue culture or mouse brain tissue 
for the detection of IgG and IgM antibodies to RVFV in animals and humans, has been 
developed and validated (Paweska et al., 2003a; Paweska et al., 2005a; Paweska et 
al., 2005b; Paweska et al., 2003b).  However, the production of this inactivated antigen 
requires high biosafety containment facilities.  The main drawbacks associated with 
the ELISA test as published are that production of the antigen is a costly process, and 
there is poor binding of the antigen to ELISA plates as it is too crude (Jansen van 
Vuren et al., 2007; Moutailler et al., 2008).  Therefore, there is a need for a cheap, 
safe and more reliable test for the presence of antibodies in animals and in humans, 




The N-protein is the major component of ribonucleoprotein complex and it plays a role 
in RNA transcription and replication (Schmaljohn and Hooper, 2001) as well as viral 
assembly (Liu et al., 2008).  It has been expressed and very well characterised in 
various expression platforms and revealed to form complex multimers (Ferron et al., 
2011; Le May et al., 2005; Liu et al., 2008; Raymond et al., 2010).  It has been shown 
to be highly immunogenic but does not exhibit neutralising activity (Boshra et al., 2011; 
Faburay et al., 2014; Lagerqvist et al., 2009). 
 
2.8 Control and prevention 
During a RVF outbreak, farmers can attempt various treatments to prevent the spread 
of mosquitoes.  Treatments are aimed at the most vulnerable animals, namely 
pregnant and young livestock.  The preferred used insecticide is pyrethroid 
deltamethrin, which has a knockdown effect, reducing the number of mosquitoes 
(Diallo et al., 2008).  Larvicidal measures at mosquito breeding sites are the most 
effective form of vector control, if the breeding sites can be clearly identified and are 
limited in size and extent.  During periods of flooding, however, the number and extent 
of breeding sites is usually too high for application of larvicides to be feasible.  
Methoprene and Bacillus thuringiensis israeliensis preparations are hormonal larvae 
growth inhibitors and microbial larvicides, respectively; these are commercially 
available and can be successfully used to treat temporary ponds and watering places 
where mosquitoes proliferate (Lacey and Lacey, 1990).   
 
2.9 RVFV Vaccines 
RVFV outbreaks in animals can be prevented by a sustained programme of animal 
vaccination.  Live attenuated and inactivated vaccines have been developed for 
veterinary use.  Only one dose of the live attenuated vaccine is required to produce 
long term immunity, but the vaccine may result in spontaneous abortion if given to 
pregnant animals (Smithburn, 1949).  On the other hand, the inactivated vaccine does 
not have side effects but requires multiple doses in order to provide adequate 
protection, which may be problematic in endemic areas (Caplen et al., 1985).  Animal 
immunization must be implemented before an outbreak if an epizootic is to be 
prevented.  Once an outbreak has occurred, animal vaccination should not be 
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implemented because there is a high risk of intensifying the outbreak.  During mass 
animal vaccination programmes, animal health workers may, unintentionally, transmit 
the virus through the use of multi-dose vials and re-use of needles and syringes, if 
some of the animals in the herd are already infected and viraemic.  Restricting or 
banning movement of livestock may be effective in slowing the expansion of the virus 
from infected to uninfected areas. 
 
Global health and animal health agencies or departments agreed to start a “One 
Health” initiative, which has as a priority to develop RVFV countermeasures whether 
for human or animals or both.  The “One Heath” initiative aims to yield a highly effective 
and long term protective immunity through interdisciplinary collaborations and 
communications in all aspects of health care for humans, animals and the 
environment.  Novel vaccines should be cost-effective and application should be safe 
regardless of the physiological state of the animal.  Be DIVA complient by use of 
appropriate discriminatory assays would also be beneficial.  Conventional vaccines 
such as live attenuated vaccines or even some inactivated vaccines are not suitable 
for DIVA, since the antibody responses elicited by these vaccines are similar or the 
same for attenuated vaccines, and may be similar for inactivated, as those induced by 
wild type virus.  DIVA strategies can help in the detection of specific antibodies which 
are induced by natural infection rather than by artificial immunisation in animals, or 
vice-versa, ensuring safe trade of products from immunised animals (Liu et al., 2013a).  
DIVA vaccines allow serological differentiation between vaccinated and infected 
animal in conjunction with proper diagnostic tests that detect antibodies against the 
protein (Mebatsion et al., 2002; van Oirschot et al., 1986; Wehrle et al., 2007).  The 
spread of RVFV can be prevented by vaccination of animals and humans but 
development of safe and effective vaccines has been difficult (Bouloy and Flick, 2009; 
Ikegami and Makino, 2009).  Numerous candidate vaccines have been developed.   
 
2.9.1 Live attenuated vaccines 
The Smithburn vaccine was developed by K C Smithburn and his fellow researchers 
in 1944 during a yellow fever outbreak in Uganda (Smithburn, 1949; Smithburn et al., 
1949).  The strain was isolated from mosquitoes, and then attenuated by sequential 
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intracerebral passages in suckling mice, which reduced the hepatotropism of the 
strain.  Smithburn showed that this virus strain could protect lambs challenged with 
virulent RVF virus.  Further analysis revealed that the vaccine protected the animals 
19 months after a single vaccination.  However, the vaccine may induce abortion and 
teratology in sheep, ewes, and cows (Botros et al., 2006; Kasari et al., 2008).  The 
strain’s affinity for foetus neural tissue causes cephalic disorder and arthrogryposis, 
resulting in abortion or stillborn young.  From 1953 – 1958 the Smithburn vaccine was 
used for vaccination purposes in South Africa, and is currently produced by 
Onderstepoort Biological Products (Barnard, 1979; Barnard and Botha, 1977).  
Although the vaccine is significantly attenuated, it has the potential for reversion, and 
hence it is not recommended for use in countries where RVFV is not endemic (1983).  
This vaccine is pathogenic to humans as well, causing febrile syndrome.  Despite the 
drawbacks it is recommended by the Food and Agriculture Organization (FAO) of the 
United Nations and it remains the most widely used vaccine against RVF in Africa 
(1983). 
 
The MP-12 attenuated strain of RVFV originates from the Egyptian RVFV strain 
ZH548, which was isolated from a human patient.  Attenuation was accomplished by 
12 serial mutagenesis passages of the wild type RVFV ZH548 strain in human diploid 
lung (MRC-5) cells using the chemical mutagen 5-fluorouracil (5FU).  The virus was 
propagated in the presence of medium containing 5FU on a monolayer of MRC-5 cells 
that were plaqued under agarose, and large plaque clones were harvested and 
amplified on monolayers of MRC-5 cells with medium lacking 5FU.  The supernatant 
from the passage of cells was then used to initiate another mutagenesis cycle for a 
total of 18 cycles.  A series of RVFV mutants with increasing attenuation was obtained 
by this approach; the product of the 12th mutagenesis passage is referred to as MP-
12 (Caplen et al., 1985).  MP-12 was selected for further investigation on the basis of 
its immunogenicity and favourable attenuation in a preliminary investigation in mice 
(Caplen et al., 1985; Schirmbeck et al., 1996; Vialat et al., 2000).  It was demonstrated 
that MP-12 had three mutations in the three segments (L, M and S) (Saluzzo and 
Smith, 1990).  Further analysis of the vaccine strain revealed that it protected sheep 
and cattle after the first trimester (Baskerville et al., 1992; Morrill et al., 1991).  The 
vaccine provides a low level of protection and its production is expensive; two 
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inoculations and frequent booster shots are required to induce protection (Hunter et 
al., 2002; Morrill et al., 1991; Morrill et al., 1997a).  This is not feasible in countries 
where a large proportion of the animals are roaming around free.  Furthermore, this 
vaccine strain also showed teratogenic effects in sheep (Hutchinson et al., 1996), 
same safety concern as observed with the Smithburn vaccine.  Nonetheless, more 
efforts are being made to attenuate the MP-12 vaccine virus strain further using 
reverse genetics to delete the NSs gene in the pre-Gn region of the M segment 
(Habjan et al., 2009; Morrill et al., 2013).  
 
Another approach is using engineered RVFV replicon particles which are highly 
effective in inducing a protective immune response, nonspreading RVFV (NSR) 
(Kortekaas et al., 2011; Oreshkova et al., 2014; Oreshkova et al., 2013; Wichgers 
Schreur et al., 2014a) and the four-segmented RVFV 4s that was constructed by 
splitting the wild type M genome segment into two segments encoding either the Gn 
or Gc protein.  In vivo studies have demonstrated that RVFV-4 is unable to spread the 
infection and disease in mice even in the presence of the main virulent factor NSs, but 
induced a protective immune response against a lethal challenge (Wichgers Schreur 
et al., 2015; Wichgers Schreur et al., 2014b). 
 
The Clone 13 vaccine was isolated from a mild human case of RVF in the Central 
African Region (Weinbren et al., 1957).  The strain showed heterogeneous plaques 
when cultured in vitro and was found to have an in-frame deletion in most of the NSs, 
lacking 70% of the coding sequence for the interferon antagonist (Muller et al., 1995; 
Nakitare and Elliott, 1993).  When assessed for safety and efficacy in sheep, the strain 
was effective without teratogenic effects (Albarino et al., 2007; Bouloy et al., 2001; 
Dungu et al., 2010; Muller et al., 1995), making it a suitable alternative to Smithburn 
and MP-12.  The deletion in the sequence encoding the virulence factor makes it a 
good alternative due to its inability to revert.  The Clone 13 based vaccine was 
commercialized in South Africa by Onderstepoort Biological Products in 2010.  Despite 
the high safety profile of Clone 13 vaccine, more research efforts are being carried out 
to further attenuate mutations on the L and M segments of MP-12 with the S segment 
of Clone 13 virus.  The re-assortant virus, named R566, contains mutations in each of 
the three genome segments (Bouloy and Flick, 2009; Kortekaas et al., 2014).  
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Currently in South Africa, both Smithburn and Clone 13 vaccines are commercially 
available for use in endemic areas.   
 
2.9.2  Inactivated vaccines 
The National Drug Biological Research (NDBR) 103 vaccine strain was initially 
isolated from mosquitoes in Uganda harbouring the Entebbe strain of RVFV.  The 
vaccine virus was developed from mouse serum master seed (184th passage) and 
amplified in primary monkey kidney cells, before being used routinely for formalin 
inactivation (Randall et al., 1962).  It was further shown that the vaccine prepared from 
chicken embryos or chick embryo cell culture was less immunogenic when it was 
prepared using primary rhesus or African green monkey kidney cells (Randall et al., 
1962) . 
 
The formalin-inactivated Salk Institute–Government Services Division (TSI-GSD) 200 
vaccine was subsequently manufactured under more stringent safety regulations by 
using the new master seed prepared from two passages of the mouse serum master 
seed of the Entebbe strain in diploid cells (FRhL-2 cells) derived from the lungs of a 
foetal rhesus monkey (Eddy and Peters, 1980).  TSI-GSD 200 is available in limited 
amount to the US for protection of military personnel and laboratory staff, but it has 
not been licensed.  The vaccine is not commercially available, but is used by 
veterinarians who work in areas endemic to RVFV as well as others who are at high 
risk of contracting the disease including lab workers in high containment areas.  As 
with most inactivated antiviral vaccines, this vaccine is expensive, difficult to make, 
and several inoculations are required to maintain immunity.  In addition, this vaccine 
is in short supply (Kark et al., 1982; Randall et al., 1964).  The NDBR 103 and TSI-
GSD 200 vaccines have been used for immunization of human volunteers (Eddy and 
Peters, 1980; Niklasson, 1982) and no adverse side effects were reported (Kark et al., 




2.9.3 Recombinant viral vaccines 
Recombinant viral vectors can express the antigen of interest through viral infection, 
thus enabling the host cell to process the recombinant protein in a manner similar to 
that of natural infection.  Advantages of using recombinant viruses are that antigens 
are not expressed in the context of the natural virus, therefore limiting the risks 
associated with attenuated vaccines and allowing DIVA. 
 
Protective epitopes in RVFV Gn and Gc glycoproteins have been mapped (Dalrymple, 
1989).  These epitopes been reported to be highly immunogenic and able to protect 
animals (Besselaar and Blackburn, 1991; Schmaljohn et al., 1989).  Different 
strategies have been used to assess the competence of recombinant Gn and Gc 
proteins for eliciting neutralising antibodies in animals.  Expression vectors such as 
the Venezuelan equine encephalitis virus (VEE) vector and the lumpy skin disease 
virus (LSDV) vector (Wallace et al., 2006; Wasmoen et al., 1988) alphavirus 
(Gorchakov et al., 2007; Heise et al., 2009) adenoviruses (Holman et al., 2009; 
Hoogstraal et al., 1979; Warimwe et al., 2013), Newcastle disease virus (Kortekaas et 
al., 2012; Kortekaas et al., 2010a; Kortekaas et al., 2014), and other poxviruses 
(Collett et al., 1987; Papin et al., 2011; Soi et al., 2010) have all been used to generate 
RVFV glycoproteins which have elicited RVFV-specific immune responses and 
induced protection against RVFV challenge in animals.  In South Africa, rLSDV was 
used for the expression of Gn and Gc to protect sheep from RVFV (Wallace et al., 
2006).  These studies suggest that viral vectors are useful for the expression of Gn 
and Gc, and may be further improved as veterinary vaccines. 
 
2.9.4  Virus-like particles as vaccines 
Virus-like particles (VLPs) are composed of one or several recombinantly expressed 
viral proteins that spontaneously assemble into molecular structures resembling the 
infectious virus.  VLPs are structurally similar to infectious viruses, and they are much 
more highly immunogenic than recombinant proteins alone (Grgacic and Anderson, 
2006).  They also lack viral nucleic acids, making them non-infectious and safe to use.  
VLPs do not elicit antibody responses to internal or non-structural proteins encoded 
by viruses, therefore allowing for vaccines to be produced that can distinguish between 
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vaccinated and non-vaccinated animals, the so-called DIVA attribute (Capua et al., 
2003).  Due to the highly repetitive surface structures, VLPs are able to elicit strong B 
cell responses (Bachmann et al., 1997), which are strong enough to elicit T cell-
independent induction of IgM antibodies (Bachmann et al., 1993; Chackerian et al., 
1999; Kouskoff et al., 2000).  VLPs also induce T-helper cells that trigger IgG secretion 
as well as affinity maturation and the generation of long-lived memory B-cells, thereby 
fulfilling the fundamental goal for any vaccine.  Multivalent antigens, like VLPs, can 
activate B-cells at much lower concentrations than monomeric antigens.  In addition 
to their ability to stimulate B-cell mediated immune responses, VLPs have been shown 
to be highly effective at stimulating CD4 proliferative responses and even cytotoxic T 
lymphocyte (CTL) responses (Meyers et al., 2008; Paliard et al., 2000; Schirmbeck et 
al., 1996). 
 
VLPs can be used as an alternative to the traditional live attenuated and formalin-
inactivated RVFV vaccines.  By expressing RVFV N-protein and GnGc together in a 
dual baculovirus expression vector, Liu and co-workers (Liu et al., 2008) showed that 
enveloped VLPs resembling wild type RVFV virions could be produced in insect cells.  
VLPs were also produced by the dual baculovirus vector system with just N-protein 
and Gc without the Gn.  These VLPs were more pleomorphic than the VLPs 
comprising both glycoproteins.  Habjan et al (Habjan et al., 2009) produced RVFV 
VLPs in mammalian cells by co-expressing recombinant RVFV RNA-dependent 
polymerase and N-protein together with a minireplicon RNP and additional expression 
of the viral glycoproteins.  These have been shown to protect mice from a lethal 
challenge of RVFV (Naslund et al., 2009).  It was also shown by de Boer et al. (de 
Boer et al., 2010) that RVFV VLPs can be produced in a Drosophila insect cell system 
expressing the Gn and Gc proteins separately.  Furthermore, these VLPs provided 
100% protection for mice when challenged with wild type virus.  The effect of soluble 
Gn in vaccinated mice was also tested and it has shown that full protection was 
afforded from lethal challenge with RVFV (de Boer et al., 2010).  Therefore, RVFV 
VLPs and even soluble Gn are a possible candidate for vaccination against RVF as 
they are stable, they are more immunogenic than recombinant proteins alone, and 
they maintain their conformational epitopes which induce neutralising antibodies.   
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Despite their efficacy, producing VLPs in mammalian or insect cells is very expensive, 
thus hindering future development and commercialization of these candidate 
vaccines.  An alternative production method such as plant-based expression for 
vaccine antigens may be more efficient and cost-effective compared to mammalian 
and insect cell production of these VLPs (; Mortimer et al., 2012). 
 
2.10 Plant production systems 
Advances in molecular biology and biotechnology have opened up new opportunities 
for development of new genetically engineered vaccines.  One of the cheaper ways of 
producing vaccines is by using plants as an expression system (Daniell et al., 2001; 
Lomonossoff and D'Aoust, 2016; Santi et al., 2006; Streatfield and Howard, 2003).  
Plant-based expression systems are safe to use as they do not contain human or 
animal pathogens, thus reducing the risk of contamination for pharmaceutical proteins.  
Plants offer a number of advantages compared to other expression systems, which 
include flexibility in the production platform and easy scale up for manufacturing 
(Rybicki, 2010; Xu et al., 2012; Youssef and Donia, 2001).  Plant expression systems 
also provide the majority of eukaryotic post-translational modification machinery 
required for complex proteins and simple low-cost scale up for manufacturing.  N-
linked glycosylation and other post-translational modifications are important for the 
folding of some eukaryotic proteins and glycoproteins are efficiently glycosylated when 
expressed in the plant expression system.  These biosafety advantages positively 
impact their commercial aspects, since they reduce purification costs and minimize 
risks associated with potential production shut-downs and facility decontamination and 
supply chain limitations leading to unmet patient or customer demand (Xu et al., 2012). 
 
Various plant species can be used as hosts for plant-based production; these include 
in vitro-grown cells (cell suspension cultures), and plant tissue culture as well as whole 
plants grown in growth chambers and in the field.  Nicotiana species, alfalfa, rice, 
wheat, potatoes, carrot, tomatoes, maize, soybeans among others can be used for 
production of recombinant proteins (Gils et al., 2005; Gleba et al., 2005; Marillonnet et 
al., 2004; Rybicki, 2009; Yusibov et al., 2002).  Certain plants such as the 
horticulturally very well understood Nicotiana benthamiana can be grown at high 
density and produce large amounts of biomass in a few weeks.  Heterologous proteins 
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can be produced in plants by two approaches: stable transformation and transient 
expression.  Stable transformation involves the integration of genes into the plant 
nuclear or chloroplast genomes (Berberich et al., 2005; Huang et al., 2005; 
Pogrebnyak et al., 2005).  This approach has advantages in terms of reproducibility 
and large-scale production.  However, it is very time consuming and it is unsuitable for 
rapid screening of a wide variety of different constructs (Kusnadi et al., 1997).  
 
Transient expression (TE) allows for robust high levels of protein production in several 
days, and while it is mostly used for rapid screening of expression constructs, TE can 
also be reliably used for large-scale recombinant protein production.  TE of 
heterologous proteins in plant leaves was first demonstrated by infiltration of 
suspensions of Agrobacterium tumefaciens harbouring a binary vector into plant 
leaves (Kapila et al., 1997), followed by the demonstrations of expression of many 
proteins that was easily achieved by A. tumefaciens mediated somatic gene transfer 
(Circelli et al., 2010; Collens et al., 2007; Fischer et al., 1999b; Maclean et al., 2007; 
Sijmons et al., 1990; Warzecha and Mason, 2003). 
 
A. tumefaciens is a Gram-negative bacterium that contains a naturally occurring 
plasmid known as Ti (tumour-inducing), which is capable of directing the transfer of 
part of the plasmid (the transfer DNA or T-DNA) into a plant cell and integrating the T-
DNA into the plant genome (Chilton et al., 1977; Eddy and Peters, 1980; Escobar and 
Dandekar, 2003).  With transient gene expression, foreign genes are generally 
introduced into the leaf tissue of intact plants by direct injection via syringe, or at larger 
scale by vacuum infiltration of whole plants with Agrobacterium containing gene(s) of 
interest within its T-DNA.  Recombinant protein production (based on the extra-
chromosomal gene expression within the plant cell) is initiated in the leaves within 24 
hours of infiltration and continues for several days up to as long as several weeks, 
depending on the vector used and protein of interest being expressed (Gleba et al., 
2005).  While chromosomal integration is possible, it occurs at considerably lower 
frequency in comparison to extra-chromosomal expression of the gene of interest 
(Circelli et al., 2010; Sheludko, 2008).  The success of this process has been well 
developed for scaling up the production of recombinant proteins in plants (D'Aoust et 
al., 2010).   
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Transient expression vectors can also be based on plant viruses such as ssDNA 
geminiviruses, the ssRNA agents Potato virus X (PVX), Tobacco mosaic virus (TMV) 
and Cowpea mosaic virus (CPMV).  These are ideal for suitable expression vectors 
due to rapid recombinant protein production, and a variety of possible regulatory 
components (Canizares et al., 2006; Giritch et al., 2006; Lindbo, 2007; Mor et al., 2003; 
Regnard et al., 2010; Sainsbury and Lomonossoff, 2008).  Most recently, during the 
outbreak of Ebola virus disease in Western Africa, much focus was on plant-derived 
pharmaceuticals; this was because the experimental drug ZMApp™, a combination of 
three humanized monoclonal antibodies that recognised an Ebola virus surface 
glycoprotein, was manufactured by agroinfiltrated rTMV-mediated transient 
expression in N. benthamiana plants by Kentucky BioProcessing under licence from 
Mapp Biopharmaceuticals Inc. (Qiu et al., 2014). 
 
2.11 Plant expression vectors 
One of the major drawbacks of plant-produced vaccines is the potentially low yields of 
protein.  Increasing protein yield remains a challenge for economic feasibility; key 
strategies used to try and improve product recovery in plant expression systems are 
summarized in Table 2.2 (Hood et al.; Rybicki, 2010).  These strategies include the 
choice of expression vector, use of signal peptides/sequences and gene sequence 
codon optimisation.   
 
For transient expression, an ideal expression vector should:  
 Have a wide selection of multiple cloning sites. 
 Have a broad host range origin of replication (ori) as well as an ori for a high 
copy number plasmid (ego li E1 from pBR322) to allow high yielding DNA 
preparations in E. coli.  
 Be of a small size, i.e. 10 – 13 Kb.  
 Have a good choice of selection markers for both bacterial and plant host.   
 Have a  high transformation efficiency (Hellens et al., 2000). 
 Have regulatory elements including a promoter such as Cauliflower mosaic 
virus (CaMV) 35S promoter, which is a constitutive promoter sequence and is 
responsible for the generation of full-length RNA copies in CaMV infected cells 
(Odell et al., 1985). 
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 Have translational enhancer elements such as the Tobacco mosaic virus (TMV) 
5’ omega leader sequence, which enhances the expression of heterologous 
protein in vitro and in vivo (Gallie et al., 1987) and Tobacco etch virus (TEV) 
(Carrington and Freed, 1990). 
 
The introduction of such elements into pre-existing viral backbones has resulted in the 
development of replicating viral vectors and non-replicating viral vectors (Regnard et 
al., 2010; Sainsbury et al., 2009a; Saunders and Lomonossoff, 2013).  
 
Table 2 2: Strategies used to improve recombinant protein yields in plants 
Production Stages Strategies 
Transformation  Attachment or fusion of SAR or LIR to DNA 
Transcription Development of strong promoters, double enhanced promoter, hybrid 
promoter 
Use of inducible promoters 
Engineering of better enhancers, activators or repressors 
Translation Optimization of 5’- and 3’-UTR (untranslated region) 
Codon optimisation 
Changes in initiation codon  
Post-translation Targeting to sub-cellular compartments such as ER or apoplast 
Co-expression with protease inhibitors and protein co-factor/subunit; 
co-expression of antibody with antigen 
Expression as a fusion to a highly expressed and stable peptide  
Modified from (Desai et al., 2010; Xu et al., 2012) 
 
2.11.1 Plant organelle targeting vectors 
These vectors mainly involve the pTRAc (Figure 2.4) vector series (Maclean et al., 
2007).  The backbone is a derivative of pPAM (Genbank AY027531).  They have an 
RK2 ori, mob and are tra deficient.  They consist of a CaMV 35S promoter with a 
25 
 
duplicated translational enhancer, chalcone synthase 5’-unltranslated region and a 
CaMV 35S polyadenylation signal.  The selection markers are ampicillin (amp) in E. 
coli and carbenicillin (carb) in Agrobacterium.  The expression cassette is flanked by 
a scaffold attachment region (SAR) on the tobacco Rb7 gene to enhance gene 
expression (Halweg et al., 2005), which in turn is flanked by the left and the right 
borders required for T-DNA integration.   
 
 
Figure 2.4:  Organelle targeting Agrobacterium vectors pTRAc, pTRAc-cTP and pTRAc-ERH.  ColE1 
origin of replication for E. coli; RK2 ori, origin of replication for A. tumefeciens; bla, ampicillin/carbenicillin 
resistance bla gene, LB and RB, left and right borders for T-DNA integration; SAR, scaffold attached 
region of the tobacco Rb7 gene; P35SS, CaMV 35S promoter with duplicated transcriptional enhancer; 
CHS, chalcone synthase 5’-untranslated region; pA35S, CaMV 35S polyadenylation signal; LHP, 
murine mAb24 heavy chain signal peptide; 6xhis, 6 x histidine tag; SEKDEL, ER retention signal; cTP, 
chloroplast transit peptide of RuBisCO small sub-unit; nptII , kanamycin resistance gene; Pnos and 
pAnos, promoter and polyadenylation signal of the nopaline synthase gene (Maclean et al., 2007). 
 
This vector series was used to demonstrate that codon optimization of the human 
papillomavirus (HPV) 16 L1 gene and targeting of the protein to different plant cell 
compartments can influence the accumulation of the L1 protein by up to 80-fold, 
resulting in yields of 108 – 375 mg/kg fresh weight (FW) (Maclean et al., 2007).  The 
vector were also used for the production of candidate vaccines for avian influenza 
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H5N1, where yields of 300 – 675 mg/kg FW of HA were obtained (Mbewana et al., 
2015; Mortimer et al., 2012); production of HPV 16 E7 protein bodies with yields from 
400 to 1100 mg/kg FW (Whitehead et al., 2014); as well as, the production of human 
rotavirus candidate vaccines (Pera et al., 2015).  
 
2.11.2 Geminivirus-based expression vector 
Bean yellow dwarf virus (BeYDV) belongs to the genus Mastrevirus, family 
Geminiviridae.  It is a twinned-capsid spherical virus with a single stranded circular 
DNA genome (Zhang et al., 2001).  The genome contains short and long intergenic 
regions (SIR and LIR respectively), which allow for the initiation of second strand 
synthesis, and initiation of linear ssDNA synthesis by rolling circle replication by viral 
Rep/RepA proteins, respectively (Halley-Stott et al., 2007; Liu et al., 1997).  Mor et al 
(Mor et al., 2003) showed that this allowed for the deployment of LSL (LIR SIR LIR) 
vectors, in which a linear construct based on BeYDV containing a SIR and flanked by 
two LIRs in an Agrobacterium vector can be delivered into plant cells, liberated as a 
linear ssDNA by Rep/RepA action, and circularise to form replicons.  A self-replicating 
vector, pRIC (Regnard et al., 2010), has a similar backbone to the pTRA vector series 
(Maclean et al., 2007) except it has a Rep gene from the BeYDV inserted into it 
between the left and right intergenic regions and has no signal sequence.  It makes 
use of the same selection markers as the pTRA vectors.  This allows for vector 
replication in planta.  The pRIC vector (Figure 2.5) multiplied to ~1000 copies per cell, 
and allowed overexpression of HPV-16 L1 (550 mg/kg FW) and HIV capsid protein 
p24 (3.23 mg/kg FW), but only by factors of up to 4-fold, so that increases in protein 








Figure 2.5:  Self-replicating Agrobacterium vector pRIC.  ColE1 origin of replication for E. coli; RK2 ori, 
origin of replication for A. tumefeciens; bla ampicillin/carbenicillin resistance bla gene, LB and RB, left 
and right borders for T-DNA integration; SAR, scaffold attached region of the tobacco Rb7 gene; 
P35SS, CaMV 35S promoter with duplicated transcriptional enhancer; CHS, chalcone synthase 5’-
untranslated region; pA35S, CaMV 35S polyadenylation signal ; LIR, BeYDV long intergenic region; 
SIR; BeYDV short intergenic region; rep, BeYDV rep gene (Regnard et al., 2010). 
 
2.11.3 Comovirus-based expression vector 
The pEAQ-HT vector series is based on and contains a mutated version of a 5’ 
untranslated region (UTR) from a CPMV RNA-2 gene, which enhances protein 
expression from recombinant protein genes in plants when they are cloned 
downstream of the modified UTR (Sainsbury et al., 2008; Sainsbury and Lomonossoff, 
2008).  Protein expression is further enhanced by placing the 3’ UTR from CPMV RNA-
2 after the coding sequence and co-expression of the P19 silencing suppressor from 
the Tomato bushy stunt virus on the same vector, to stabilize the mRNA (Sainsbury et 
al., 2009b).  The backbone of this vector is modified from the commercially available 
pBIN plant expression vector.  The selection is carried out using kanamycin .  The 
pEAQ-HT (Figure 2.6) expression system has been used for the production of VLPs 
for different viruses such as Hepatitis B core particles (Peyret et al., 2015), Bluetongue 
virus (Thuenemann et al., 2013) as well as human (Matic et al., 2012) and bovine 





Figure 2.6: Hypertranslatable Agrobacterium pEAQ-HT vector.  LB and RB, left and right borders for 
T-DNA integration; CaMV 35S, cauliflower mosaic virus promoter, CPMV RNA-2 UTRs; NosT nopaline 
synthase terminator; OviV, pRK2 replication origin, ColE1, pBR322 origin of replication, npt II, neomycin 
phosphotransferase; 6xhis, 6 x histidine tag, P19, silencing suppressor; TrfA, replication essential locus 
(Sainsbury et al., 2009a). 
 
2.11.4 Tobamovirus-based expression vector 
Tobacco mosaic virus (TMV) is the type species of genus Tobamovirus, family 
Virgaviridae, which are rod-shaped, single stranded positive sense RNA viruses.  
Numerous TMV-based vectors have been used for protein expression in plants 
(Dawson et al., 1985; Donson et al., 1991; Sugiyama et al., 1995).  The TMV-based 
MagnICON system is the first of a series of deconstructed virus-based systems, made 
with the objective of obtaining high recombinant protein yields (Marillonnet et al., 
2004).  This system comprises of 3 modules which contain the gene of interest in place 
of the sequence of the viral coat protein along with the nos terminator; the 5’ module 
contains the Arabidopsis actin 2 (ACT2) promoter along with the tobamovirus RNA 
polymerase and movement protein (MP) genes, while the recombinase module 
containing the PhiC31 integrase gene (Streptomyces phage C31) acts to fuse the 3’ 
and 5’ modules together in the nucleus to allow the formation of a complete 
tobamovirus-based replicon, with the gene of interest under the control of the sub-
genomic promoter present within the MP sequence.  When Agrobacterium strains 
containing these constructs are co-infiltrated into plant cells, recombinase-mediated 
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recombination takes place at the recombinant sites, resulting in viral expression 
vector.  Expression of genes in these vectors generates desired recombinant protein 
and MP facilitates cell to cell movement of the vector as well as modified TMW 
replicons which increases the levels of recombinant protein produced.  Selection is 
carried out with ampicillin in E. coli and kanamycin in Agrobacterium (Marillonnet et 
al., 2004; Marillonnet et al., 2005).  
 
As proof of concept, yields of green fluorescent protein (GFP) as high as 5  g/kg of 
fresh weight (FW) were obtained from N. benthamiana (Marillonnet et al., 2004).  This 
system has been used for the production of plague bacillus antigens, which reached 
yields of 2 g/kg FW (Santi et al., 2006); Hepatitis B virus core VLPs at 2.4 g/kg FW 
(Huang et al., 2006) and Norwalk virus VLPs at 800 mg/kg FW (Santi et al., 2008). 
 
2.12 Codon optimisation 
Proteins are often difficult to express outside their original context.  They might contain 
codons that are rarely used in the desired host, come from organisms that use non-
canonical genetic code, or contain expression-limiting regulatory elements within the 
coding sequence (Gustafsson et al., 2004).  Various strategies such as the 
modification of translation initiation regions, alteration of mRNA structural elements 
and use of different codon biases can improve protein expression.  The DNA sequence 
used to encode a protein in one organism is often different from the sequence that 
would be used to encode the same protein in a different organism, as the degeneracy 
of the genetic code enables many alternative nucleic acid sequences to encode the 
same protein.  The frequency at which different codons are used varies significantly 
between different organisms, between proteins expressed at high or low levels within 
the same organism, and sometimes within the same operon in bacteria (Gouy and 
Gautier, 1982; Webster et al., 2016).  The more codons that a gene contains that are 
rarely used in the expression host, the less likely it is that the heterologous protein will 
be expressed at reasonable levels (Kane, 1995).  Codon usage bias is positively 
correlated with gene transcription levels (Wang and Roossinck, 2006). 
 
Codon optimisation has been widely used to enhance protein expression in 
heterologous systems (Batard et al., 2000; Perlak et al., 1991; Rouwendal et al., 1997; 
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Zhou et al., 2015).  Even though codon optimisation plays an essential role in gene 
expression, the choice of expression vectors and transcriptional promoters as well as 
signal peptides are also important.  The nucleotide sequence around the N-terminal 
region of the protein is sensitive to rare codons (Deana et al., 1998; Hoekema et al., 
1987) and to codons immediately adjacent to the initiation AUG codon (Sato et al., 
2001). 
 
2.13 Signal peptide fusions 
The success of transient expression is also dependant on intercellular organs to which 
the protein of interest is targeted; this is directed by the appropriate signal peptide 
fused to the gene of interest which targets recombinant proteins to  plant tissue 
compartments such as the ER or chloroplast (Maclean et al., 2007). Such targeting 
could lead to higher levels of accumulation of recombinant proteins in the secretory 
pathway or within specific organelles (Yoshida et al., 2004).  The plant’s vesicular 
transport system is valuable for the production of recombinant proteins that require 
post-translational modifications for their activity, such as antibodies and glycoproteins.  
Secretion of heterologous protein becomes possible by the attachment of a signal 
peptide at the N-terminus of the proteins that allows entry into the vesicular transport 
system.  The secretory pathway directs the accumulation of recombinant proteins in 
the cell wall region, apoplastic space or ER.  Varying the signal peptide of recombinant 
proteins can affect the degree of protein production (Yoshida et al., 2004).  Signal 
peptides vary in their amino acid composition and length, but they all contain a 
positively charged N-terminus of one to five residues, a central hydrophobic core of 6-
15 amino acids, and a polar region of three to seven amino acids that serves as a 
recognition site for signal peptidase, which cleave the signal peptide from the protein 
which it is fused to.  The signal peptide ensures effective direction of the expressed 
protein across the membrane of the ER (Kjærulff and Jensen, 2005).  The ER targeting 
efficiency increases with signal peptide hydrophobicity (Milstein et al., 1972; Perlmann 






2.14 Final Remarks 
The agricultural and health problems associated with RVF due to the lack of a safe, 
easy to produce and affordable vaccine as well as an affordable reagent which is DIVA 
complaint.  This allows for more research and development on RVF using the plant 




Chapter 3: Expression strategies for RVFV GnGc genes in N. benthamiana to 
identify suitable candidates for vaccines or reagent development 
 
3.1 Introduction  
 
RVF is an emerging disease that is rapidly expanding its geographical range, and 
which may quickly become a worldwide threat.  The spread of the disease could be 
prevented by vaccination against RVFV: however, despite much effort having been 
made in developing safe and efficacious vaccines, none have yet been released for 
general use (Bird et al., 2008; Mandell et al., 2010b; Morrill et al., 1987; Muller et al., 
1995; Naslund et al., 2009; Schmaljohn et al., 1989).  
 
Vaccination is an important and effective public-health measure for control and 
prevention against infectious diseases.  RVFV vaccines have been developed in 
expression systems such as bacteria (Keegan and Collett, 1986; Wallace et al., 2006) 
and mammalian cell cultures (Bird et al., 2008; Mandell et al., 2010b).  Cell cultures 
can be difficult to maintain and require expensive equipment and media.  In 
downstream processing, oncogenic sequences or viral contamination must be 
removed if in vivo applications are anticipated.  While bacterial cultures on the other 
hand do not produce glycosylated proteins, contaminating endotoxins are difficult to 
remove and recombinant proteins often form inclusion bodies, making labour and cost 
intensive in vitro refolding necessary to recover functional proteins (Fischer et al., 
1999a).  Plants offer an alternative cost-effective approach for mass production of 
recombinant proteins due to their high biomass and ability to carry out posttranslational 
modifications similar to other higher eukaryotes (Rybicki, 2009; Rybicki, 2010).  
 
The RVFV M segment RNA has one open reading frame that encodes the two 
envelope glycoproteins Gn and Gc with an additional upstream NSm region.  Gene 
translation depends on the alternative usage of five in-frame ATG codons.  
Translational products of the M segment have been characterised in vitro and consist 
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of polyproteins that are expressed from different ATG codons (Kakach et al., 1988; 
Suzich et al., 1990; Suzich and Collett, 1988).  After transcription of the viral genes, 
GnGc is translated as a polyprotein in the endoplasmic reticulum (ER) where it is N-
glycosylated and is then cleaved by signal peptidase in the ER into Gn and Gc 
glycoproteins (Gerrard and Nichol, 2007; Suzich et al., 1990).  Both Gn and Gc localise 
to the Golgi apparatus when expressed as a polyprotein.  The Golgi localization signal 
is found within the Gn protein transmembrane domain (Gerrard and Nichol, 2002; 
Schmaljohn and Hooper, 2001).  
 
Glycoproteins of RVFV (Gn and Gc) are found on the outermost surface of the virus 
and are the most exposed parts of the virus; they have therefore been tested by 
different approaches for competence to induce neutralising antibodies, which can 
protect against the disease.  The production of recombinant RVFV proteins as 
vaccines has been made possible by the mapping of their protective determinants 
using vaccinia virus expressing GnGc and a series of truncated Gn (Dalrymple, 1989).  
Three neutralizing epitopes have been mapped in Gn (Keegan and Collett, 1986).  
Animals immunised with Gn produced neutralising antibodies against RVFV 
(Schmaljohn et al., 1989).  Subsequently, there have been several other examples of 
the efficacy of recombinant vaccines: Gorchakov et al., (Gorchakov et al., 2007) 
showed that mice were protected from wild type ZH501 RVFV challenge following 
immunisation with Venezuelan equine encephalitis virus (VEEV) replicon expressing 
Gn.  Holman et al., 2009 (Holman et al., 2009) developed a complex adenovirus 
system encoding RVFV Gn and Gc with human CD4 signal peptides under the human 
cytomegalovirus promoter for human vaccines.  Mice were protected from the wild 
type ZH501 RVFV challenge.  A recombinant Newcastle disease virus LaSota strain 
expressing Gn (NDFL-Gn) (Kortekaas et al., 2010b) and GnGc (NDFL2-GnGc) 
(Kortekaas et al., 2010a) were developed and characterised.  Animals immunised with 
the recombinant protein produced neutralising antibodies and were protected from a 
challenge.   
 
The aim of the work reported in this chapter was to test different cloning strategies for 
the expression of the RVFV vaccine candidates GnGc, and Gn alone.  The expression 
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of wild type, plant- and human-codon optimised GnGc was tested using several 
different plant expression vectors to compare which one would result in the highest 
levels of recombinant protein: these were a self-replicating pRIC3.0 vector, the 
cytoplasm-targeting pTRAc vector, the ER-targeting pTRAc-ERH vector and the 
CMPV based hypertranslatable pEAQ-HT vector.   
 
3.2 Materials and Methods 
 
3.2.1 Rift Valley fever virus (RVFV) GnGc genes 
The Rift Valley fever (RVF) wild type strain (ZH548 M12) GnGc gene was kindly 
provided by Prof A Williamson (IIDMM, UCT) in the pSCRV6 plasmid (Figure 3.1 A).  
The RVF GnGc from South African isolate M35/74 (GenBank accession number JF 
784 387.1) was both Nicotiana sp. (Figure 3.1 B) and human-codon optimised (Figure 
3.1 C).  Both genes were synthesised by GenScript (GenScript Biotechnologies, 
Piscataway, NJ, USA) inclusive of the 4th ATG.   
 
 
Figure 3.1:  RVFV GnGc genes of:  A) wild type RVFV strain ZH548 M12, B) plant-codon optimised 
South African isolate M35/74 synthesised inclusive of the 4th ATG, C) human codon optimised South 
African isolate M35/74 synthesised inclusive of the 4th ATG. 
 
3.2.2 Plant expression vectors 
The plant expression vectors used for these studies are shown in Table 3.1 and 
depicted schematically in Figure 3.2. 
Table 3.1: Plant expressed vectors used in this study 
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Plasmid Description  Reference 
pEAQ-HT CPMV-based hypertranslatable 
expression vector  
(Sainsbury et al., 2009a) 





(Maclean et al., 2007) 
pRIC3.0 Self-replicating vector (Regnard et al., 2010) 
pTRAc-HT Cytoplasm- targeting vector with 5’ 
6xhis tag 
aBRU-Culture Collection 
a Biopharming Research Unit, Department of Molecular and Cell Biology, UCT 
 
3.2.3 Bacterial and plant growth conditions 
Chemically competent Escherichia coli DH5α™ cells (E. cloni™, Lucigen, WI) were 
grown in Luria Bertani medium (LB) (0.5% yeast, 1% tryptone, 0.5% sodium chloride) 
(Sambrook et al., 1989) supplemented with either 100 µg/mL kanamycin (kan) (for 
pEAQ-HT) or 100 µg/mL ampicillin (amp) (for pTRAc vectors and pRIC3.0) as the 
selection agent and incubated at 37 ˚C for 16 hours (h), shaking at 180 rpm. 
 
Agrobacterium tumefaciens LBA4404 was grown in LB supplemented with 10 mM 
MES, 30 µg/mL kan, 50 µg/mL rifampicin (rif) and 2 mM MgSO4 to prevent clumping 
of the cells and incubated for 2 - 3 days at 27 ˚C, shaking at 180 rpm.  A. tumefaciens 
GV3101::pMP90RK was grown in LB supplemented with 10 mM MES, 30 µg/mL kan, 
50 µg/mL rif, and 50 µg/mL carbenicillin (carb) and incubated for 2 – 3 days at 27 ˚C, 
shaking at 180 rpm.  In addition, the Agrobacterium LBA4404 (pBIN-NSs) strain 
obtained from Marcel Prins (Laboratory of Virology, University of Wageningen) was 
also cultured.  This strain contains a silencing suppressor gene of tomato spotted wilt 
virus (TSWV) to prolong and increase recombinant gene expression. 
 
Nicotiana benthamiana plants were grown in a plant growth room, at 22 ˚C with a 16:8 
h light/dark photoperiod, light intensity of 60 – 80 µE/m2/s and 45% relative humidity.  
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Plants were supplemented with a commercially available organic fertilizer weekly 
(Chemicult® hydroponic nutrient powder). 
 
Figure 3.2: Plant expression vectors.  (A) pRIC3.0 vector - refer to figure 2.5 for vector elements (B-
D) pTRA vectors – refer to figure 2.4 for vector elements (E) pEAQ-HT vector – refer to figure 2.6 for 
vector elements.  
 
3.2.4 DNA manipulation and analysis 
Recombinant plasmids were transformed into chemically competent E. coli DH5α cells 
(E. cloni™, Lucigen, WI) according to Sambrook et al., (Sambrook, 1989), unless 
otherwise stated.  The transformed cells were plated out onto LB agar plates with 
appropriate antibiotics and incubated overnight at 37 °C.  Recombinant single colonies 
were picked and grown overnight as described in section 3.2.3.  Plasmid DNA was 
isolated with the QIAprep® Spin Miniprep kit (Qiagen Gnbh, Hilden, Germany) 
according to the manufacturer’s instructions.  DNA concentrations were obtained using 
the NanoDrop (ND1000 Spectophotometer).  All DNA sequencing was carried out with 
appropriate primers by Macrogen Inc. (Netherlands) and sequences were analysed 
with CLC Main Workbench 6.0 (CLC Bio) or SnapGene Viewer (GSL Biotech LLC).  
Plasmid integrity was confirmed by restriction enzyme digestion for 1h at 37 °C with 
1U appropriate restriction enzyme (Fermentas, Hanover, MD) unless otherwise stated.  
Digested DNA fragments were separated on 0.8% (w/v) Tris-borate-EDTA (TBE) (89 
mM Tris base, 89 mM boric acid and 2 mM EDTA) agarose gels containing 2.5 mg/mL 
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ethidium bromide.  The gels were visualised either under short wavelength ultraviolet 
(UV) (245 nm) or long-wavelength (360 nm) illumination depending on requirements.  
O’GeneRuler™ 1kb DNA ladder (Fermentas, Hanover, MD) was used as a molecular 
weight marker on all agarose gels.  Digested DNA fragments were gel-purified using 
the QIAquick® Gel Extraction kit (Qiagen Gnbh, Hilden, Germany) and de-
phosphorylated using 1U rAPid Alkaline Phosphatase kit (Roche Diagnostics GmbH, 
Mannheim, Germany) according to the manufacturer’s instructions. 
 
Insert DNA was ligated into a plant expression vector in a 1:3 vector: insert ratio using 
the Fermentas ligate kit (Fermentas, Hanover, MD) according to manufacturer’s 
instruction.  The ligation mix is transformed into E. coli cells as describe in section 
3.2.4.  Putative positive colonies were screened by PCR with vector specific primers, 
with the PCR profile in section 3.2.5.  Recombinant plasmids were confirmed by 
restriction enzyme digest mapping. 
 
3.2.5 Gene amplification by PCR 
DNA sequences were amplified by PCR using primers listed in Chapter 8 Appendix B.  
PCR reactions were conducted in the BioRad Biocycler automated temperature cycler.  
All PCR reactions were carried out in 25 µL with 0.5 Units (U) of KAPA Taq DNA 
polymerase (KAPA Biosystems, South Africa), 1x buffer, 200 µM dNTPs, 2 mM MgCl2, 
200 µM of each primer and 1-5 ng of DNA template.  Cycles were performed using the 
following parameters: denaturation at 95 ˚C for 2 min, followed by 30 cycles of 
denaturation at 95 ˚C for 30 s, primer annealing for 30 s and extension at 72 ˚C for 30 
s.  A final elongation step at 72 ˚C for 5 min was performed.  The annealing 
temperature was adjusted depending on the primer set used. 
 
3.2.6 Sub-cloning of RVFV glycoprotein genes for sequencing  
Purified recombinant DNA was sub-cloned using a 1:3 vector:insert ratio into the 
pGEM®-T-Easy sequencing vector (Promega Corporation, Madison) according to the 
manufacturer’s instructions.  Ligated plasmid DNA was transformed into chemically 
competent E. coli DH5α cells (E. cloni ™, Lucigen, WI).  Transformed cells were 
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selected on LB agar plates with 100 µg/mL amp, 80 µg/mL X-gal (5-bromo-chloro-3-
indolyl-β-D-galactopyranoside) and 0.5 mM IPTG (Isoprophylthio-β-D-galactoside).   
 
Positive colonies were screened by PCR with M13 universal primers using the PCR 
profile described in 3.2.4, annealing at 65 ˚C.  Plasmid DNA from positive colonies 
was isolated, confirmed by restriction enzyme digest mapping and sequenced with 
M13 universal primers as described in 3.2.4.  
 
3.2.7 Cloning of glycoprotein genes into plant expression vectors 
Plant expression vector DNA was prepared for cloning by digestion with appropriate 
restriction enzymes, gel-purified and de-phosphorylated as described in 3.2.4.   
 
3.2.8 Cloning of WT strain RVFV GnGc glycoprotein gene 
3.2.8.1 Cloning of GnGc into pGEM®-T-Easy for sequencing  
The WT RVFV Gn and GnGc sequences were amplified from pSCRV6 by PCR using 
G1 Fw and G1 Rev as well as G1 Fw and G2 Rev gene-specific primers, respectively 
(primers sequences found in Table 1, Appendix B), annealing at 54 ˚C with the PCR 
profile described in section 3.2.5.  The DNA was resolved on an agarose gel and gel-
purified as described in section 3.2.4.  The purified DNA was ligated into pGEM®-T-
Easy as described in section 3.2.6.  Plasmid DNA was purified and recombinant 
pGEM®-T-Easy–Gn and pGEM®-T-Easy–GnGc clones confirmed by restriction 
enzyme digest mapping with EcoRI and SalI.  
 
3.2.8.2 Modification of Gn and GnGc glycoprotein for cloning into plant 
expression vectors 
The Gn and GnGc gene fragments were amplified from pGEM®-T-Easy-Gn and 
pGEM®-T-Easy-GnGc, respectively.  Gene amplification was performed by PCR with 
the following different pairs of primers (primer sequences in Table 1, Appendix B) to 
introduce the appropriate restriction enzyme sites for cloning into pRIC3.0 (Figure 3.2 
A) and pEAQ-HT (Figure 3.2 E) plant expression vectors: Gn NruI Fw and Gc XmaI 
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Rev; Gn NruI Fw and Gn XmaI Rev; Gn NruI Fw and Gc XhoI Rev; Gn NruI Fw and 
Gn XhoI Rev; Gn NcoI Fw and Gn XhoI Rev as well as Gn NcoI Fw and GnGc XhoI 
Rev respectively.  Gene amplification was performed using the PCR profile described 
in section 3.2.5 with the annealing temperature set at 55 ˚C.  Amplified DNA was gel-
purified as described in section 3.2.4.   
 
Gel-purified DNA was sub-cloned into pGEM®-T-Easy as described in section 3.2.6.  
The ligated plasmid DNA was transformed into E. coli C43 cells (Lucigen, WI) 
according to (Sambrook and Russell, 2001).  The cells were made competent 
according to Draper et al., 1988.  The resulting plasmids are found on Table 3.2.  
Recombinant plasmids were confirmed by restriction digest and sequenced with M13F 
and M13R universal primers as well as gene internal primers Appendix B, Table 1 (G1 
Fw979, G1 R1023, G2 Fw2693, G2 Rev2749). 
 
3.2.8.3 Cloning into pEAQ-HT  
The pEAQ-HT vector (Figure 3.1 E) was linearized by restriction enzyme digest with 
NruI and XmaI (for a C terminal 6xhis tag), SmaI and XhoI (for an N terminal 6xhis tag) 
and NruI and XhoI (for no 6xhis tag).  Gn and GnGc were excised from pGEM®-T-
Easy-GnNruI, pGEM®-T-Easy-GnSmaI, pGEM®-T-Easy-GnXhoI, pGEM®-T-Easy-
GnGcNruI, pGEM®-T-Easy-GnGcSmaI, and pGEM®-T-Easy-GnGcXhoI clones (Table 
3.1) with corresponding restriction enzymes and cloned into pEAQ-HT as described in 
section 3.2.7.  Putative positive colonies were screened by PCR using gene-specific 
primers pEAQ Fw and pEAQ Rev (primers sequences found in Table1, Appendix B) 
and PCR cycle parameters described in section 3.2.5, primer set annealing at 55 ˚C  
Recombinant DNA was isolated from bacterial cultures (see section 3.2.4) and the 
recombinant pEAQ-HT-his-Gn (c), pEAQ-HT-his-Gn (n), pEAQ-HT-Gn, pEAQ-HT-his-
GnGc (c), pEAQ-HT-GnGc (n) and pEAQ-HT-GnGc (see Table 3.2) plasmids were 
confirmed by restriction digest mapping with AfIIII (Roche Diagnostics GmbH, 




3.2.8.4 Cloning into pRIC3.0  
The pRIC3.0 geminivirus-derived replicating vector (Regnard et al., 2010) was 
linearized with AflIII and XhoI (Roche Diagnostics GmbH, Mannheim, Germany), gel-
purified and de-phosphorylated (section 3.2.4).  Gn and GnGc was excised from 
pGEM®-T-Easy-GnNcoI and pGEM®-T-Easy-GnGcNcoI with NcoI and XhoI.  The 
insert DNA was cloned into pRIC3.0 as described in section 3.2.7.  The ligation 
reactions were transformed into competent E. coli C43 cells as described 3.2.8.2.  
Putative positive colonies were screened by PCR using pTRAc-specific primers 
(Appendix B, Table1) using the PCR profile described in section 3.2.5.  The 
recombinant pRIC3.0-Gn and pRIC3.0-GnGc plasmids were verified by restriction 
enzyme digest mapping using BamHI and EcoRI, respectively.  
 
3.2.9 Cloning of human and Nicotiana sp. codon optimised RVFV GnGc  
The RVFV Nicotiana sp. (p) codon optimised pCC1-pGnGn (Figure 3.1 B) and human 
(h)-codon optimised pUC57-hGnGc (Figure 3.1 C) plasmids were transformed into 
chemically competent E. coli DH5α cells (E. cloni™, Lucigen, WI) as described in 
section 3.2.4. 
 
3.2.9.1 Modification of codon optimised Gn and GnGc genes for cloning into 
plant expression vectors 
pCC1-pGnGc was used as a template to amplify pGn and pGnGc for cloning into 
pEAQ-HT and pRIC3.0.  Enzyme cloning sites for inserting pGn into plant expression 
vectors were introduced by PCR with GnNcoI Fw and GnStuI pair and GnNcoI Fw and 
Gc Rev primer (primer sequences listed in Appendix B, Table 3,).  The PCR cycle 
profile is described in section 3.2.5, primers annealing at 53 ̊ C and 50 ̊ C, respectively.  
Amplified DNA was gel purified as described in section 3.2.4 and sub-cloned into 
pGEM®-T-Easy as described in section 3.2.6.  Recombinant plasmids pGEM®-T-Easy-
pGnAgel, pGEM®-T-Easy-pGnNcol, and pGEM®-T-Easy-pGnGcNcol were confirmed 
by restriction digest with AgeI and StuI and sequenced with M13F and M13R universal 





3.2.9.2 Cloning codon-optimised RVFV Gn and GnGc into pEAQ-HT  
RVFV pGn encoding sequence was excised from pGEM®-T-Easy-pGnAgeI (Table 
3.3), while the full length pGnGc and hGnGc were excised from pCC1-pGnGc and 
pUC57-hGnGc respectively, using appropriate restriction enzymes.  pEAQ-HT was 
linearized with the Agel and StuI restriction enzymes respectively.  pGn, pGnGc and 
hGnGc were cloned into pEAQ-HT as described in section 3.2.7 to generate pEAQ-
HT-pGn, pEAQ-HT-pGnGc and pEAQ-HT-hGnGc (Table 3.3). Recombinant plasmids 
were verified by PCR using pEAQ Fw and pEAQ Rev primers and confirmed by 
restriction digest mapping with AgeI and StuI.   
 
3.2.9.3 Cloning codon optimised RVFV Gn and GnGc into pRIC3.0  
pGn, and pGnGc sequences were subsequently excised from the pGEM®-T-Easy-
pGnNcol, and pGEM®-T-Easy-pGnGcNcol vectors, while hGnGc was directly cloned 
from pUC57-hGnGc with NcoI & Xmal and gel purified.  These were cloned into 
pRIC3.0 linearized with AflIII and XmaI as described in section 3.2.7.  Positive colonies 
were verified by PCR using pTRAc Fw and pTRAc Rev primers with the PCR profile 
in section 3.2.5.  Plasmid integrity of pRIC3.0-pGn by digest with EcoRI, and pRIC3.0-
hGnGc was confirmed by digestion with EcoRV while pRIC3.0-pGnGc was confirmed 
by digestion with BamHI. 
 
3.2.9.4 Cloning of codon optimised RVFV GnGc into the pTRAc and pTRAc-
ERH plant expression vectors 
Full length hGnGc was directly cloned from pUC57-hGnGc into the pTRAc (Figure 3.2 
B) and pTRAc-ERH (Figure 3.2 D) vectors as described in section 3.2.7.  The vectors 
were linearized with AflIII or NcoI and XhoI restriction enzymes respectively.  Positive 
colonies were verified by PCR with pTRAc vector-specific primers as described in 
section 3.2.5.  Recombinant pTRAc-hGnGc and pTRAc-ERH-hGnGc were confirmed 
by restriction mapping with EcoRI.  
 
3.2.10 Agrobacterium transformation  
A. tumefaciens LBA4404 and GV3101::pMP90RK cells were made electrocompetent 
using the method described by Shen and Forde (1989) (Shen and Forde, 1989).  One 
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hundred ng of the recombinant plasmid DNA was electroporated using a GenePulser 
(BioRad) into A. tumefaciens LBA4404 and GV3101::pMP90RK cells, respectively in 
1 mm gap electroporation cuvettes (Molecular BioProducts, USA) as described by 
Mclean et al., 2007 (Maclean et al., 2007).  Transformed Agrobacterium cells were 
plated on LB agar plates and grown as in section 3.2.3.  Recombinant Agrobacterium 
was verified by PCR using the PCR profile described in section 3.2.5 using vector 
specific primers listed in Table 1 (Appendix B). 
 
3.2.11 Transient expression of recombinant proteins 
Recombinant A. tumefaciens was grown in LB supplemented with the appropriate 
antibiotics to maintain selection of transformants.  Cultures containing the recombinant 
plasmids were cultured in induction medium (LB broth, 10 mM MES, 20 μM 
acetosyringone and 2 mM MgSO4, pH 5.6) containing antibiotics at 27 °C overnight.  
Bacteria were cultured to exponential phase (OD600 = 0.5) and centrifuged at low 
speed (4000 x g).  The pellet was re-suspended in infiltration buffer (10 mM MES, 10 
mM MgCl2, 150 μg acetosyringone/mL and 2% sucrose) and incubated at room 
temperature for two h.  The recombinant A. tumefaciens GV3101::pMP90RK and 
LBA4404 (pBIN-NSS) cells were diluted with infiltration medium to generate a final 
OD600 (UltraSpec™ 10) of 0.25 for each strain (total Agrobacterium OD600 of the 
suspension was 0.5).  The recombinant Agrobacterium LBA4404 was diluted to 
generate a final OD600 of 0.5. 
 
Six week old N. benthamiana plants were infiltrated with a 1 mL needleless syringe 
directly into the abaxial air spaces with recombinant Agrobacterium cultures.  Infiltrated 
leaves were harvested from 1 – 9 days post infiltration (dpi). 
 
3.2.12 Small scale protein extraction  
Four leaf discs (~ 8mm diameter) were harvested using an Eppendorf vial lid as a 
cutter, and ground in liquid nitrogen.  The protein was extracted with 250 µL buffer 
(100 mM Tris/HCl pH 7.5 and 1% Triton X-100), by vortexing for 1 min and incubation 
on ice for 10 min.  Crude plant extracts were clarified by centrifugation at 14 000 rpm 




3.2.13 Protein expression analysis 
For western blot analysis, the plant crude extracts were boiled at 95 ˚C for 5 min in 5x 
sample application buffer (5x SAB) (940 uL 10% SDS, 470 uL 1 M Tris/Cl pH 7.5 (250 
mM), 95 uL 100 mM EDTA, 205 uL β-mercaptoethanol, 2.45 mL glycerol, 0.2 mg 
Bromophenol blue (0.1%), 545 uL dH2O).  An equal amount of total soluble protein 
(TSP) were loaded in each well and separated on 10% sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis (PAGE).  For all western blots PageRuler™ 
Prestained Protein Ladder (Thermo Scientific, MA, USA) was used as a molecular 
weight marker.   
 
The proteins were transferred by semi dry blotting on nitrocellulose blotting membrane 
(Amersham™ Protran™ Premium 0.45 µm NC) using a Trans-blot®SD semi dry 
transfer cell (BioRad Power Pack 200) at 15 volts (V) for 1.5 h.  Following the transfer, 
membranes were blocked in blocking buffer (1 x PBS [137 mM NaCl, 10 mM Na2HPO4, 
2.7 mM KCl, 2 mM KH2PO4] at pH 7.4, 0.1% Tween-20 and 5% fat free milk).  After 
blocking, the membranes were incubated with polyclonal rabbit antibodies raised in 
rabbits inoculated with KLH-linked synthetic peptides derived from Gn (374-
CFEHKGQYKGTMDSGQTKRE-393) (GenScript, Piscataway, NJ, USA) as described 
by de Boer et al., 2010 (de Boer et al., 2010) or incubated with 6xhis antibody.  The 
membranes were washed four times with blocking buffer for 15 min each and 
subsequently incubated with alkaline phosphatase-conjugated goat anti-rabbit 
antibody (1: 7000, Sigma Aldrich) or alkaline phosphatase-conjugated goat anti-
mouse antibody (1:7000, Sigma Aldrich) in blocking buffer for 1 h at 37 ˚C.  This was 
followed by four washes, 15 min each, with wash buffer (1x PBS pH 7.4, 0.1% Tween-
20).  Blots were developed using 5-bromo-4-chloro-3-indolyl phosphate/Nitro blue 
tetrazolium chloride (BCIP/NBT 1-component, KPL) as a substrate.  Protein 
expression, extraction and western blot analysis were repeated at least three times to 




3.3 Result  
 
3.3.1 Cloning of WT Gn and GnGc 
RVFV WT GnGc was successfully amplified from pSCRV6 and cloned into the 
pGEM®-T-Easy to yield pGEM®-T-Easy-GnGc.  The 3885 nucleotide sequence was 
confirmed to be 100% homologous to the ZH548 M12 strain from Egypt in 1977 
(GenBank accession no NC_014396) as expected.   
 
In addition, Gn was amplified from pSCRV6 and sub-cloned into pGEM®-T-Easy to 
yield pGEM®-T-Easy-Gn (Table 3.2).  Gn and GnGc were subsequently successfully 
amplified in order to attach appropriate restriction sites for cloning into pEAQ-HT and 
pRIC3.0 plant expression vectors.  Amplified Gn and GnGc fragments were cloned 
into the pEAQ-HT vector using different restriction enzyme sites such that both Gn 
and GnGc could be expressed with a N terminal 6xhis tag (pEAQ-HT-GnGc (n); pEAQ-
HT-Gn (n)), a C terminal 6xhis tag (pEAQ-HT-GnGc (c); pEAQ-HT-Gn (c)) or no 6xhis 
tag (pEAQ-HT-GnGc; pEAQ-HT-Gn) – Table 3.2.  Amplified GnGc and Gn fragments 
were also successfully cloned into pRIC3.0 resulting in pRIC3.0-GnGc and pRIC3.0-
Gn, respectively (Table 3.2).  Recombinant clones were confirmed successfully by 











Table 3.2: Wild type Rift Valley Fever ZH548 M12 strain Gn and GnGc glycoprotein 
encoding plasmids.  Refer to the Appendix B (Table 1) for primer sequences. 
 
 
3.3.2 Expression of WT Gn and GnGc in N. benthamiana  
All plant expression constructs made in Section 3.3.1 were infiltrated into N. 
benthamiana and plants were sampled from 2 to 9 days post infiltration (dpi) in order 
to screen for recombinant Gn and GnGc expression by western blotting of crude leaf 
extracts.  The Gn and GnGc glycoprotein transient expression time trial showed no 
physiological or morphological differences observed between the experiment and the 
control plants.  However, the expected protein band sizes of 60.9 kDa for WT Gn and 
112.0 kDa for WT GnGc could not be detected with Gn-specific antibodies or the 6xhis 
antibody. 
 
3.3.3 Cloning of human (h) and N. benthamiana (p) codon optimised Gn and GnGc 
It was thought that the reason for the lack of detection of WT Gn or GnGc in crude N. 
benthamiana extracts may have been because the gene sequence used was not 
codon optimised for optimal host expression.  Thus, 2 new gene sequences, namely 
a Nicotiana sp. and a human-codon optimised gene, were synthesised, cloned into 
various plant expression vectors and screened for recombinant protein expression 




3.3.3.1 Analysis of Nicotiana sp. and human-codon optimised GnGc 
RVFV GnGc of the South African M35/74 strain was selected as it was considered to 
be more relevant in the South African context and sequence analysis showed 95% 
protein homology to the WT RVFV ZH548 strain, with 11 aa differences.  The 3225 bp 
sequence was Nicotiana sp. codon optimised and human-codon optimised.  Sequence 
analysis showed that Nicotiana sp. codon optimised GnGc was 79.50% homologous 
to the WT M35/74 strain, while human-codon optimised GnGc was 77.31%.  Plant-
codon optimisation resulted in a lower GC content of GnGc compared to the WT 
M35/74 GnGc, decreasing from 50% to 41%.  Human-codon optimisation resulted in 
a higher GC content of GnGc increasing from 50% to 56.39%.  Both genes were 
successfully assembled and cloned into pCC1 and pUC57 respectfully by GenScript 
(GenScript Biotechnologies, Piscataway, NJ, USA).  GnGc and Gn were subsequently 
cloned into the following plant expression vectors to determine and compare 
expression: there were pEAQ-HT, pRIC3.0 and pTRAc. 
 
3.3.3.2 Cloning of Gn and GnGc into the pEAQ-HT expression vector 
Nicotiana sp. and human-codon optimised GnGc were successfully cloned directly into 
pEAQ-HT to yield pEAQ-HT-pGnGc and pEAQ-HT-hGnGc (Table 3.3).  The plant-
codono ptimised pGn was amplified by PCR to introduce enzyme cloning sites for the 
vector and sub-cloned into pGEM®-T-Easy successfully to yield pGEM®-T-Easy-pGn.  
Restriction enzyme mapping and sequencing confirmed the construct.  pGn was 
subsequently cloned successfully into pEAQ-HT to yield pEAQ-HT-pGn (Table 3.3).  
Restriction enzyme digest mapping of the final plasmids gave the expected DNA 
banding pattern.  pEAQ-HT-pGnGc resulted in DNA bands of the expected sizes of 
9947 and 3222 bp (Figure 3.3 A), while pEAQ-HT-pGn showed the expected banding 
pattern of 9947, 1698, 73 bp (Figure 3.3 B).  Digestion of pEAQ-HT-hGnGc resulted 
in the expected DNA band sizes of 3069, 2639, 2580, 2345, 1414, 1005 and 122 bp 







Table 3.3: Codon optimised RVFV glycoproteins from South Africa M35/74 strain 





Figure 3.3: Restriction enzyme digest mapping of codon optimised RVFV Gn and GnGc with EcoRV in 
the CPMV-based hyplerslatable expression vector.  A) pEAQ-HT-pGnGc (9947, 3222 bp), B) pEAQ-
HT-pGn (9942, 1698, 17 bp), C) pEAQ-HT-hGnGc (3069, 2639, 2580, 1414, 1005, 122).  Lane M 
represents the 1 kb O’GreenGene ruler used as a DNA ladder.  DNA was resolved on 0.8% (w/v) TBE 
agarose gel. 
 
3.3.3.3 Cloning of Gn and GnGc into the pRIC3.0 plant expression vector 
Human-codon optimised hGnGc was directly cloned into the vector resulting in 
pRIC3.0-hGnGc.  Restriction enzyme digest mapping gave the expected DNA banding 
pattern of 8159, 953 bp (Figure 3.4 A).  pGn and pGnGc were amplified by PCR to 
48 
 
introduce enzyme cloning sites for the vector and sub-cloned into the sequencing 
vector and successfully cloned into pRIC3.0.  Restriction digest mapping gave the 
expected DNA banding pattern for pRIC3.0-pGn (6544, 1080 bp) (Figure 3.4 B) and 
pRIC3.0 – pGnGc (5452, 2495, 727, 362 bp) (Figure 3.4 C).   
 
 
Figure 3.4: Verification of codon optimised Gn and GnGc in the self-replicating pRIC3.0 plasmids.  A) 
pRIC3.0-hGnGc (8159, 953 bp) with EcoRV, B) pRIC3.0-pGn (6544, 1080 bp) EcoRI and C) pRIC3.0-
pGnGc (5452, 2495, 727, 362 bp) digested with BamHI.  Resolved on 0.8% (w/v) TBE agarose gel.  
The 1 kb O’GreenGene ruler was used as a DNA ladder is presented by lane M. 
 
3.3.3.4 Cloning of GnGc into the pTRAc vectors 
hGnGc was directly cloned, successfully from pUC57-hGnGc into pTRAc, the 
cytoplasm targeting and pTRAc-ERH, the endoplasmic reticulum (ER) organelle 
targeting vectors (Table 3.3).  Restriction enzyme digest mapping confirmed the 
constructs.  Expected DNA band sizes for digestion of pTRAc-ERH-hGnGc (6766, 





Figure 3.5: Restriction enzyme digest mapping with of pTRAc plasmids with EcoRV of human-codon 
optimised RVFV polyproteins expression plasmids.  A) mapping in non-replicating expression vector 
which targets protein expression in the ER.  B) mapping in a non-replicating vector pTRAc which allows 
expression in the cytoplasm.  1 kb O’GreenGene ruler (M) was used as a DNA ladder.  DNA was 
resolved on 0.8% (w/v) TBE agarose gel. 
 
3.3.3.5 Expression analysis of recombinant Gn and GnGc 
All recombinant expression plasmids were successfully electroporated into the 
appropriate A. tumefaciens cells.  N. benthamiana leaves were infiltrated with 
recombinant Agrobacterium cultures and expression was determined by western 
blotting of crude leaf extracts harvested at various dpi and probing with the appropriate 
antibodies.  However, bands corresponding to the Gn and GnGc proteins of expected 
sizes of ~60 and 116.3 kDa, respectively, still could not be detected at any time points 




RVFV VLPs have been made in mammalian and bacterial expression systems as 
candidate vaccines by expressing Gn and GnGc (de Boer et al., 2010; Kortekaas et 
al., 2012; Wallace et al., 2006).  This is the first time an attempt has been made to 
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express RVFV GnGc glycoproteins in tobacco.  An attempt has been made recently 
to express a mutated Gn in Arabidopsis (Kalbina et al., 2016).  Compared to the other 
expression systems used, plants are easy to use, inexpensive, are scalable and do 
not require biosafety containment (Rybicki, 2009; Rybicki, 2010).  These advantages 
are very suitable for production of recombinant protein products such as vaccines in 
African countries, where low costs are desirable and they are often the source of target 
diseases which are mainly endemic.  In addition, there have been several examples 
of successful VLP production in plants. 
 
Initially, I tested whether a readily available WT RVFV ZH548 M12 strain GnGc could 
be first, expressed transiently in N. benthamiana when cloned into 2 different plant 
expression vectors, pEAQ-HT and pRIC3.0 and second, if so, whether it assembled 
into VLPs.  The reason for testing 2 different vectors was because these vectors direct 
expression in different ways, and it has been shown that optimising recombinant 
protein expression in planta is highly empirical.  Gn was also tested for expression, as 
it has been shown by de Boer et al. 2010 (de Boer et al., 2010; Wallace et al., 2006) 
that Gn on its own can be appropriately immunogenic.  Western blotting was the 
technique used for detection, since it was suggested that if expression occurred, albeit 
low, that western blotting would be sensitive enough for detection of any expressed 
protein.  It was suggested that the lack of detection could be due to antibody not 
binding to any of the expressed protein.  Hence, the genes were cloned into pEAQ-
HT such that they resulted in being fused to a 6xhis tag, either on the 5’ terminus or 
the 3’ terminus.  This was to facilitate detection of expressed protein using an anti-
6xhis antibody.  Attaching the histidine tag at the N- or C-terminal was to ensure that 
the tag does not prevent correct protein folding which might result in lack of protein 
expression or detection.  However, recombinant GnGc or Gn protein expression was 
still not detected using this strategy either. 
 
The lack of recombinant protein detection could also be due to the possibility that the 
plasmid encoding the gene of interest was no longer present in the host Agrobacterium 
cells.  On carrying out PCR on DNA extracted from the cells, this was found to be the 
case.  They were all negative; the plasmids could not be detected by PCR or restriction 
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enzyme digest.  The recombinant gene seemed to be toxic to bacterial culture.  This 
could be a result of gene toxicity to the cells, as it has been previously demonstrated 
that the full length GnGc is toxic to E. coli, even in the absence of detectable protein 
expression (Kakach et al., 1988).  
 
One of the reasons for lack of expression could be the lack of use of codon optimised 
sequences.  Proteins are generally difficult to express outside their host since they 
might contain codons that are rarely used in the desired expression system or 
expression limiting regulatory elements within their coding sequence.  It was thus 
decided to address this problem of lack of expression in N. benthamiana by testing 
codon optimised GnGc and Gn instead.  
 
The degeneracy of the generic code allows different codon sequences to encode the 
same amino acids (Gouy and Gautier, 1982), making codon-use optimisation possible.  
Codon optimisation has been widely used to enhance protein expression in 
heterologous systems by exchanging codons which are rarely found in the host 
organism, with frequently used codons.  This was demonstrated by (Maclean et al., 
2007) when they expressed plant- and human-codon optimised HPV 16 and found 
that the human-codon optimised gene gave much higher expression levels than the 
plant-codon optimised gene.  Gao et al., 2004 (Gao et al., 2004) revealed that the 
main obstacle to human immunodeficiency virus DNA-based vaccines is the low 
expression levels of the genes, which is attributed to rare codon usage and AU-rich 
elements.  The frequencies at which the various codons are used varies significantly 
between different organisms, between proteins expressed at high or low levels within 
the same organisms (Knight RD et al., 2001).  Codon usage is involved in the control 
of transcription, splicing and RNA structure (Cannarozzi et al., 2010; Gu et al., 2010; 
Tuller et al., 2010). 
 
For this study, it was decided to synthesise a RVFV GnGc gene from a South African 
strain, making it more relevant to the South African situation.  The RVFV isolate 
M35/74 was codon optimised for both the Nicotiana sp. expression host as well as for 
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human expression, since it has been shown in some cases that increases in 
expression levels are not necessarily attributed to expression host, but to GC content.  
Despite being a different strain to that originally tested, I did not expect this to influence 
the development of the revised strategy.  The N. benthamiana sp. codon optimised 
gene shared 79.5% of nucleotide sequence identity with the WT gene.  A total of 754 
nucleotides were changed and the G+C content decreased from 50% to 41.6%.  The 
human optimised gene shared 77.31% nucleotide sequence identity with the WT gene.  
A total of 709 nucleotides (see Chapter 8, Appendix A) were changed and the G+C 
content increased from 50% to 56.39%.  The plant- and human-codon optimised 
genes shared 71.37% nucleotide identity.  The WT gene employs tandem rare codons 
that can reduce the efficiency of translation or even disengage the translation 
machinery (Webster et al., 2016).  The codon usage bias was optimised with a codon 
adaptation index, which measures the degree of preference at which the 
host/organism prefers specific codon (Carbone et al., 2003), to be 0.87.  The stem-
loop structures, which impact ribosomal binding and stability of mRNA, were disrupted, 
which may be an advantage. 
 
For the plant-codon optimised genes, Gn and GnGc were cloned into pEAQ-HT and 
pRIC3.0 while human-codon optimised GnGc encoding genes were successfully 
cloned into three different plant expression vectors.  The pTRAc suite of plant 
expression vectors which allow protein expression and subsequent targeting to 
different plant organelles such as the ER or cytoplasm may have an effect in protein 
expression.  The expression and targeting of heterologous proteins to different plant 
organelles has been previously demonstrated to significantly enhance protein 
expression (Maclean et al., 2007; Mortimer et al., 2012).  The use of pRIC3.0, which 
allows vector replication in planta (Regnard et al., 2010), also resulted in the lack of 
recombinant protein expression.  The genes were cloned into the CPMV based pEAQ-
HT plant expression vector which enhances recombinant protein expression when 
they are cloned downstream of the UTR (Sainsbury et al., 2008; Sainsbury et al., 
2009a).  However, gene codon optimisation and compartmentalisation seemed to 





The native signal peptide is required for the proteolytic processing of the GnGc 
precursor molecules into mature envelope glycoproteins.  The Gn hydrophobic domain 
acts as a signal peptide when translation initiates at the second, fourth or fifth ATG by 
leaky scanning of the host translational mechanism (Gerrard and Nichol, 2002).  The 
native signal peptide might be poorly recognised by the plant’s mechanism, which 
could result in lack of or impaired ribosomal binding for protein translation, thus no 
protein expression.  The secretion of foreign proteins is often enhanced by fusion of a 
signal peptide at the N-terminus of a protein that allows entry into the vesicular 
transport system of the specific host.  The complete lack of expression of any RVFV 
GnGc recombinant proteins led to the decision to work only with Gn, in order to 
troubleshoot the lack of expression problem.  Gn was also selected as it has been 
shown to be immunogenic on its own, and to elicit protection (de Boer et al., 2010; 




Chapter 4: The modification and expression of RVFV Gn as a candidate subunit 
vaccine 
 
4.1 Introduction  
 
Viral glycoproteins are often synthesised as precursors containing a 5’ signal peptide 
or leader sequence.  Signal peptide sequences contain 15 – 30 amino acid residues, 
which are involved at the start of the secretion pathway (Milstein et al., 1972).  Signal 
peptide sequences are not conserved, but they share certain structural features, such 
as a positively charged N-terminal region, a central hydrophobic core and a polar 
carboxyl-terminal region with a peptidase cleavage site (Milstein et al., 1972; Perlmann 
et al., 1967).  They usually direct the proteins across the membrane of the ER and are 
cleaved off within the lumen by a signal peptidase.  Translocation of proteins from the 
cytosol into the ER mediated by the signal peptide is an imperative step in protein 
secretion.  The secretion process leads to the accumulation of recombinant protein in 
different plant organelles such as the cell membrane, apoplastic space or the ER 
(Yoshida et al., 2004).  Different signal peptides for the same recombinant proteins 
can significantly affect the amount of protein produced: this has been demonstrated 
successfully in various production systems (Chen et al., 2016; Haryadi et al., 2015; 
Herrera-Estrella et al., 1990; Herrera et al., 2000; Shahryari et al., 2013; Singh et al., 
2013; Tamura et al., 2008).  For example, the use of a murine signal peptide 
sequences (Fischer et al., 1999b; Fischer et al., 1999c; Shahryari et al., 2013) for 
recombinant single-chain antibody production in planta has been successful; the 
secretion of HIV type 1 envelope glycoprotein gp 120 in mammalian cells was 
improved when the native signal sequence was replaced with a leader sequence from 
pJW4303 vector (Wang and Roossinck, 2006), honeybee mellitin or murine interleukin 
(Li et al., 1994); the use of tissue plasminogen activator and Gaussia luciferase signal 
peptides were also successfully demonstrated in the expression and secretion of E1 
and E2 envelope glycoproteins of hepatitis C virus in mammalian cells (Eddy and 




RVFV GnGc has a native signal peptide which is required for proteolytic processing of 
the GnGc precursor molecules into mature envelope glycoproteins (Gerrard and 
Nichol, 2002).  In this work, in an effort to develop a Gn candidate vaccine for RVFV, 
two modifications were carried out to Gn to determine whether it could be expressed 
in planta.  The first involved the removal of the native 5’ signal sequence and 
substitution with an alternative one; the second involved the removal of the 
transmembrane domain and cytosolic tail (TMD/CT) region of Gn.  For substitution of 
the N-terminal signal sequence of Gn, two different heterologous signal peptides were 
selected (Table 4.1): these were the protein disulphide isomerase (PDI) signal peptide 
of Medicago sativa L. (Shorrosh and Dixon, 1991; Shorrosh and Dixon, 1992), which 
is an ER luminal protein that aids the formation of disulphide bonds of nascent 
polypeptide chains in the lumen (Houston et al., 2005); and a plant-codon optimised 
murine mAb24 heavy chain signal sequence (LPH) (Fischer et al., 1999b; Vaquero et 
al., 1999), which targets proteins into the ER.   
 
Table 4.1: Rift Valley fever wild type and heterologous signal peptides substituted at 
the N-terminus of Gn 




Murine mAb24 MEWSWIFLFLLSGTAGVHS 19 LPH 
Medicago sativa. L Alfalfa MAKNVAIFGLLFSLLLLVPSQIF 23 PDI 
Bunyaviridae RVFV WT  MAGIAMTVLPALAVFALAPVVF 22 homologous  
 
The second modification involved truncating Gn by deleting the TMD/CT sequences.  
Gn is a type 1 integral membrane protein: it spans the viral membrane in such a 
manner that the C-terminal (cytosolic) tail points towards the intraviral space, while the 
N-terminal part is in contact with the outer environment (ecto-domain) (Strandin et al., 
2013).  Correct folding, heterodimerization and trafficking of the enveloped 
glycoprotein is important for Golgi-located assembly and budding of virus particles 
(Gerrard and Nichol, 2002). 
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This chapter describes the testing of the different heterologous signal peptides for 
expression of South African isolate M35/74 Gn in N. benthamiana with a view to 
developing it as a candidate subunit vaccine.  The expression of modified Gn with PDI 
or LPH signal peptide with and without a TMD/CT were tested using different plant 
expression vectors.  N. benthamiana plants were syringe-infiltrated with recombinant 
Agrobacterium encoding the different genes, and their expression was determined by 
western blotting.  The modified recombinant protein was enriched for by ammonium 
sulphate precipitation and purified by ion exchange chromatography.  Protein 
concentration was quantified by using bovine serum albumin as a standard.   
 
4.2 Materials and Methods 
 
4.2.1 Cloning and sequencing of constructs 
All bacterial and plant growth conditions were as described in section 3.2.3.  All DNA 
manipulation and analysis was carried out as described in section 3.2.4.  Gn 
modifications were made by PCR, with the PCR profile described in section 3.2.5.  All 
PCR primer sequences are listed in Table 2, Appendix B.  The modified RVFV Gn 
(pGn and hGn) genes were sub-cloned into pGEM®-T-Easy vector as described in 
section 3.2.6.  The constructs were verified by restriction enzyme mapping and 
sequencing with M13 universal primers (Macrogen Inc.).  The modified genes were 
subsequently cloned into plant expression vectors (pTRAc, pTRAc-ERH and pEAQ-
HT) as described in section 3.2.7. 
 
4.2.2 Modification of N. benthamiana codon optimised pGn and construction of 
plasmids 
4.2.2.1 Removal of native 5’ signal peptide from pGn to form ∆pGn 
∆pGn was amplified from pGEM®-T-Easy-pGnNcoI (section 3.2.8.4) using Gn∆SP Fw 
and GnStuI Rev primers (Table 3, Appendix B) annealing at 55 ˚C and sub-cloned into 
pGEM®-T-Easy to yield pGEM®-T-Easy-∆pGn.  The construct was verified by 
restriction enzyme digest using NotI.  ∆pGn was subsequently cloned from pGEM®-T-
Easy-∆pGn using restriction enzymes NcoI and XhoI into pTRAc AflIII and XhoI 
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restriction enzyme cloning sites, to yield pTRAc-∆pGn.  The construct was verified by 
restriction enzyme digest mapping with EcoRV. 
 
4.2.2.2 Truncation of transmembrane domain and cytosolic tail (TMD/CT) from 
pGn to form truncated pGn (ptGn) 
ptGn was amplified by PCR from pGEM®-T-Easy-pGn using GnNcoI Fw and tGnXhoI 
Rev using a 55 ˚C annealing temperature.  Amplified DNA was sub-cloned into 
pGEM®-T-Easy to yield pGEM®-T-Easy-ptGn.  This construct was verified by 
restriction enzyme digest using NotI.  tGn was subsequently cloned from pGEM®-T-
Easy-ptGn using restriction enzymes NcoI and XhoI into pTRAc AflIII and XhoI 
restriction enzyme cloning sites to yield pTRAc-ptGn.  The recombinant plasmid was 
verified by restriction enzyme digest mapping with EcoRV. 
 
4.2.2.3 Truncation of TMD/CT from ptGn to form ∆ptGn 
∆ptGn was amplified from pGEM®-T-Easy-ptGn using Gn∆SP Fw and tGnXhoI Rev 
primers at 50 ˚C annealing temperature and sub-cloned into pGEM®-T-Easy to yield 
pGEM®-T-Easy-∆ptGn.  The construct was verified by restriction enzyme digest with 
NotI.  ∆ptGn was subsequently cloned from pGEM®-T-Easy-∆ptGn using restriction 
enzymes NcoI and XhoI into pTRAc AflIII and XhoI restriction enzyme cloning sites to 
yield pTRAc-∆ptGn.  The recombinant construct was verified restriction enzyme digest 
mapping with EcoRV. 
 
4.2.2.4 Addition of PDI signal peptide to ∆pGn and ∆ptGn to form PDI-∆pGn 
and PDI-∆ptGn 
PDI-∆pGn and PDI-∆ptGn were constructed by overlap extension PCR (Figure 4.1).  
The signal peptide of PDI from Medicago sativa L., was amplified from a pre-existing 
construct in the laboratory (pUC57-3ABC synthesised by GenScript) with Primer 1 Fw 
and PDI rev Table 3, Appendix B) primers and an annealing temperature of 55 ˚C 
resulting in PDI with ∆pGn 5’ overhang.  ∆pGn with PDI 3’ overhangs were amplified 
by with Gn_PDI Fw and Gn Rev/ tGnXhoI Rev primers, and annealing at 50 ˚C.  
Amplified PDI with ∆pGn 5’overhangs were fused with ∆pGn with PDI 3’ overhangs by 
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overlapping PCR with Primer 1 Fw and GnStuI Rev, annealing at 55 ˚C.  Amplified 
PDI-∆pGn was sub-cloned into pGEM®-T-Easy to yield pGEM®-T-Easy-PDI-∆pGn and 
pGEM®-T-Easy-PDI-∆ptGn.  The constructs were verified with NotI restriction enzyme. 
 
 
Figure 4.1: Schematic diagram for amplification and overlap extension of PDI signal peptide with 
modified Gn. 
 
PDI-∆pGn and PDI-∆ptGn were subsequently cloned from pGEM®-T-Easy-PDI-∆pGn 
and pGEM®-T-Easy-PDI-∆ptGn with NcoI and XhoI into pTRAc with AflIII and XhoI 
restriction enzyme cloning sites, as well as with Cfr91 and XhoI into pEAQ-HT AgeI 
and XhoI restriction enzyme sites to yield pTRAc-PDI-∆pGn, pTRAc-PDI-∆tpGn, 
pEAQ-HT-PDI-∆pGn and pEAQ-HT-PDI-∆ptGn, respectively.  Recombinant pTRAc-
PDI-∆pGn, pTRAc-PDI-∆tpGn plasmid integrity was confirmed by restriction enzyme 
digest mapping with EcoRV and pEAQ-HT-PDI-∆pGn and pEAQ-HT-PDI-∆ptGn 




4.2.2.5 Addition of LPH signal peptide sequence to ∆pGn and ∆ptGn to form 
LPH-∆pGn and LPH-∆ptGn 
∆pGn and ∆ptGn were cloned from pGEM®-T-Easy-∆pGn and pGEM®-T-Easy-∆ptGn 
into pTRAc-ERH, introducing the LPH signal peptide on the 5’ terminus using NcoI 
and XhoI restriction enzymes.  This resulted in pTRAc-LPH-∆pGn and pTRAc-LPH-
∆ptGn.  The integrity of the recombinant plasmids was confirmed by restriction enzyme 
mapping with EcoRV. 
 
In order to make pEAQ-HT-LPH-∆pGn and pEAQ-HT-LPH-∆ptGn (Figure 4.2), ∆pGn 
and ∆ptGn were excised from pGEM®-T-Easy-∆pGn and pGEM®-T-Easy-∆ptGn with 
NcoI and XhoI restriction enzymes.  The fragments were ligated into pUC18-LPH 
which was linearized with NcoI and XhoI, to yield pUC18-LPH-∆pGn and pUC18-LPH-
∆ptGn plasmids which were confirmed by PCR with M13 primers annealing at 65 ˚C 
and restriction enzyme mapping with Agel and SalI. 
 
 
Figure 4.2: Schematic diagram representing the construction of pEAQ-HT plasmids with LPH fused to 
∆ptGn and ∆htGn.  
 
LPH-∆pGn and LPH-∆ptGn DNA was subsequently excised from pUC18-LPH-∆pGn 
and pUC18-LPH-∆ptGn with Agel and XhoI restriction enzymes.  The pEAQ-HT vector 
was linearized with Agel and XhoI restriction enzymes.  The insert DNA was cloned 
60 
 
into pEAQ-HT to yield pEAQ-HT-LPH-∆pGn and pEAQ-HT-LPH-∆ptGn.  The integrity 
of the recombinant vectors was confirmed with Agel and StuI. 
 
4.2.3 Modification of human-codon optimised Gn (hGn) and construction of plasmids 
4.2.3.1 Substitution of 5’ signal peptide sequence and truncation of TMD/CT 
∆htGn was amplified from human-codon optimised GnGc (pUC57-hGnGc) using 
∆hGn Fw and htGn Rev primers, annealing temperature at 50 ˚C.  Amplified DNA was 
sub-cloned into pGEM®-T-Easy to yield pGEM®-T-Easy-∆htGn.  The construct was 
confirmed by restriction enzyme mapping with EcoRV. 
 
In order to make pTRAc-LPH-∆htGn, ∆htGn was excised from pGEM®-T-Easy-∆htGn 
using NcoI and XhoI restriction enzymes and cloned into pTRAc-ERH, introducing the 
LPH signal peptide, using NcoI and XhoI restriction enzyme cloning sites to yield 
pTRAc-LPH-∆htGn.  The recombinant clone was confirmed by restriction enzyme 
digest with EcoRV according to the manufacturer’s instruction. 
 
In order to make pEAQ-HT-LPH-∆htGn (Figure 4.2), ∆htGn was excised from pGEM®-
T-Easy-∆htGn using NcoI and XhoI restriction enzymes into pUC18-LPH, resulting in 
pUC18-LPH-∆htGn.  The plasmid was screened by PCR with M13 universal primers, 
annealing at 65 ˚C and restriction enzyme digest with AgeI and SalI.  Insert DNA was 
excised from pUC18-LPH-∆htGn with Agel and SalI restriction enzymes.  The pEAQ-
HT vector was linearized with Agel and XhoI restriction enzymes and cloned into 
pEAQ-HT to yield pEAQ-HT-LPH-∆htGn.  The integrity of the recombinant plasmid 
was confirmed by restriction enzyme mapping with Agel and StuI. 
 
4.2.4 Agrobacterium transformation and recombinant protein expression  
The recombinant plasmids were transformed by electroporation into A. tumefaciens 
GV3101::pMP90RK and A. tumefaciens LBA4404 respectively, as described in 
section 3.2.10.  A preliminary expression time trial was conducted by syringe infiltration 
as described in section 3.2.11.  Crude plant extract was obtained as described in 
section 3.2.12.  The concentration of total soluble protein (TSP) in the crude extract 
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was determined by Bradford assay using BSA (Sigma-Aldrich, MO, USA) as a 
standard.  Protein expression was analysed by western blotting as described in section 
3.2.13. 
 
4.2.5 Optimal buffer composition  
Four different buffers were tested for protein extraction efficiency from infiltrated 
leaves:  
1. 100 mM Tris/HCl, pH 7.5 + 1% Triton X-100 
2. 10 mM Tris/HCl, pH 7.5, 1 mM EDTA, 100 mM NaCl 
3. 20 mM Na2HPO4, 150 mM NaCl 
4. 100 mM Tris/HCl pH 7.5 
Crude plant protein was extracted as described in section 3.2.12 and protein 
expression was analysed by western blotting as described in section 3.2.13. 
 
4.2.6 Large scale protein expression 
Recombinant Agrobacterium cultures were grown in LBB medium (trytone 2.5 g/L, 
yeast extract 12.5 g/L, NaCl 5 g/L) supplemented with 10 mM MES, pH 5.6, 20 µM 
acetosyringone, 50 µg/mL kan and 2 mM MgSO4 until they reached an OD600 of 
between 3 and 4.  Agrobacterium cultures were subsequently diluted to an OD600 of 
0.25 in resuspension medium (10 mM MgCl2 and 5 mM MES, pH 5.6).  Six week old 
whole plants of N. benthamiana were placed upside down in the bacterial suspension 
culture in an airtight steel tank under vacuum of -90 to -100 kPa.  Following vacuum 
infiltration the plants were returned to the plant growth room for 5 days incubation 
period until harvest.  
 
4.2.7 Protein purification of pEAQ-HT-LPH-∆ptGn 
4.2.7.1 Ammonium precipitation  
Plant material was harvested at 5 dpi.  Crude plant protein was extracted with 100 mM 
Tris/HCl pH 7.5 in 1:2 w/v plant to buffer ratio with a food blender (HBF500S Series, 
Hamilton Beach) and filtered twice through two layers of Miracloth™ (EMD Millipore 
Corp., Billirica, MA USA).  The crude extract was clarified by centrifugation at 13 000 
rpm, for 20 min at 4 ˚C four times or until the pellet was no longer visible at the bottom 
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of the tube.  Ammonium sulphate precipitation was performed with series of increasing 
(NH4)2SO4 (0 – 40%, 40 – 60% and 60 – 80%) (Englard and Seifter, 1990).  The 
amount of solid (NH4)2SO4 required was calculated using the online tool available at 
http://ww.encorbio.com/protocols/AM-SO4.htm.  The solid (NH4)2SO4 was added 
slowly to the crude protein and kept at 4 ˚C, stirring for 1 hr.  The protein was pelleted 
by centrifugation at 13 000 rpm, 20 min at 4 ˚C.  The protein pellet was re-suspended 
with half the original buffer volume with 50 mM NaOAc, pH 5.6 and was dialysed O/N 
at 4 ˚C using dialysis tubing with a molecular weight cut-off of 10 kDa (Thermo Fischer 
Scientific, USA) in 5L against the same buffer.  The extract was clarified by 
centrifugation at 13 000 rpm, 4 ˚C, for 20 min.  Clarification was repeated four times 
or until the pellet disappeared.  
 
4.2.7.2 Ion Exchange Chromatography 
The partially purified LPH-∆ptGn was filtered firstly through a 0.45 µm and 
subsequently through a 0.2 µm membrane filter (Merck Millipore).  The protein was 
loaded on a 20 mL HiPrep SP XL 16/10 cation column (GE Healthcare) and purified 
with an automated fast protein liquid chromatography (FPLC) system ÄKTA Purifier 
Plus 10 (GE-Healthcare Life Sciences).  Non-specific proteins were washed off the 
column with 10 column volumes (CV) of buffer B (50 mM NaOAc pH 5.6).  Thereafter, 
10 CV of buffer C (50 mM NaOAc, pH 5.6, 1M NaCl) was applied to elute the target 
protein.  Five mL fractions were collected with a fraction collector and absorbance 
readings at 280 nm of each fraction was determined.  The protein containing fractions 
were dialysed O/N at 4 ˚C using dialysis tubing with a molecular weight cut-off of 10 
kDa (Thermo Fischer Scientific, USA) in 1L sterile 100 mM Tris/HCl pH 7.5.  The 
fractions were collected and stored at -80 ̊ C for further analysis.  A non-infiltrated plant 
was included as a negative control. 
 
Endotoxin levels were measured using the ToxinSensor™ Chromogenic LAL 
Endotoxin Assay Kit (GenScript Biotechnologies, Piscataway, NJ, USA) as per the 
manufacturer’s instructions. The presence of contaminant bacteria was tested for by 




4.2.8 Protein expression analysis 
Purified protein was resolved on SDS-PAGE gels and analysed by western blot as 
described in section 3.2.13.  Proteins were also resolved on SDS-PAGE gel and 
stained with Coomassie-blue (0.1% Brilliant Blue R-250, 50% methanol and 10% 
glacial acetic acid).  Total soluble protein present in the collected fractions was 
determined using the Bio-Rad Protein Assay according to the manufacturer’s 
instructions.  Bovine serum albumin (BSA, Sigma-Aldrich) was used as protein 
standard and the absorbance was read at 750 nm using a Bio-Tek Powerwave XS 
spectrophotometer.   
 
4.2.9 Liquid chromatography - mass spectrometry (LC-MS)  
Following Coomassie blue staining of SDS-PAGE gels, the bands of interest were 
excised and sent to the Centre for Proteomic and Genomic Research (Cape Town, 
South Africa) for LC-MS analysis.  The proteins were enzymatically digested with 
trypsin alongside a BSA standard and the resulting peptides were separated by 
reverse-phase high performance liquid chromatography.  The peptides were injected 
into a Thermo Q-Exactive mass spectrometer (Thermo Fisher Scientific) and the 
resulting spectra were analysed using Byionic Software (Protein Metrics USA) using 
reviewed sequences available from UniProt (www.uniprot.org).  Gel-digested samples 
were compared against a merged database comprised of N. benthamiana, N. 
tabacum, A. tumefaciens and Bunyaviridae. 
 
4.2.10 Immunisation of mice 
Female BALB/c mice were bred by the Animal Unit at the Health Science Faculty, 
University of Cape Town and were housed in filter top micro-insulator cages under 
Biosafety Level 2 (BSL 2) conditions.  Approval for this study was granted by the 
Animal Research Committee at the University of Cape Town (AEC# 015-048).  Female 
mice (8-10 weeks old) were immunised with the plant-produced vaccine candidate 





The immunogenicity study was carried out in duplicate (experiment 1 and 2), with each 
experiment containing a total of 10 mice, divided into 2 groups (group 1 - vaccine and 
group 2 – negative control) of 5 mice each.  The TSP of the vaccine candidate and 
negative control was determined using the Bio-Rad DC Protein Assay Kit.  The vaccine 
candidates were prepared to contain 5 µg antigen in 100 µL Tris/HCl pH 8.  Pre-bleeds 
were collected from each mice via the saphenous vein three days prior (Day -3) to 
vaccination.  The vaccine candidates were administrated by subcutaneous injection 
into both left and right flanks (50 µL each) on Day 0.  The mice were boosted on day 
13 and 27 with doses containing 10 µg of appropriate antigen.  Final bleeds were 
obtained via cardiac puncture at Day 58.  Serum was collected from the blood and 
stored at -80 ˚C. 
 
4.2.11 Indirect ELISA detection of anti-Gn antibodies in mouse sera 
The anti-Gn responses were determined by ELISA.  96-well Maxisorp® microtiter 
plates (Nunc) were coated with 100 µL/well (1 µg) of N. benthamiana produced 
human-codon optimised RVFV LPH-∆tGn, diluted in 10 mM Tris/HCl pH 8) coating 
buffer and incubated O/N at 4 ˚C.  The plates were blocked with TBP blocking buffer 
(5% non-fat dry milk in 1 x TBS [50 mM Tris, NaCl, pH 7.5]) for 2 h at RT after which 
they were washed four times with 1 x TST buffer (1x PBS, pH 7.5, 0.05% Tween®20). 
 
To evaluate the anti-Gn immune response elicited by each mouse, the pre- and final 
bleed sera were diluted 1:100 in 100 µL TBS blocking buffer and added to each well, 
after which the plates were incubated for 2 h, RT.  Blank wells contained no antibody 
we included as background control.  The plates were washed four times with 1x TST 
buffer and 100 µL of anti-goat anti-mouse IgG alkaline phosphatase conjugates (1:10 
000, Sigma) diluted in blocking buffer was added to each well and incubated for 1 h at 
37 ˚C.  After incubation, the plates were washed four times with 1x TBS, pH 9 and 200 
µL SIGMAFAST™ p-Nitrophenyl phosphate (pNPP, Sigma) was added to each well.  
The plates were developed in the dark for 30 min after which absorbance was detected 




To determine the anti-Gn binding titres, mouse sera from each group were pooled into 
vaccine groups (5 mice/vaccine) for analysis.  Final bleed sera were diluted in TBS 
locking buffer in a 4-fold series in triplicate ranging from 1:50 to 1: 51 200.  Mouse sera 
from the mice vaccinated with non-infiltrated plant protein served as a negative control.  
Blank wells with no antibody were included for background control in all the ELISA’s. 
 
The serum was pre-absorbed by lunchbox immunoabsorbent technique.  Briefly, on a 
nitrocellulose blotting membrane (Amersham™ Protran™ Premium 0.45 µm NC) ~25 
mL volume of crude plant extract was added, and incubated at 37 ˚C for 1 hr.  This 
was followed by then blocking in blocking buffer (1 x PBS [137 mM NaCl, 10 mM 
Na2HPO4, 2.7 mM KCl, 2 mM KH2PO4] at pH 7.4, 0.1% Tween-20 and 5% fat free 
milk).  Sera to be absorbed was diluted to 1:50 in blocking buffer and agitated on the 





4.3.1 Cloning of the recombinant modified Gn constructs into plant expression vectors 
The South African isolate M35/74 RVFV Gn modified constructs shown in Figure 4.3 
were all successfully made.  All recombinant plasmids were confirmed by restriction 
enzyme mapping, giving the expected banding patterns (results not shown) as well as 
by sequencing, confirming gene orientation and no mutations were introduced by 
PCR.  The recombinant modified genes were successfully cloned into the appropriate 
plant expression vectors as depicted in Figure 4.4 (A-K).  The sizes (bp) of the 





Figure 4.3: RVFV Gn truncation and substitution of signal peptide.  A) the full-length pGn/hGn 
glycoprotein, B) pGn without the native signal peptide, C) pGn with LPH substitution of WT RVFV signal 
peptide, D) pGn with PDI substitution of RVFV WT signal peptide, E) pGn without the native signal 
peptide and transmembrane domain (TMD), F) pGn with native signal peptide and no TMD/CT, G) 
pGn/hGn with LPH substitution of WT RVFV signal peptide and no TMD/CT, H) pGn with PDI 
substitution of WT RVFV signal peptide and no TMD/CT. 
 
The plant- and human-codon optimised full length Gn (Figure 4.3 A) were cloned 
successfully into pTRAc resulting in plant expression plasmid represented by Figure 
4.4 A.  The truncated ptGn, ∆pGn and ∆ptGn (Figure 4.3 B, C and D) encoding genes 
were successfully cloned into pTRAc, resulting in the plant expression plasmids 
represented by Figure 4.4 B, C and D.  ∆pGn and ∆ptGn/∆htGn were successfully 
cloned into pTRAc-ERH, introducing the LPH signal sequence, resulting in the plant 
expression plasmids in Figure 4.4 E and H, which targets the protein to the ER.  PDI-
∆pGn and PDI-∆ptGn (Figure 4.3 D and H) gene encoding sequences were 
successfully cloned into pTRAc and pEAQ-HT plant expression vectors resulting in 
plasmids in Figure 4.4 F, G, J and K.  The plant- and human-codon optimised RVFV 
∆tGn were fused to the LPH signal peptide at the N-terminus (Figure 4.3 G) and cloned 
successfully into pEAQ-HT resulting in the construct represented by Figure 4.4 I.  
Recombinant plasmids were successfully confirmed by restriction enzyme digest 





Figure 4.4:  Schematic presentation of recombinant RVFV Gn expression plasmids.  A) Full length 
RVFV plant (pGn)- and human (hGn)-codon optimised glycoprotein,  B) pGn lacking transmembrane 
domain and cytosolic tail (TMD/CT) - ptGn,  C) pGn lacking the native signal peptide - ∆pGn,  D) pGn 
lacking the native signal peptide and TMD/CT - ∆ptGn,  E)  native signal sequence substituted with a 
plant-codon optimised murine mAb24 heavy chain signal sequence (LPH) - LPH-∆pGn,  F)  native signal 
sequence substituted with PDI (protein disulphide isomerase) signal sequence and no TMD/CT - PDI-
∆ptGn,  G) pGn with LPH signal sequence and no TMD/CT region in pTRAc - ∆pGn,  H) Gn with LPH 
signal sequence and lacking TMD/CT region in pEAQ-HT – plant (∆ptGn)- and human (∆htGn)-codon 
optimised,  I) pGn with PDI signal sequence and lacking TMD/CT region - PDI-ΔptGn.  Red stars 
indicate the plant – and human-codon optimised genes in pTRAc and pEAQ-HT that expressed 





















pTRAc-pGn 7 841 1783-3462 1680 559 60.9 
pTRAc-hGn 7 841 1783-3462 1680 559 60.9 
pTRAc-ptGn 7 517 1783-3150 1368 455 49.1 
pTRAc-∆pGn 7 772 1783-3393 1611 536 58.7 
pTRAc-∆ptGn 7 448  1783-3081 1299 432 46.9 
pTRAc-PDI-∆pGn 7 844 1783-3465 1683 560 61.3 
pTRAc-PDI-∆ptGn 7 520 1783-3153 1371 456 49.5 
pTRAc-LPH-∆pGn 9 242 1653-3452 1800   599 66.3 
pTRAc-LPH-∆ptGn 8 918 1851-3141 1301 432 46.9 
pTRAc-LPH-∆htGn 8 918 1653-3140 1488 495 54.5 
pEAQ-HT-LPH-∆ptGn 11 323 1301-2656 1356 451 49.0 
pEAQ-HT-LPH-∆htGn 11 323  1301-2656 1356 451 49.0 
pEAQ-HT-PDI-∆pGn 11 653 1304-2986 1683 560 61.3 
pEAQ-HT-PDI-∆ptGn 11 329 1304-2674 1371 456 49.5 
 
4.3.2 Expression and detection of recombinant protein in crude leaf extracts 
Recombinant protein expression was assessed with small scale expression time trials 
and western blotting of crude leaf extracts harvested at different days post infiltration 
(dpi).  Recombinant protein expression could not be detected using anti-Gn antibody 
on samples from leaves infiltrated with Agrobacterium strains harbouring plasmids 
depicted in Figure 4.4 A – G and J - K (results not shown).  However, recombinant 
protein expression was successfully detected in leaf extracts from plants infiltrated 
with pTRAc-LPH-∆ptGn i.e. truncated Gn with a substituted LPH signal sequence, 
showing an expected protein band size of 46.3 kDa (432 amino acids).  Figure 4.5 
shows these results compared to samples from leaves infiltrated with the full length 
Gn gene including the TMD/CT region and the heterologous LPH signal peptide 
(pTRAc-LPH-∆pGn) which had the expected band size of 66.3 kDa (599 aa), but did 
not show detectable recombinant protein expression.  The protein was detectable from 
1 dpi, with day 5 showing the highest level of recombinant protein expression over the 
5 days tested.  A protein band of ~55 kDa was detected in the empty vector negative 





Figure 4.5:  Western blot comparing expression levels of recombinant protein extracted from leaves 
infiltrated with pTRAc-LPH-∆ptGn lacking the TMD/CT and pTRAc-LPH-∆pGn with the TMD/CT.  30 µg 
was loaded in each well.  The time trial was conducted at OD600 of 0.5.  Lanes 1, 3 and 5 denote the 
number of days harvested post infiltration (dpi).  Lane “-“, – negative control represented by extract from 
leaves infiltrated with an empty vector.  Lane M contains PageRuler™ Prestained protein ladder 
(Thermo Scientific, MA, USA).  The red arrow indicated the ∆ptGn expected band. 
 
Due to the successful expression of protein from pTRAc-LPH-∆ptGn, the construct 
encoding the cognate human-codon optimised gene (LPH-∆htGn) cloned into pTRAc-
ERH (pTRAc-LPH-∆htGn) was also tested for expression in N. benthamiana.  
Expression of LPH-∆htGn and LPH-∆ptGn after infiltration at optical densities of 0.25 
and 0.5 and harvesting at 1-7 dpi is shown Figure 4.6 A and B.  TSP of crude leaf 
extracts indicated that an OD600 of 0.25 was better for infiltration compared to an OD600 
of 0.5 for Nicotiana sp. codon optimised gene, while the TSP of crude leaf extracts for 
the human-codon optimised gene indicated that an OD600 of 0.5 was better for 
infiltration when compared to an OD600 of 0.25.  The recombinant protein was 
expressed from days 1 to 3 with the highest level of recombinant protein expression 
at 3 dpi, after which protein expression levels decreased and were not detectable by 
day 7.  Due to the successful expression of these constructs, LPH-∆ptGn and LPH-
∆htGn were similarly successfully cloned into pEAQ-HT and tested for expression in 
N. benthamiana.  An expression time trial for LPH-∆ptGn (Figure 4.6 C) and LPH-
∆htGn (Figure 4.6 D) was carried out with an infiltration OD600 of 0.25 and 0.5.  TSP 
of crude leaf extracts indicated that an OD600 of 0.5 gave lower protein expression 
levels when compared to that of an OD600 of 0.25 which showed the highest expression 
levels.  Recombinant plant produced protein was detectable from day 1 up to 7 dpi.  
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Samples from day 5 showed the highest level of recombinant protein expression, after 




Figure 4.6:  Expression time trial of plant- and human-codon optimised ∆tGn fused with LPH signal peptide.  The top panel represents plant-codon optimised 
genes, the bottom represents the human-codon optimised gene.  30 µg of TSP for A) pTRAc-LPH-∆ptGn (removed the SEKDEL sequence), B) pTRAc-LPH-
∆htGn, C) pEAQ-HT-LPH-∆ptGn, D) pEAQ-HT-LPH-∆htGn, E) pTRAc-LPH-∆ptGn vs pEAQ-HT-LPH-∆ptGn, F) pTRAc-LPH-∆htGn vs pEAQ-HT-LPH-∆htGn 
was loaded in each lane.  Lane - indicates is the negative control, a plant infiltrated with pEAQ-HT empty vector.  Lane M contains PageRuler™ Prestained 
protein ladder (Thermo Scientific, MA, USA).  DPI denote day 1, 3, 5 and 7 post infiltration.  The time trials were at OD600 of 0.25 and 0.5 respectively.  The 
protein was detected with anti-Gn antibody.   
72 
 
Having established that the highest levels of expression were obtained at 0.25 for 
pEAQ-HT and 0.5 for pTRAc, to determine which expression vector (pEAQ-HT or 
pTRAc) gave the highest levels of recombinant protein (∆htGn and ∆ptGn) expression, 
(Figure 4.6 E and F).  pTRAc-LPH was infiltrated at an OD600 of 0.5 and pEAQ-HT-
LPH-∆ptGn/ ∆htGn was infiltrated at an OD600 of 0.25.  pTRAc-LPH-∆ptGn showed 
expression at 1 and 3 dpi, with the highest expression levels at 3 dpi.  Specific protein 
expression was barely detectable for 5 and 7 dpi.  pEAQ-HT-LPH-∆ptGn/ ∆htGn 
showed expression from day 1 to 7, with day 5 giving the highest level of recombinant 
expression.  These results demonstrated that pEAQ-HT-LPH-∆ptGn/ ∆htGn 
expressed the recombinant protein exceptionally well, giving the highest protein levels 
for plant- and human-codon optimised modified Gn genes.  The pEAQ-HT-LPH-
∆ptGn/ ∆htGn recombinant plasmids were selected for further analysis.   
 
Having established that the pEAQ-HT vector yielded the highest levels of recombinant 
protein, the two constructs encoding plant- and human-codon-optimised tGn (∆ptGn 
and ∆htGn) were used to determine whether the use of different protein extraction 
buffers could improve protein yields. Four different extraction buffers were assessed 
for protein extraction efficiency.  Comparisons of protein levels by western blots 
probed with anti-Gn antibody showed that 100 mM Tris/HCl pH 7.5 buffer was the most 
effective in yielding higher yields as determined by density of protein bands on western 
blot (results not shown). 
 
Finally, to determine which codon preference yielded the highest levels of recombinant 
protein in N. benthamiana, expression was compared between crude leaf extracts 
sampled from plants infiltrated at an OD600 of 0.25 with pEAQ-HT-LPH-∆htGn and 
pEAQ-HT-∆ptGn (Figure 4.7).  The highest recombinant protein levels were detected 
using the Nicotiana sp. (∆ptGn) codon optimised gene.  Thus, the pEAQ-HT-LPH-
∆ptGn construct was selected for further work including scaled-up infiltration at an 





Figure 4.7:  Comparison between plant- and human-codon optimised RVFV recombinant modified 
protein:  30 µg of TSP for pEAQ-HT-LPH-∆htGn and pEAQ-HT-LPH-∆ptGn infiltrated at OD600 = 0.25.  
The protein was detected with anti-Gn (1:1000).  “–“indicates a negative control, plant infiltrated with 
pEAQ-HT empty vector.  Lane M contains PageRuler™ Prestained protein ladder (Thermo Scientific, 
MA, USA).  1, 3, 5 and 7 indicate the number of days post infiltration (dpi).   
 
4.3.3 Purification of pEAQ-HT-LPH-∆ptGn product 
For large scale purification, ∆ptGn was successfully partially purified by (NH4)2SO4 
precipitation, with the majority of the protein being found in the 40 – 60% fraction.  
 
 
Figure 4.8:  Purification of pEAQ-HT-LPH-∆ptGn with ion exchange chromatography.  A) 
chromatographic trace showing LPH-∆ptGn elution from the HiPrep SP XL 16/10 cation column with 
increasing salt concentration (Pink line).  B) Coomassie staining and western blot analysis of affinity 
chromatography fractions collected.  Lane 1 contains crude plant extract, lane 2; contained 
PageRuler™ Prestained protein ladder plus (Thermo Scientific, MA, USA), lane 3 contained 40 – 60% 
(NH4)2SO4 precipitate, lane 4 contained unbound wash fraction, lane 5 - 8 contained fractions 45 – 48 
and lane 9 contained fraction 68.  The protein was detected with 1:100 anti-Gn primary antibody and 
1:5000 anti-rabbit secondary antibody.  The red arrows indicate the LPH-∆ptGn expected size.  The 
blue arrows indicate the bands analysed by LC-MS.  
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Recombinant RVF LPH-∆ptGn protein was calculated to have a pI of 8.05, and was 
thus purified using ion exchange chromatography (IEX).  The protein was eluted off 
the column with a 30% salt concentration, corresponding to a protein peak visualised 
from fractions 45 to 48 (Figure 4.8 A).  Western blot analysis and Coomassie gel 
staining of the fractions showed that the expected protein of 46.3 kDa was mainly 
present in fraction 46 (Figure 4.8 B; lane 6).  The additional protein band sizes of ~70 
kDa and 36 kDa were detected, which correspond to Nicotiana sp. ATP synthase unit 
beta, chloroplastic and methionine synthase respectively, as demonstrated by LC-MS. 
 
4.3.4 Total soluble protein (TSP) quantification 
Coomassie-stained SDS-PAGE gel analysis showed other contaminating plant 
proteins were co-purified with recombinant LPH-∆tGn on the column.  Due to the 
bands smearing, TSP of the fraction was determined using the Bio-Rad DC Protein 
Assay Kit.  A standard curve was plotted using the average absorbance values 
obtained for the BSA standards.  Using the equation on the chart, the TSP was 
calculated to be ~1.23 mg/mL in a total volume of 5 mL.  The final protein yield was 
calculated to be ~56.81 mg TSP per kilogram of fresh leaf material. 
 
4.3.5 Immunisation of mice with LPH-∆tGn and animal serum analysis 
Two experiments in mice were conducted to determine whether the modified RVFV 
Gn vaccine candidate produced in tobacco was immunogenic.  The analysis of the 
final bleed sera of the individual mice showed the presence of Gn-specific antibodies, 
therefore mouse sera from each group were pooled (5 mice/group) for the analysis of 
anti-Gn binding (Figure 4.9 A).  The antibody binding titres were expressed as a 
reciprocal of the maximum serum dilution containing absorbance values that were 
three times greater than the corresponding pre-bleed serum at 1:100.  Preliminary 
data analysis for the presence of anti-Gn specific antibodies was analysed by indirect 
ELISA using plant-produced Gn protein as coating antigen.  No binding was detected 
using the pre-bleed serum (Figure 4.9 B); however, binding was seen for antiserum 
raised against the candidate vaccine as well as for the negative plant control (Figure 
4.9 B).  No significant differences were observed in the absorbance readings between 
vaccine candidate and the negative plant control, despite the antiserum having been 
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pre-absorbed against a crude plant extract.  Antiserum titration analysis revealed an 
apparently stronger antibody binding affinity to the vaccine candidate as compared to 
the negative plant control (Figure 4.9 C).  The indirect IgG ELISA at serum dilution of 
1:50 showed an 8-fold difference between the vaccine candidate and the negative 




Figure 4.9:  Analysis of antibody response in mice by vaccination with LPH-∆tGn vaccine candidate.  A) Titration of mice antiserum against the LPH-∆tGn 
vaccine candidate (yellow) and plant negative control (pink).  The absorbance readings are shown as an average (n =10).  B) Absorbance values of pre- and 
final -bleeds at 1:100 reciprocal dilution.  C) Titration of pre-absorbed mice antiserum against the LPH-∆tGn vaccine (yellow) and plant negative control (pink).  






In this study an attempt was made to develop a RVFV subunit candidate vaccine by 
modifying the immunogenic RVFV Gn glycoprotein gene.  I focused on using codon 
optimised genes since gene-codon optimisation has been shown to significantly 
enhance gene expression in plants (Maclean et al., 2007).  This phenomenon has also 
been demonstrated with RVFV-encoded genes when it was shown that 293-gag cells 
transfected with expression plasmids encoding native RVFV or mammalian-codon 
optimised RVFV GnGc and Gn resulted in the enhanced expression of chimaeric VLPs 
using the codon optimized genes (Mandell et al., 2010c). 
 
In this work, RVFV plant- and human- codon optimised (pGn and hGn) genes were 
successfully cloned into the pTRAc suite of plant expression vectors.  However, the 
expression of recombinant protein from these genes was not detectable by western 
blots probed with a specific anti-Gn antibody.  Faburay et al (2013)  showed similar 
difficulties with expressing full-length RVFV Gn in Sf9 cells which resulted in no or very 
low expression of Gn (Faburay et al., 2013).  In eukaryotes, translation efficiency is 
thought to be controlled by the rate of initiation.  Initiation is known to follow a scanning 
mechanism whereby the 40S ribosomal unit together with co-factors such as elF2, 
elF3, elF4, met tRNA and GTP, bind to the 5’ cap of mRNA and then descend through 
the untranslated leader scanning for the first AUG codon (Kozak, 1989).  The lack of 
RVFV Gn protein expression could be due to the lack of ribosome translocation during 
protein translation in plant host cells.  Since rare codons or stable secondary structure 
in mRNA might cause pausing of the ribosome translocation it results in premature 
termination of transcription (Angenon et al., 1990).  
 
In this project, efforts to promote RVFV Gn protein expression were made mainly using 
the plant-codon optimised gene (pGn).  It was further thought that the presence of the 
native RVFV Gn signal peptide on the 5’ terminus of the gene may not be suitable for 
initiation of transcription.  Although mRNA and protein levels are generally correlated, 
the nucleotide sequence flanking the translation start codon and specific features of 
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the 5’ and 3’ un-translated regions (UTR) contribute to translation efficiency.  In 
eukaryotes, translation has been shown to initiate efficiently when the AUG is in the 
context of a leader sequence (RNNAUGG, where R is A or G).  When the AUG is not 
in this context, the ribosome will continue scanning in the 3’ direction until an AUG in 
the preferred context is located (Kozak, 2002).  Thus, in our case the Gn gene was 
modified, by removing the native signal peptide and replacing it with heterologous PDI 
(PDI-∆pGn) or LPH (LPH-∆pGn) signal peptides which target translation into the ER 
where post-translation modifications occur (Gomord and Faye, 2004).  The reason for 
this was to ensure correct protein trafficking through the lumen of the ER, where 
glycosylation enzymes and signal peptidase are located (Gerrard and Nichol, 2002; 
Gerrard and Nichol, 2007).  Alone, changing the signal peptide did not affect protein 
expression as no expressed Gn was detected.   
 
It was subsequently thought that perhaps the TMD/CT was interfering with expression.  
This has been shown with the HIV type 2 envelope glycoprotein with a carboxy 
terminal residue that did not allow the formation of infectious retroviral particles.  
Expression of HIV-2 envelope protein with 7 cytoplasmic amino acids was more 
efficient compared to HIV-2 with a slightly longer (11 amino acids) cytoplasmic tail 
which had reduced expression levels (Höhne et al., 1999).  Due to the similarities 
between HIV-2 and RVFV glycoproteins which are type 1 transmembrane proteins, 
the RVFV ∆Gn genes were further modified by truncating the TMD/CT resulting in PDI-
∆ptGn and LPH-∆ptGn.  Unfortunately, there was still no protein expression from the 
recombinant plasmid PDI-∆ptGn using the PDI signal peptide.  However, when LPH-
∆ptGn cloned into the pTRAc vector was infiltrated into plants, expression of ∆ptGn 
was successfully detected.  Expression was detected with infiltration OD600 of 0.25 
from 1 dpi, with the highest expression levels detected at 3 dpi.  This suggests that 
both the 5’ signal peptide and TMD/CT have a significant effect on gene translation 
and expression in planta.  These results are similar to those reported for expression 
of RVFV Gn in insect cells.  De Boer and co-workers expressed the Gn ectodomain 
(Gn-e) (Gn lacking TMD/CT) with the Drosophila BiP secretion signal in Drosophila 
Schneider (S2) cells (de Boer et al., 2010).  In addition, the same gene Gn-e was also 
fused with a Flag-tag and expressed with three Strep-tags and successfully expressed 
in S2 cells (Kortekaas et al., 2012).  Recombinant Gn expression was also 
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demonstrated when Gn was fused to a 54 nucleotide sequence beginning from the 5th 
ATG of the RVFV M segment (Faburay et al., 2013) and expressed without the 
TMD/CT in Sf9 cells (Faburay et al., 2014; Faburay et al., 2013). 
 
With this work, the successful expression of the plant-codon optimised ∆tGn in the 
pTRAc vector, fused to the LPH signal peptide, lead to the construction of a cognate 
construct encoding the human-codon optimised truncated Gn (∆htGn).  Optimal 
protein expression conditions were determined and shown to be different to those 
used for the ∆ptGn (infiltration OD600 of 0.5 and expression at 3 dpi compared to 0.25 
at 3 dpi). 
 
To test whether expression levels could be increased, the recombinant modified genes 
were cloned into the CPMV-based hypertranslatable expression vector, pEAQ-HT.  A 
comparison of protein expression levels between the pTRAc and pEAQ-HT vector, 
showed that the pEAQ-HT vector yielded higher expression levels than the pTRAc 
vector and thus pEAQ-HT vector was selected for continuation of scaled up infiltration 
and purification. 
 
To determine whether codon optimisation had a significant effect on expression a 
comparison of the codon optimised genes revealed that plant-codon optimisation for 
Nicotiana sp. gave higher expression levels compared to human-codon optimisation.  
The advantages of codon optimisation for protein expression has previously been 
demonstrated by Maclean and co-workers.  They revealed that human-codon 
optimisation was had higher protein expression levels than plant-codon optimisation 
for HPV16 L1 in planta (Maclean et al., 2007).  However, in this study, I discovered 
the opposite: plant-codon optimised genes were expressed at higher levels at a higher 
optical density of Agrobacterium compared to those of the human-codon optimised 
genes.  Since the human-codon optimised gene required higher ODs to achieve 
similar expression levels as the Nicotiana sp. codon optimised gene, this suggests 
that RVFV WT gene codons might affect transcription in a heterologous expression 
system.  The plant-codon optimised gene was selected for further analysis. 
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This is the first time to our knowledge that the RVFV Gn protein has been able to be 
produced in N. benthamiana.  While Kalbina et al., (2016) were able to show that 
putative transgenic Arabidopsis plant lines had Gn-specific mRNA expression by RT-
PCR, they were unable to demonstrate recombinant Gn expression (Kalbina et al., 
2016).  I managed to successfully express recombinant RVFV LPH-∆ptGn protein and 
purify it using ammonium sulphate precipitation and subsequent cation exchange 
chromatography.  Protein yields of 56.81 mg/kg fresh weight, with a soluble protein 
concentration of 1.25 mg/mL were obtained.  These yields are comparable to those 
that have been achieved from recombinantly-produced E. coli (6 mg) (El Salam, 2014) 
and mammalian cell (3.6 µg/mL) production systems (Mandell et al., 2010b).  A few 
contaminating plant proteins with a similar pI to LPH-∆ptGn co-eluted off the column 
at the same salt concentration, as shown by protein analysis (see Figure 4.8 B).  It is 
possible that the protein can be further purified by size exclusion chromatography to 
separate Gn from the contaminating proteins.   
 
The plant-produced RVFV Gn candidate vaccine was preliminarily assessed for 
immunogenicity in BALB/c mice by subcutaneous vaccination.  Detection of antibodies 
in mouse antisera was determined by indirect ELISA using plant-produced LPH-∆tGn 
as a coating antigen.  The pre-bleed sera gave no detectable antibody binding 
responses, as expected.  For both the vaccine and plant negative control, however, 
antibodies that bound to the coating antigen were detected.  Similar antibody titres 
were observed for both vaccine and negative plant controls.  This is almost certainly 
due to the co-purified plant contaminating proteins, which would be present in both 
vaccine inocula and coating antigen, thus making it difficult to accurately determine if 
the antibodies detected in sera elicited using the vaccine candidate was purely due to 
the vaccine antigen.  Therefore, the antisera were pre-absorbed against plant crude 
extract to absorb the anti-plant antibodies from the sera, with the hope that this would 
allow me to demonstrate a positive difference between reactions with the vaccine 
candidate and with the negative control plant material.  This was previously 
demonstrated for a plant virus (Rybicki, 1984).  The pre-absorbed serum showed 
significant differences in binding between the vaccine candidate and the negative plant 
control, indicating that the recombinant protein is weakly immunogenic.  These results 
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are far more promising compared to the vaccine candidate produced in transgenic 
Arabidopsis which acted as a booster in mice (Kalbina et al., 2016).   
 
In conclusion, gene codon optimisation seems to have played a significant role in 
improving yield, since both codon optimisations allowed for expression of modified Gn 
but at different ODs of A. tumefaciens.  The substitution of the homologous signal 
peptide alone also seems to not have influenced protein expression, since no Gn 
protein was detected with just substituting the native signal peptide.  The removal of 
the TMD/CT, however, played a significant role when ∆ptGn was fused to a mouse 
LPH signal peptide.  Expression of constructs lacking the TMD/CT coding sequence 
resulted in successful expression of the ∆ptGn protein, while fusion with a plant PDI 
signal peptide, with or without the TMD/CT, resulted in no expression.  This shows 
that the choice of heterologous signal peptide played a significant role in the 
expression of recombinant proteins in a heterologous expression system.  Protein 
expression was further improved by the choice of expression vector.  Chromatography 
allowed for the purification of the protein and a weak specific antibody response was 
detected in the immunogenicity studies.  Since no adjuvant was used in this study, a 




Chapter 5: The modification and expression of a chimaeric RVFV virus-like 




Recombinant protein vaccines in their monomeric forms are generally weakly 
immunogenic despite the use of adjuvants to enhance their efficacy.  Particulate 
vaccines such as VLPs, however, provide a much better immune response due to the 
presence of multiple epitopes which resemble the virus in shape and morphology 
(Kushnir et al., 2012; Roldao et al., 2010).  VLPs are more immunogenic than protein 
immunogens or subunit vaccines because their proteins are displayed in a more 
authentic conformation (Garcea and Gissmann, 2004; Meyers et al., 2014).  The VLP 
vaccine platform is a viable option for the development of a safe and efficient RVFV 
vaccine, since VLPs are free of viral genetic material and therefore cannot be 
encumbered by the possible safety-related drawbacks of live-attenuated virus 
vaccines such as reversion, recombination and reassortment (Mandell et al., 2010b).  
They have also been shown to stimulate T-cell independent B cell-mediated immune 
responses and are highly effective at stimulating CD4 proliferative and cytotoxic T 
lymphocyte responses (Paliard et al., 2000; Schirmbeck et al., 1996). 
 
Several different RVFV VLP expression systems have been successfully developed 
using Spodoptera (Liu et al., 2008), Drosophila (de Boer et al., 2010) and mammalian 
cells (Habjan et al., 2009; Mandell et al., 2010a; Naslund et al., 2009).  These VLPs 
were made up primarily of Gn and Gc, which display the external virion immunogenic 
determinants, or a Gn and Gc with nucleocapsid (N) protein recruited inside the core 
(Habjan et al., 2009; Liu et al., 2008).  Some of these have been tested in animals and 
shown to be immunogenic (Kortekaas et al., 2010a; Naslund et al., 2009).  Studies 
have demonstrated that antibodies to Gn alone are sufficient for virus neutralization 
(Naslund et al., 2009; Oreshkova et al., 2013), and such antibodies were found to be 
fully protective in mice (de Boer et al., 2010).  Gn expressed with N-protein on the 
same plasmid was found to be fully protective in lambs (Oreshkova et al., 2013) and 
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mice (Pichlmair et al., 2010).  In another study with VLPs containing the N-protein, 
56% of the mice survived a challenge, compared to VLPs without the N-protein, where 
19% of the mice survived (Mandell et al., 2010a). 
 
Since I previously showed that I was unable to express GnGc in N. benthamiana using 
plant expression vectors available in our laboratory (Chapter 3), I looked at alternative 
strategies for making particles with present Gn (the most immunogenic RVFV protein).  
RVFV GnGc, influenza virus HA (White et al., 2008), Ebola virus GP (Mohan et al., 
2015) and human immunodeficiency virus (HIV) Env are all type 1 transmembrane 
glycoproteins having C-terminal TMD/CT.  They are presented on the virion envelope 
as homotrimeric spikes.  It has been previously found that HIV envelope (Env) protein 
is poorly incorporated into VLPs compared to other enveloped glycoproteins; this 
problem was to some extent resolved by substituting the native TMD/CT with various 
heterologous TMD/CT sequences including that of the avian influenza virus 
hemagglutinin (HA) protein.  The study showed that the heterologous TMD/CT 
significantly increased the incorporation of HIV Env into the VLPs due to the length of 
the heterologous TMD/CT being shorter than the long native TMD/CT (Wang et al., 
2007).  Each HA monomer is made up of two subunits: these are HA1, which contains 
the receptor binding and major antigenic sites, and HA2, which is primarily responsible 
for fusion.  HA2 contains an NH2-termination fusion peptide, a 27 aa transmembrane 
domain (TMD) and a 10 aa cytosolic tail (CT) (Armstrong et al., 2000). 
 
I reasoned that by substituting the native TMD/CT of RVFV Gn with that of the 
influenza HA TMD/CT, that this may similarly encourage the formation of chimaeric 
RVFV VLPs.  Part of this chapter describes the production of chimaeric RVFV Gn 
VLPs by expressing the modified recombinant LPH-∆tGn construct fused to the highly 
pathogenic H5N1 avian influenza HA TMD/CT (LPH-∆tGnHA) in plants.   
 
In addition, unlike other enveloped viruses such as influenza and HIV, RVFV lacks the 
structural matrix protein linking the viral envelope with the virus core.  Instead, there 
is a direct interaction between the RVFV glycoprotein CT and the RNP complexes.  
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The bridging density complexes observed among capsomers of RVFV may help with 
assembly and stabilisation of the virus particles (Freiberg et al., 2008).  Matrix proteins 
are the driving force of assembly of enveloped proteins.  Their main function is to 
interact with and polymerise at cellular membranes and link other viral components to 
the matrix-membrane resulting in individual particles.  They ensure the integrity of the 
viral particles by interacting with membranes and providing a link between the CT of 
the glycoprotein and N-protein (Baudin et al., 2001; Noton et al., 2007).  The influenza 
virus matrix protein (M1) is composed of 252 amino acids (~28 kDa) and consists of 
an N-terminal (1 to 164 aa) linker, middle and C-terminal domains (Harris et al., 2001; 
Noton et al., 2007).  It plays a role in viral assembly and budding.  It interacts with the 
cytoplasmic tail of the virus transmembrane thus contributing to the formation of the 
budding particle, by forming a virion protein matrix in the inner surface of the viral 
envelope (Gomez-Puertas et al., 2000; Latham and Galarza, 2001).   
 
Therefore, to further encourage more stable chimaeric VLP formation, the recombinant 
LPH-∆tGnHA construct was co-expressed with two other proteins: the H5N1 avian 
influenza M1 protein and RVF N-protein.  It was reasoned that the influenza M1 may 
interact with the influenza TMD/CT and contribute to the formation of more stable 
RVFV chimaeric VLPs; also, the RVF N-protein could possibly be recruited into the 
∆tGn and assist with stabilisation of VLPs.  The RVFV Gn endodomain is known to 
interact with N-protein and the interaction is important for genome packaging (Ferron 
et al., 2011). 
 
This chapter describes experiments involving the fusion of RVFV ∆tGn with the 
TMD/CT of avian influenza H5N1 HA glycoprotein, cloning into different plant 
expression vectors, and testing for expression in N. benthamiana as well as monitoring 
for particle assembly.  In addition, leaves previously infiltrated with this construct were 
subsequently infiltrated with constructs either encoding RVF N-protein or influenza M1 
in order to determine whether this enhanced the production/stability of particles 
presenting Gn.  Putative recombinant protein-based particles were purified by 
discontinuous gradient ultracentrifugation and tested for immunogenicity in mice. 
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5.2 Materials and Methods 
 
5.2.1 Genes 
The RVFV genes used to make the chimaeric VLP constructs were ptGn (Nicotiana 
sp. codon optimised Gn with a native signal peptide and no native TMD/CT) and ∆ptGn 
(Nicotiana sp. codon optimised Gn lacking the native signal peptide of the 5’ terminus 
and no native TMD/CT) the generation of which are described in 4.2.2.3.  The influenza 
HA TMD/CT was amplified from a human-codon optimised construct previously made 
in our laboratory encoding avian influenza H5N1 A/Vietnam/1194/2004 (GenBank 
accession number AY651333).  ∆ptGn and ptGn modifications were made by PCR, 
using the PCR profile described in section 2.2.5.  All PCR primer sequences are listed 
in Table 3, Appendix B.  All DNA manipulation and analysis was carried out as 
described in section 2.2.4.  All bacteria and plant growth conditions used were carried 
out as described in section 2.2.3.   
 
Table 5.1: Plasmids used in this study 
Plasmid Description  Reference 
pTRAc-ptGnHA ptGnHA cloned in pTRAc vector This study 
pTRAkc-LPH-∆ptGnHA ∆ptGnHA cloned in pTRAc-ERH vector This study 
pEAQ-HT-LPH-∆ptGnHA LPH-∆ptGnHA cloned into pEAQ-HT vector  This study 
pEAQ-HT-his-N N cloned in pEAQ-HT vector Chapter 6 
pRIC3.0-M1 M1 cloned into pRIC3.0 vector  aBRU-Culture 
Collection  
a Biopharming Research Unit, Department of Molecular and Cell Biology, UCT 
 
5.2.2 Fusion of Nicotiana sp. codon optimised glycoprotein (∆tGn and tGn) with avian 
influenza transmembrane domain and cytosolic tail of HA 
The HA TMD/CT was fused to tGn or ∆tGn by overlap extension PCR as described in 
section 4.2.2.4 using HA-tGn For and HA TMD Rev and annealing at 55 ˚C, resulting 
in TMD/CT with tGn 3’ overhangs.  tGn and ∆tGn with HA TMD/CT 3’ overhangs were 
amplified with Gn For/ ∆Gn Fw and tGnHA Rev with an annealing temperature of 55 
˚C.  This resulted in tGn with HA TMD/CT 5’ overhangs, as well as ∆tGn with HA 




The amplified tGn and ∆tGn with HA TMD/CT 5’ overhangs were fused with HA with 
tGn/∆tGn with HA 3’ overhangs.  Final full length fragments were assembled by PCR 
with Gn1 Fw /Gn∆SP NcoI Fw and HA TMD Rev, with a primer annealing temperature 
of 55 ˚C.  This resulted in DNA fragments ∆tGnHA and tGnHA. 
 
5.2.3 Cloning of ∆tGnHA and tGnHA into pTRAc and pTRAkc-ERH 
The amplified ∆tGnHA and tGnHA insert DNA was digested with NcoI and XbaI 
restriction enzymes and directly cloned into plant expression vectors pTRAkc-ERH 
and pTRAc using NcoI/ AflIII and XbaI (Roche Diagnostics, GmbH, Mannheim, 
Germany), respectively.  The recombinant plasmids were confirmed by PCR using 
vector-specific pTRAc primers as well as restriction enzyme digestion with EcoRV.  
This resulted in constructs pTRAc-tGnHA with the (native signal peptide and HA 
TMD/CT) and pTRAc-LPH-∆tGnHA (LPH signal peptide and HA TMD/CT) 
recombinant vectors.   
 
5.2.4 Cloning of LPH-∆tGnHA into pEAQ-HT plant expression vector 
LPH-∆tGnHA was cloned into pEAQ-HT as described in section 4.2.2.5, resulting in 
pEAQ-HT-LPH-∆tGnHA. 
 
5.2.5 Agrobacterium transformation and recombinant protein expression  
The pTRA- and pEAQ-recombinant plasmids were transformed by electroporation into 
A. tumefaciens GV3101::pMP90RK and A. tumefaciens LBA4404 respectively, as 
described in section 3.2.10.  A preliminary expression time trial was conducted by 
syringe infiltration as described in section 3.2.11.  Crude plant extract was prepared 
from infiltrated leaves as described in 3.2.12.  Protein expression was analysed by 
western blotting as described in section 3.2.13, loading equal amounts of total soluble 
protein (TSP) as determined by Bradford assay using BSA (Sigma-Aldrich, MO, USA) 




5.2.6 Large scale expression of pEAQ-HT-LPH-∆tGnHA 
Large scale expression by vacuum infiltration of pEAQ-HT-LPH-∆tGnHA was 
conducted as described in section 4.2.6. 
 
5.2.7 Staggered infiltration with M1 and N-protein  
In order to favour the formation of particles, plants infiltrated with pEAQ-HT-LPH-
∆tGnHA were re-infiltrated with pEAQ-HT-his-N or pRIC3.0-M1 at 3 days post the first 
infiltration, with an infiltration OD600 of 0.5.  The plants were incubated for a further 2 
days of pEAQ-HT-LPH-∆tGnHA (and harvested at 5 days post first infiltration). 
 
5.2.8 Purification of pEAQ-HT-LPH-∆tGnHA chimaeric particles 
Plant material was harvested at 5 dpi.  Crude plant protein was extracted using a high 
pH buffer, 100 mM Tris/HCl pH 7.5 or a low pH buffer 100 mM NaOAc pH 5.6, in a 1:2 
mass:volume ratio as described in 4.2.7.1.  The protein was purified by sedimentation 
through a 20% iodixanol cushion onto a 60% iodixanol cushion using a  SW32Ti rotor  
in a Optima™ L-100 ultracentrifuge (Beckman Coulter) at 32 000 rpm for 2 h at 4 ˚C.  
Two mL fractions from the interface at the 20%/60% iodixanol boundary were 
collected, pooled, layered onto a 20%, 30%, 40% and 50% 2 mL step gradient, and 
re-centrifuged as described above for 16 h.  One ml fractions were collected from the 
gradient and stored at -80 ˚C for further analysis. 
 
5.2.9 Protein expression analysis 
Protein expression analysis was by western blot and Coomassie Blue gel staining as 
described in section 4.2.8.  Endotoxin levels were measured using the ToxinSensor™ 
Chromogenic LAL Endotoxin Assay Kit (GenScript Biotechnologies, Piscataway, NJ, 
USA) as per the manufacturer’s instructions.  The presence of contaminant bacteria 
was tested for by plating samples on LB agar with no antibiotics and incubating O/N 




5.2.10 Transmission electron microscopy (TEM) 
Copper-coated grids (mesh size 200) were made hydrophilic by glow discharging at 
25 mA for 30 s using a Model 900 SmartSet Cold Stage Controller (Electron 
Microscopy Sciences).  Three uL of sample was aliquoted onto grids, incubated for 30 
s and washed twice with sterile water.  The samples were negatively stained for 30 s 
with 3% (w/v) uranyl acetate and viewed using a Technai G2 transmission electron 
microscope (FEI).  Particles were measured using the Ruler tool in Adobe. 
 
5.2.11 Immunisation of mice 
Eight to ten week old female BALB/c mice were obtained from South African Vaccine 
Producers (SAVP, Johannesburg, South Africa) and housed in filter top micro-isolator 
cages under Biosafety Level 2 (BSL-2) conditions in the Research Animal Facility at 
the Heath Science Faculty, UCT.  Approval for this study was granted by the Animal 
Research Committee at the University of Cape Town (AEC# 015-048).  The study was 
carried out as described in 4.2.9 with five mice per group. 
 
5.2.12 Indirect ELISA detection of anti-Gn antibodies in mouse sera 
The anti-Gn responses were determined by ELISA as described in 4.2.10.  To evaluate 
the anti-Gn immune response elicited by each mouse, the pre- and final bleed sera 




5.3.1 PCR fusion of Nicotiana sp. codon optimised glycoprotein (∆tGn and tGn) with 
avian influenza TMD/CT of HA 
To further optimise the truncated Gn to enhance protein expression and formation of 
chimaeric particles, the native 418 bp TMD was removed (section 4.2.2.4).  The plant-
codon optimised RVFV ∆tGn was successfully fused with 108 bp of the influenza HA 
TMD/CT at its C- terminal position 1298.  Sequencing confirmed the gene fusion and 
that no mutations were introduced by PCR.  ∆tGnHA and LPH-∆tGnHA were 
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successfully cloned into plant expression vectors pTRAc, pTRAkc-ERH and pEAQ-HT 
(Figure 5.1 A-C) respectively.   
 
 
Figure 5.1: The schematic presentation of plasmids with Nicotiana sp. RVFV ∆tGn fused with avian 
influenza TMD/CT (HA).  A) pTRAc-∆tGnHA, ∆tGn with the native signal peptide and influenza TMD/CT, 
B) pTRAc-LPH-∆tGnHA, ∆tGn with the LPH signal peptide and influenza TMD/CT and C) pEAQ-HT-
LPH-∆tGnHA. 
 
Restriction enzyme digest mapping confirmed the plasmid integrity as depicted in 
Figure 5.2 A, giving the expected banding pattern for pTRAc-∆tGnHA (6657 and 884 
bp), pTRAkc-LPH-∆tGnHA (5011, 1652, 1405 and 943 bp) and Figure 5.2 B 






Figure 5.2: Restriction digest mapping confirming the recombinant expression plasmids.  A) pTRAc 
suite vectors digested with EcoRV (Fermentas, Hanover, MD) restriction enzyme, B) pEAQ-HT vector 
digest with AgeI and StuI restriction enzymes.  The bands represent the expected banding pattern.  The 
marker lane (M) contains the O’GeneRuler™ 1kb DNA ladder (Fermentas, Hanover, MD) was used as 
molecular weight marker.   
 
5.3.2 Transient expression of recombinant proteins in Nicotiana benthamiana 
The recombinant plasmids were successfully electroporated into A. tumefaciens cells.  
Infiltration of N. benthamiana plants was conducted at culture OD600 values of 0.25 
and 0.5.  Recombinant protein expression was assessed with small scale expression 
time trials and western blotting of crude leaf extracts harvested at 1, 3, 5 and 7 dpi.  
Thirty µg of TSP was loaded in each well.  Recombinant protein expression could not 
be detected in the samples from leaves infiltrated with recombinant Agrobacterium 
strains harbouring plasmids pTRAc-tGnHA and pTRAc-LPH-∆tGnHA (results not 
shown).  However, protein expression was successfully detected in leaf extract from 
plants infiltrated with pEAQ-HT-LPH-∆tGnHA (Figure 5.3).  Western blotting showed 
a 64.5 kDa band corresponding to the expected protein size (591 aa) in samples from 
1, 3, 5 and 7 dpi at OD600 of 0.25 and 0.5.  Expression at OD600 of 0.25 showed the 
highest expression levels at 3 dpi and gradually decreased to 7dpi.  Expression of 
OD600 of 0.5 gradually increased from 3 dpi to day 7 showing the overall highest 
expression levels.  These results also showed that the highest expression levels were 
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obtained using an OD600 of 0.5 compared to 0.25.  Thus, parameters of pEAQ-HT-
LPH-∆GnHA infiltrated at OD600 of 0.5, and leaves harvested at 7 dpi were used for 
further experimentation.  
 
Figure 5.3: Expression time trial of Nicotiana sp.  RVFV ∆tGn fused with Influenza TMD/CT.  pEAQ-
HT-LPH-∆tGnHA, expressed at two different OD600 of 0.25 and 0.5, TSP of 30 µg was loaded in each 
lane for 1, 3, 5 and 7 dpi.  The recombinant protein was detected with 1: 1000 anti-Gn primary antibody.  
Lane “-“indicates the un-infiltrated negative control, Lane M contains PageRuler™ Prestained protein 
ladder (Fermentas, Hanover, MD ).  The arrow indicated the expected band size of 64.5 kDa. 
 
5.3.3 Protein purification and characterisation of LPH-∆tGnHA 
In order to determine whether LPH-∆tGnHA assembled into particles, crude leaf 
extracts from plants infiltrated with pEAQ-HT-LPH-∆tGnHA were centrifuged through 
a 20%  iodixanol cushion onto a 60% cushion.  Two mL of sample was collected from 
the interface (Figure 5.4 A).  Western blot analysis confirmed the recombinant protein 
was mainly in the interface (F1), although detectable both in  F2 and F3 fractions.  
However, there were also other plant proteins detected in fractions F2 and F3 as 
detected by their  binding to the anti-Gn serum antibodies (Figure 5.4 B).  Plant 
proteins were present in all fractions as demonstrated by results with the pEAQ-HT 
empty vector control.  The protein collected in the interface (F1) was characterised by 
TEM for particle formation.  Protein aggregates were observed ranging from 15 - 19 
nm in diameter (Figure 5.4 C), these protein aggregtes were not observed in the 





Figure 5.4:  Purfication of LPH-∆tGnHA by sedimentation through a 20% iodixanol cushion and onto a 
60% iodixanol cushion.  A) Tube after sedimentation.  The red arrow indicates the interface  B) western 
blot analysis of different fractions using anti-Gn antibody.  F1 represents the interface, F2 is a 2 mL 
layer above the interface and F3 is 2 mL above F2.  Lane M contains PageRuler™ Prestained protein 
ladder.  C) Protein aggregates observed in the 20%/60% interface.  D) pEAQ-HT empty vector control 
observed in the 20%/60% interphase.  Scale bar indicates 50 nm. 
 
5.3.4 Staggered infiltration of LPH-∆tGnHA with M1 and N-protein 
In order to promote better particle assembly rather than simply having protein 
aggregates, the LPH-∆tGnHA protein was co-expressed with RVF N-protein or with 
the influenza M1 protein.  Co-expression of LPH-∆tGnHA with M1 or N-protein-
encoding constructs at infiltration ratios of 2:1 or 1:1 ratio (LPH-∆tGnHA:M1/N) 
resulted in high expression levels of the co-expressed proteins M1 and N-protein and 
low expression level of LPH-∆tGnHA as determined by western blot (Figure 5.5 A and 
B).  It was thought that possibly the higher expression of either M1 or N-protein may 
be hindering the expression of the LPH-∆tGnHA and that staggering the days of 
infiltration by infiltrating M1 and N-protein 3 days after infiltration of LPH-∆tGnHA may 
increase the initial expressed levels LPH-∆tGnHA.  This was subsequently carried out 
at an infiltration ratio of 1:1 which resulted in detectable protein expression levels of 
93 
 
all the proteins (Figure 5.5 C and D).  Infiltration at OD of 0.5 and co-infiltration (re-
infiltrating the same plant) at 3 dpi of LPH-∆tGnHA and harvesting at 5 dpi of LPH-





Figure 5.5:  Western blotting of crude leaf extracts infiltrated with ∆tGnHA co-expression and subsequent staggered expression of N and M1.  A) Represents 
the co-expression of ∆tGnHA with N-protein at 1:1 ratio, the left panel detected with anti-Gn and N at 1:100, the right panel with anti-N at 1:100, B) represents 
co-expression of ∆tGnHA with M1 at 1:1 ratio, the left panel detected with anti-Gn at 1:100 and M1at 1:2000, the right panel with anti-M1 at 1:2000, C) staggered 
expresstion of ∆tGnHA with N-protein, D) staggered expression of ∆tGnHA with M1.  The pink arrows indicate the expected protein bands. 
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High levels of contaminating plant proteins were present, therefore a low pH extraction 
buffer was tested to get rid of the excess.  This phenomenon was also observed with 
other proteins analysed in our laboratory.  The protein was extracted with a low pH 
buffer (100 mM NaOAc pH 5.6) and the routine high pH (100 mM Tris/HCl pH7.5) 
buffer, and the two extracts were compared.  Putative particles were purified by 
centrifugation with a double cushion as described in Figure 5.5.  Low pH buffer extracts 
did not show appropriately sized protein bands on western blots for all the recombinant 
proteins tested (Figure 5.5 A and B, 5.6 A and B, 5.7 A and B), yet protein aggregates 
were visible using TEM although samples had fewer contaminating proteins than those 
extracted with high pH buffer.  However, Gn, N and M1 protein were detectable on 
western blots when leaves were processed with high pH buffer (Figure 5.5 A and B, 
5.6 A and B, 5.7 A and B). 
 
Recombinant LPH-∆tGnHA was co-expressed with RVF N-protein: N-protein alone 
and LPH-∆tGnHA alone were expressed as positive controls.  This was to confirm that 
the N-protein was expressed in the staggered infiltration.  The expected N-protein 
band size of 27 kDa was detected with the anti-N-protein specific antibody (Figure 5.5 
A), confirming the expression of N-protein on its own at 2 dpi and when co-infiltrated 
with LPH-∆tGnHA with high pH buffer extraction were successfully expressed.  The 
LPH-∆tGnHA was detected with the anti-Gn specific antibody (Figure 5.6 B).  pRIC3.0-
M1 was used as a negative control.  A protein band of ~55 kDa was detected in the 
pRIC3.0-M1 negative control plant which is indicative of the RuBisCo protein.  TEM 
showed protein aggregates for protein extraction in the high pH buffer (Figure 5.6 C); 
these aggregates seemed to be smaller (~20 nm) in low pH buffer-extracted samples 
(Figure 5.6 D).  The purified protein extract had less protein contaminants with the low 
pH buffer as compared with the high pH buffer. No particles were observed in the 









Figure 5.6:  Western blotting and TEM representing the co-expression of LPH-∆tGnHA with RVFV N-
rotein, confirming the expression of N-protein in the staggered expresssion.  A) Left panel represents 
pEAQ-HT-his-N only, the right panel presents pEAQ-HT-LPH-∆tGnHA co-expressed with pEAQ-HT-
his-N.  The protein was detected with 1:100 anti-N.  B) Left panel presents pEAQ-HT-LPH-∆tGnHA co-
expressed with pEAQ-HT-his-N, the right panel presents pEAQ-HT-LPH-∆tGnHA only.  Protein 
detection with 1:100 anti-Gn.  C represents the crude sample, P represents the interface and N is the 
pRIC3.0-M1 used as a negative control.  The pink arrow indicates the protein of interest.  C) 
Recombinant protein extracted with high pH buffer, D) Recombinant protein with low pH buffer,  E) 
represents pRIC3.0-M1 used as a negative control extracted with high pH buffer.  The grids were 
stained with 3% uranyl acetate.  Scale bar represents 100 nm. 
 
Recombinant LPH-∆tGnHA was co-expressed with avian influenza M1; M1 on its own 
and LPH-∆tGnHA alone were expressed as positive controls.  This was to confirm that 
the M1 protein was expressed in the staggered infiltration.  The expected band size of 
64.5 kDa was detected with the anti-Gn specific antibody (Figure 5.7 A).  A band size 
of 55 kDa indicative of RuBiSco was detected in the negative control lane (N).  The 
expected protein band size of 27 kDa and dimer 54 kDa were detected with the anti-
M1-specific serum (Figure 5.7 B), confirming the expression of M1 protein on its own 
at 2 dpi and when co-infiltrated with LPH-∆tGnHA with high pH buffer extraction.  
pEAQ-HT-his-N was used as a negative control.  TEM showed protein aggregates that 
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varied in sizes (~20 – 30 nm) (Figure 5.7 C and D).  Figure 5.6 E displays pEAQ-HT-
his-N negative control.   
 
 
Figure 5.7:  Western blotting and TEM representing the co-expression of LPH-∆tGnHA with influenza 
the M1 protein confirming the expression of M1 in the staggered infiltration  A) Left panel represents 
pEAQ-HT-LPH-∆tGnHA only, the right panel presents pEAQ-HT-LPH-∆tGnHA co-expressed with 
pRIC3.0-M1.  The protein was detected with 1:100 anti-Gn.  B) Left panel presents pEAQ-HT-LPH-
∆tGnHA co-expressed with pRIC3.0-M1, the right panel presents pRIC3.0-M1 only.  Protein detection 
with 1:2000 anti-M1 serum.  C presents the crude sample, P is the interface and N is the pEAQ-HT-his-
N used as a negative control.  The orange arrow indicates the protein of interest.  TEM of  C) 
Recombinant protein extracted with high pH extraction buffer, D) Recombinant protein with low pH 
buffer,  E) represents pEAQ-HT-his-N used as a negative control extracted with high pH extraction 
buffer.  Grids were stained with 3% uranyl acetate.  Scale bar are 100 nm. 
 
RVFV LPH-∆tGnHA expressed on its own, its co-expression with N-protein (Figure 5.8 
A) and with M1 (Figure 5.8 B) were used as controls.  This was to confirm that the 
RVFV ∆tGnHA recombinant protein was expressed in the staggered infiltration.  The 
recombinant protein was detected with anti-Gn specific antibody.  The high pH 
extraction buffer consistently showed particles ranging from 49 – 60 nm (Figure 5.8 C) 
in diameter while the low pH extraction buffer gave protein aggregates or smaller 
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particles which range from 15 - 19 nm (Figure 5.8 D).  These experiments were 
conducted in triplicate.  Since particles of similar size were consistently viewed by 
TEM, the production of LPH-∆tGnHA alone was selected for further studies rather than 
when co-expressed with M1 and N-protein.  
 
 
Figure 5.8: Western blotting and transmission electron microscope representing the expression of 
RVFV LPH-∆tGnHA in the staggered infiltration.  A)  Left panel presents pEAQ-HT-LPH-∆tGnHA co-
expressed with pEAQ-HT-his-N, the right panel presents pEAQ-HT-LPH-∆tGnHA only.  N presents 
pRIC3.0-M1 used as negative control.  The protein was detected with 1:100 anti-Gn.  B) Left panel 
represents pEAQ-HT-LPH-∆tGnHA only, the right panel presents pEAQ-HT-LPH-∆tGnHA co-
expressed with pRIC3.0-M1.  N presents pEAQ-HT-his-N used as negative control.  Protein detection 
with 1:100 anti-Gn.  C presents the crude sample and P is the interface.  The green arrow indicates the 
protein of interest.  TEM of C) Recombinant protein extracted with high pH buffer, D) Recombinant 
protein with low pH extraction buffer,  E) represents pEAQ-HT-his-N used as a negative control 
extracted with high pH extraction buffer.  Grids were stained with 3% uranyl acetate.  Scale bar 
represents 100 nm. 
 
5.3.5 Large-scale production of chimaeric particles 
For large-scale expression, LPH-∆tGnHA was expressed on its own.  Putative 
chimaeric VLPs were purified by sedimentation through a 20% iodixanol cushion onto 
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a 60% cushion.  Two mL was collected from the interface (Figure 5.4 A) and 
subsequently centrifuged through the discontinous gradient and quantified by gel 
densitometry.  The protein was further purified by differential centrifugation.  One mL 
fractions were collected from the bottom of the tube and analysed by western blotting 
with anti-Gn specific antibody (Figure 5.9 A). and SDS-PAGE gel staining (Figure 5.9 
B).   
 
The recombinant protein was detected as a doublet, and was seen mainly in sample 
from the 40% and 50% iodixanol layers (Figure 5.9 A, F2 & 3).  RuBisCo, the most 
abundant protein in plants partially co-purified with the Gn protein and was detected 
mostly in the 50% iodixanol fraction.  TEM showed that most of the fractions contained 
protein aggregates and what looked like capsomers, with apparent VLPs in the 30% 
iodixanol fraction (Figure 5.9 F5); these chimaeric VLPs (Figure 5.7 C) were similar to 
those produced by de Boer et al 2010 in baculovirus (Figure 5.9 E).  However, these 
particles were present at very low concentrations.  
 
 
Figure 5.9:  Western blot analyis of fractions collected from a step iodixanol gradient and transmission 
electron microscope of pEAQ-HT-LPH-∆tGnHA.  A) protein detected with anti-Gn specific antibody, B) 
coomasie gel staining of the collected fractions.  Lane M contains PageRuler™ Prestained protein 
ladder.  Lane 1 contains crude recombinant protein Lane 2 contains partially purified with double 
cushion protein.  F1 and 2 represents 50%, F3 and 4 represent 40%, F5 and 6 represents 30% and F7 
represents 20% iodixanol.  C) TEM of F5 stained with 3% uranyl acetate.  Green arrows indicate VLPs, 
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scale bar is 100 nm.  D) TEM of pEAQ-HT empty vector stained with 3% uranyl acetate, scale bar is 50 
nm.  E) TEM of baculovirus expressed GnGc VLPs (de Boer et al., 2010). 
 
5.3.6 Immunisation and animal serum analyisis 
Due to the low protein concentration levels obtained from discontinous gradient 
purification, mice were immunised with protein purified by sedimentation through the 
20% iodixanol cushion onto a 60% cushion.  Two mL collected from the interface was 
used for immunisation.  Two experiments in mice were conducted to determine if the 
modified RVFV Gn vaccine candidate produced in N. benthamiana was immunogenic.  
The analysis of the pre- and final bleed sera of the individual mice showed the 
apparent presence of specific antibodies in the final bleed sera, therefore sera from 
each group were pooled (5 mice/group) for the analysis of anti-Gn binding (Figure 5.10 
A).  The antibody binding titres were expressed as a reciprocal of the maximum serum 
dilution containing absorbance values that were three times greater than the 
corresponding pre-bleed serum at 1:1000.  Preliminary data analysis for the presence 
of anti-Gn specific antibodies was analysed by indirect ELISA using plant-produced 
Gn protein as coating antigen.   
 
No binding to coating antigen was detected in the pre-bleed serum (Figure 5.10 B).  
Binding was seen for sera raised against the candidate vaccine as well as the negative 
plant control, however (Figure 5.10 C).  From the grouped individual mice sera, no 
differences in binding were observed between sera to the vaccine candidate and to 
the plant extract negative control. The mice antisera were accordingly pre-absorbed 
against a crude plant extract, as described previously (Chapter 4, section 4.2.11).  
Antiserum titration analysis revealed a stronger antibody binding for the vaccine 
candidate sera compared to sera to the negative plant control (Figure 4.9 C).  The 
indirect IgG ELISA at serum dilution of 1:800 showed a 2-fold difference between the 
vaccine candidate and the negative plant control (Figure 4.9 D). 




Figure 5.10:  Analysis of antibody response in mice after vaccination with LPH-∆tGnHA vaccine candidate.  A) Titration of mice antiserum against the LPH-
∆tGnHA vaccine candidate (yellow) and plant negative control (pink).  The absorbance readings are shown as an average (n =10).  B) Absorbance value of 
pre- and final bleeds at reciprocal dilution of 1:1000.  C) Titration of pre-absorbed mice antiserum against the LPH-∆tGnHA vaccine (yellow) and plant negative 
control (pink).  The error bars indicate standard deviation.  D) Absorbance values of the vaccine candidate (blue) and plant negative (orange) control from pre-





I previously showed that RVFV GnGc could not be detectably expressed in N. 
benthamiana with our available plant expression systems.  I therefore tried a different 
approach in an effort to develop a particulate vaccine, by fusing part of the 
immunogenic RVFV Gn gene to the influenza HA TMD/CT.  The modified plant-codon 
optimised (LPH-∆tGn) gene sequence was fused to the influenza HA TMD/CT (108 
bp) to encourage the formation of chimaeric particles displaying RVFV Gn.  The 
resultant LPH-∆tGnHA was cloned successfully into the pTRAc suite of the plant 
expression vectors.   
 
However, recombinant Gn-derived protein was not detected in leaves infiltrated with 
the recombinant pTRAc constructs by western blotting with a specific anti-Gn antibody.  
This reaffirms what was discussed in Chapter 4, which is that the native signal peptide 
and TMD/CT significantly affected the expression of the full length RVFV Gn in planta.  
Even use of a heterologous TMD/CT with a native signal peptide resulted in no 
detectable gene expression.  Irrespective of which TMD/CT is on the Gn gene, it 
seems not to allow for successful protein expression. Moreover, using the 
heterologous LPH signal peptide with the HA TMD/CT also did not show recombinant 
Gn expression: the reason for this is unknown, since our laboratory has previously 
been able to successfully express the H5N1 avian influenza HA and soluble HAtr at 
high concentration using the pTRAc suite in planta (Mortimer et al., 2012). 
 
To determine whether the expression vector promoter elements could affect 
expression, the gene was cloned between the CPMV untranslated regions (UTRs) in 
the plant expression vector pEAQ-HT, resulting in pEAQ-HT-LPH-∆tGnHA: this 
resulted in successful expression of LPH-∆tGnHA in N. benthamiana.  The choice of 
vector is known to be important when expressing recombinant proteins, since there 
are various elements on the vector which play a role in driving the expression of the 
protein.  It has been previously demonstrated that flanking the gene of interest with 
the modified 5’ UTR and the 3’ UTR from CMPV with the hypertranslatable (HT) leader 
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sequence region significantly increases recombinant protein expression levels 
(Sainsbury and Lomonossoff, 2008; Sainsbury et al., 2009b).  The highest expression 
levels were obtained at OD600 of 0.5 at 7dpi.  Therefore, the choice of expression 
vector pEAQ-HT allowed for successful expression of the recombinant LPH-∆tGnHA. 
 
Recombinant Gn-derived protein expression was subsequently scaled up by use of 
vacuum infiltration, and the putative particle fraction purified by centrifugation with a 
double Optiprep™ cushion.  TEM analysis showed the presence of abundant protein 
aggregates.  The RVFV Gn C-terminal tail interacts directly with ribonucleoproteins 
(RNPs) during the natural budding process to ensure the proper packaging of the 
RNPs.  The interaction between RNP and the GnGc stabilises the RVFV virions and 
drives assembly (Huiskonen et al., 2009).  Since in this case the glycoprotein C-
terminal tail has been removed, in order to try and stabilise VLP formation, the LPH-
∆tGnHA protein was co-expressed with M1 and N-protein.  Co-expression at a 2:1 or 
1:1 ratio resulted in high expression levels of the co-expressed proteins; however LPH-
∆tGnHA was expressed at low levels.  This could be due to the small M1 and N 
proteins (28 kDa), which are the most abundant proteins in their virions, exceeding the 
production rate of the large 64.5 kDa LPH-∆tGnHA glycoprotein.  
 
TEM analysis of the co-expressed proteins showed inconsistency in results between 
extractions, and variability in particle formation.  It was hoped that co-expression with 
influenza M1 would favour better VLP formation, with the influenza TMD/CT interacting 
with M1 as it does in influenza virus virions.  The M1 protein is the most abundant 
structural protein of the influenza particle, and it plays a role in the assembly and 
release of the particles (Gomez-Puertas et al., 2000).  It has the ability to form core-
like particles with an average diameter of 30 nm (Baniasadi and Lal, 2014).  However, 
we have not been able to see such particles (personal communication, Francisco 
Pêra), since they form at low pH (4.0) (Bui et al., 1996; Shtykova et al., 2013).  Co-
expression with the RVF N-protein was anticipated to facilitate the formation of VLPs, 
since formation of RVFV VLPs has been demonstrated by transfection of animal cells 
with plasmids encoding GnGc as well as co-transfection of GnGc with RVF N-protein 
(de Boer et al., 2010; Habjan et al., 2009; Mandell et al., 2010a).   
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Expression and analysis of LPH-∆tGnHA expressed alone and fractionated on a 
discontinuous gradient resulted in virus-like particles consistently being found, 
together with abundant protein aggregates.  These protein aggregates were also 
observed by Huiskonen et al., (Huiskonen et al., 2009).  This could be due to weak 
bonds between the proteins leading to formation of subviral particles.  Stabilisation of 
the VLPs can achieved by fixation of the particles with 0.5% glutaraldehyde prior to 
purification to preserve the fragile complexes (de Boer et al., 2010; Huiskonen et al., 
2009).  Discontinuous gradient purification showed particles and apparent capsomer-
like aggregates in the various iodixanol fractions.  VLPs varying in size from 49 – 60 
nm were detected in the 30% fraction.  The native RVFV virion surface is covered by 
a glycoprotein shell of 122 capsomers with a diameter of 101 to 106 nm (Huiskonen 
et al., 2009).  While the VLPs were not morphologically identical to those obtained in 
other systems – via recombinant baculovirus expression in insect cells, for example 
(de Boer et al., 2010) – their consistent recovery indicates that the strategy of using 
H5N1 TMD/CT as a particle-forming display vehicle was successful, which is a highly 
novel finding. 
 
Preliminary immunogenicity studies of the candidate chimaeric vaccine was carried 
out in BALB/c mice.  The purified fraction from 30% iodixanol had low protein 
concentration levels.  With the objective of increasing the probability of an immune 
response, the protein that was purified by sedimentation through the 20% iodixanol 
cushion onto a 60% cushion interface was used for immunisation.  However, this 
fraction included a lot of native plant proteins.  Antibody binding to putative RVFV-
specific coating antigen was detected at similar levels in indirect ELISA for the vaccine- 
and plant negative control-specific sera.  Pre-absorption of the antiserum with plant 
extract, however, revealed a significant difference in binding between the sera to the 
vaccine candidate and to the plant negative control.  The chimaeric RVFV Gn 
candidate vaccine was therefore immunogenic.  
 
In conclusion, in an attempt to produce a VLP based vaccine candidate, I successfully 
fused the modified Gn with influenza TMD/CT and cloned it into both the pTRAc suite 
and pEAQ-HT plant expression vectors.  Successful recombinant protein expression 
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was attributed to our choice of vector.  Protein purification was optimised and 
consistent recovery of Gn particles confirmed the novelty of using the influenza 
TMD/CT as a particle-forming carrier to be a qualified success.  These chimaeric Gn 




Chapter 6: Production of Rift Valley fever virus N-protein in plants for use as a 




The requirement for monitoring of RVFV outbreaks has become ever more urgent due 
to global warming, which has expanded the regions of vector distribution.  This in turn 
has increased the demand for diagnostic assays which are reliable and rapid, to 
implement the control of spread of RVFV outbreaks.  There are several different ways 
of diagnosing RVFV infections.  Quantitative real-time PCR can be used to detect 
viraemic animals (Bird et al., 2007; Chengula et al., 2014; Drosten et al., 2002; Garcia 
et al., 2001).  In addition, a real-time reverse transcription loop-mediated isothermal 
amplification (LAMP) test for rapid detection of RVFV has been developed (Euler et 
al., 2012; Le Roux et al., 2009; Peyrefitte et al., 2008).  Most recently, a method for 
rapid inactivation of virus and single step rRT-PCR for detection on RVFV RNA has 
been developed (Drolet et al., 2012).  However, although viremia in individuals infected 
with RVFV reaches high levels, it is short-lived, which makes monitoring of the spread 
of the virus in the field using PCR inadequate.  In addition, PCR requires specialised 
laboratory equipment and well trained personnel which are additional drawbacks when 
an outbreak occurs in remote areas. 
 
Serological testing of samples is more appropriate, and the ELISA is considered a 
rapid and reliable diagnosis tool.  Development of this tool led to a highly sensitive and 
specific indirect assay for the detection of IgG and IgM antibodies to RVFin animal and 
human serum, using purified, inactivated sucrose-acetone extracted RVFV protein as 
the coating antigen (Niklasson et al., 1984; Paweska et al., 2003a; Paweska et al., 
2005a; Paweska et al., 2005b; Paweska et al., 2003b).  However, there are several 
disadvantages to using inactivated antigens:  they tend to bind poorly to plates (Jansen 
van Vuren et al., 2007), and production of the antigen requires the use of a biosafety 
containment facility which increases the cost of production as well as the risk of 
exposure to laboratory personnel (Fafetine et al., 2013; Jansen van Vuren et al., 
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2007).  In addition, these ELISAs cannot be used in RVFV non-endemic areas due to 
the presence of virus-derived antigen and the risk of viral escape.   
 
The N-protein is highly conserved among various RVFV isolates (Bird et al., 2007) is 
the most abundant protein in the virion and highly immunogenic (Boshra et al., 2011; 
Faburay et al., 2014; Lagerqvist et al., 2009).  It has led to the development of the 
production of recombinant RVF N-protein in several different expression systems: RVF 
N-protein has been successfully produced in Aedes pseudoscaullaris mosquito cell 
lines (Zaki et al., 2006); Trichoplusia ni (Tn5) insect cells (Fukushi et al., 2012) as well 
as E. coli (Fafetine et al., 2013; Jansen van Vuren et al., 2007; McElroy et al., 2009; 
van der Wal et al., 2012).  At least two of the commercially available RVFV ELISAs 
now incorporate recombinant E. coli-produced N-protein for the detection of RVFV 
antibodies in animal serum (Kortekaas et al., 2013).  A double antigen ELISA for the 
simultaneous identification of IgM and IgG of RVFV antibodies, using N-protein 
produced in E. coli, has also been developed and validated using animal serum (Ellis 
et al., 2014). 
 
Despite the success of E. coli-produced N-protein in ELISA, there are some 
disadvantages: E. coli recombinant proteins are often incorrectly folded and/or often 
insoluble or aggregated, which may influence functionality in an ELISA.  Recombinant 
proteins produced in plants, on the other hand, are normally correctly folded and post-
translationally modified as the expression host is also eukaryotic, and the production 
system is immune to contamination by animal-infecting agents.  In addition, the 
production of recombinant proteins in plants is deemed to be more cost-effective than 
other expression platforms (Fischer et al., 2015; Rybicki, 2010). 
 
RVF N-protein has been recently produced in transgenic Arabidopsis (Kalbina et al., 
2016).  The work described in this chapter explored the potential for transient 
production in Nicotiana benthamiana plants as a cost-effective and safe RVFV N 
antigen for diagnostic use.   
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6.2 Materials and Methods 
 
6.2.1 Growth conditions and DNA manipulation 
All bacterial and plant growth conditions were carried out as described in section 3.2.3.  
All DNA manipulation and analysis was carried out as described in section 3.2.4.   
 
6.2.2 Cloning of N-protein into pEAQ-HT  
The RVF nucleoprotein (N)-encoding DNA sequence of South African isolate M35/74 
(GenBank accession number JF784 388) was human-codon optimised, synthesised 
by GenScript (GenScript Biotechnologies, Piscataway, NJ, USA) and cloned into 
pUC57 to yield pUC57-N.  This was transformed into E. coli DH5α (E. cloni ™, Lucigen, 
WI).  N was cloned from pUC57-N using restriction enzymes AgeI and StuI into pEAQ-
HT AgeI/ Cfr91 and StuI cloning sites respectively, to yield pEAQ-HT-N and pEAQ-
HT-his-N 
 
6.2.3 Agrobacterium transformation and recombinant protein expression analysis 
The recombinant plasmids were transformed by electroporation into A. tumefaciens 
LBA4404 as described in section 3.2.10.  A preliminary expression time trial was 
conducted by syringe infiltration as described in section 3.2.11.  The protein was 
extracted from N. benthamiana leaves by grinding up leaf samples in 250 µL extraction 
buffer (100 mM Tris/HCl pH 7.5 and 1% Triton X-100), vortexing and subsequent 
incubation on ice for 10 min.  The crude extracts were clarified by centrifugation at 14 
000 rpm for 5 min in a bench top centrifuge. The concentration of total soluble protein 
(TSP) in the crude extract was determined by Bradford assay using BSA (Sigma-
Aldrich, MO, USA) as a standard.  Recombinant protein expression analysis was 
conducted as described in section 3.2.13 using anti-N antibody (keyhole limpet 
haemocyanin-linked anti-N peptide (NKPRRMMMKMSEKEG); GenScript, 




6.2.4 Large scale protein expression  
Large scale protein expression was conducted by vacuum infiltration as described in 
section 4.2.6.  One hundred and ninety-seven grams of plant material was harvested 
at 3 dpi. 
 
6.2.5 Protein purification  
6.2.5.1 Ammonium sulphate precipitation  
Crude plant protein was extracted with 100 mM Tris/HCl pH 7.5, 1% Triton X-100 in a 
1:2 plant mass: buffer volume ratio, with an Ultra-Turrax® homogeniser (IKA® Works 
Inc., NC, USA) and filtered twice with four layers of Miracloth™ (EMD Millipore Corp., 
Billirica, MA USA).  The crude extract was clarified by centrifugation at 13 000 rpm, 20 
min, 4 ˚C four times or until there was no longer a pellet visible at the bottom of the 
tube.  Ammonium sulphate precipitation was performed as described in section 
4.2.7.1.  The 0 – 40% precipitated pellet was re-suspended with half the original 
volume of buffer (50 mM Na2HPO4, 0.5 M NaCl, pH 8) and was dialysed O/N at 4 ˚C 
using dialysis tubing with a molecular weight cut-off of 10 kDa (Thermo Fischer 
Scientific, USA) in 2L against the same buffer.  The extract was clarified by 
centrifugation at 13 000 rpm, 4 ˚C, for 20 min.  This was repeated four times or until 
the pellet became invisible.  
 
6.2.5.2 Nickel affinity chromatography 
The crude extract was filtered through a 0.45 µm and subsequently a 0.2 µm filter.  
The protein was loaded on a 5 mL HIS-chelating affinity column (Sigma-Aldrich, St. 
Louis, USA) and purified with an automated fast protein liquid chromatography (FPLC) 
system (ÄKTA Purifier Plus, GE-Healthcare Life Technologies) at a flow rate of 2.5 
min/mL.  The column was equilibrated with binding buffer (50 mM Na2HPO4, 0.5 M 
NaCl and 20 mM imidazole, pH 8).  N-protein was eluted with elution buffer (50 mM 
Na2HPO4, 0.5 M NaCl, 500 mM imidazole, pH 8).  Five mL fractions were collected 
with a fraction collector and an absorbance reading at 280 nm determined for each 




6.2.6 Protein expression analysis 
Fractions corresponding to the protein peak were analysed for the presence of N-
protein.  Samples from the 5 mL fractions were resolved on SDS-PAGE gels and 
analysed by western blotting as described in section 3.2.13 and staining as described 
in section 4.2.8.  Protein concentration of the N-protein was quantified by gel 
densitometry of a coomassie blue strained gel using a Gene Genius Bioimaging 
System – GeneTools (version 3.07.03) (Syngne) and BSA (Roche Diagnostics, 
Germany) was used to construct a linear standard curve. 
 
6.2.7 Liquid chromatography - mass spectrometry (LC-MS)  
LC-MS analysis was conducted as described in 4.2.9 
 
6.2.8 Transmission electron microscopy (TEM) 
The purified protein fractions were put onto copper-coated grids (mesh size 200) made 
hydrophilic by glow discharging at 25 mA for 30 s using a Model 900 SmartSet Cold 
Stage Controller (Electron Microscopy Sciences).  Three uL of sample was aliquoted 
on the grid for 30 s and washed twice with sterile water.  The samples were negatively 
stained for 30 s with 3% (w/v) uranyl acetate and viewed using a Technai G2 
transmission electron microscope (FEI).  Particles were measured using the Ruler tool 
in Adobe. 
 
6.2.9 IgG ELISA assays 
6.2.9.1 Serum samples   
To determine whether the purified RVF N-protein was functionally active and able to 
detect IgG antibody against RVF, the antigen was reacted against known RVFV-
positive and RVFV-negative sera from animals using ELISA.  A group of 24 
seronegative sheep were previously experimentally infected with RVFV strain M35/74 
by Williams et al., as part of their validation of their assay at the Agricultural Research 
Council-Onderstepoort Veterinary Institute (ARC-OVI) (Williams et al., 2011).  A group 
of negative reference sera from sheep was included.  
111 
 
6.2.9.2 Preparation of mock antigen 
Mock antigen was prepared by Agrobacterium-mediated infiltration of pEAQ-HT empty 
vector into N. benthamiana.  Crude extract was prepared in the same manner as the 
purified N-protein as described in section 6.2.5, precipitated with (NH4)2SO4 at 0-40% 
fraction, followed by affinity chromatography.   
 
6.2.9.3 Indirect RVF IgG ELISA 
Fractions containing the purified N-protein were analysed with a standard protocol 
(VT_ME_016-03) for RVF indirect IgG ELISA (Ellis et al., 2014; Williams et al., 2011) 
at the ARC-OVI.  The test is accredited by the South African National Accreditation 
System (SANAS).  Briefly, Nunc Polysorp plates (Nunc, Rosklilde, Denmark) were 
coated with purified recombinant plant-produced N-protein, followed by the addition of 
different sera and detection of binding by addition of secondary antibody (Williams et 
al., 2011).  A total of 40 serum samples were tested (in duplicate) - twenty positive and 
twenty negative for RVF antibodies (Williams et al., 2011).  E. coli produced N-protein 
was included as a positive control.  
 
Optical density (OD) values were read at 405 nm.  The net OD405 for each serum 
tested was calculated by subtracting the OD405 reading of the mock antigen from the 
cognate reading of that obtained using the plant-produced N antigen to account for 
any background absorbance in ten separate experiments.  OD readings were 
converted to PP values (percentage of positive control serum) (Williams et al., 2011) 
using the following equation: 
 
%𝑃𝑃 =
Mean OD of test sample − Mean OD of negative control
Mean OD of positive control − Mean OD of negative control 
 𝑥 100 
 
6.2.10 Protein stability assays 
To determine the protein stability of the plant-produced N-protein, 30 uL aliquots of 
purified protein were stored at RT, 4 ˚C, -20 ˚C and -80 ˚C.  Stability was assessed at 
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four week intervals by monitoring of protein integrity on Coomassie-stained SDS 
polyacrylamide gels and western blotting as described in section 6.2.6. 
 
6.3 Results  
 
6.3.1 Cloning of Rift Valley fever nucleocapsid (N) protein gene 
The N gene is 750 nucleotides long with an open reading frame of 254 aa.  The N-
encoding gene was directly cloned with two different restriction enzymes between the 
CPMV untranslated region (UTRs) in the plant expression vector pEAQ-HT, resulting 
in the plasmids pEAQ-HT-his-N (N terminal 6xhis affinity tag) (Figure 6.1.A) and 
pEAQ-HT-N (Figure 6.1 B).  These recombinant plasmids were confirmed by 
restriction digest mapping (Figure 6.2) giving the expected banding pattern of 9947 




Figure 6.1: Schematic presentation of recombinant RVFV N-protein in pEAQ-HT vector.  A)  N protein 
with N-terminal 6xhis tag, B) N protein without the 6xhis tag.  pEAQ-HT vector components: RB and 
LB: right and left borders for T-DNA integration, 35S promoter from Cauliflower mosaic virus (CaMV), 
5’UTR: modified 5’ UTR from CPMV RNA-2, 3’UTR from CPMV RNA-2, NosT: nopaline synthase 
terminator, P19: suppressor of gene silencing from TBSV, 35S terminator from CaMV, nptII: kanamycin 
resistance gene, OriV: pRK2 origin of replication, TrfA: replication essential locus and ColEI; the 





Figure 6.2: Confirmation of pEAQ-HT-his-N (9947 and 773 bp) and pEAQ-HT-N (9947 and 746 bp) by 
restriction enzyme digest mapping with NruI and StuI, 1 kb O’GreenGene ruler (M) was used as a DNA 
ladder.  DNA was resolved on 0.8% (w/v) TBE agarose gel. 
 
6.3.2 Transient expression and detection of recombinant N-protein in crude leaf 
extracts 
The recombinant plasmids were successfully electroporated into A. tumefaciens LBA 
4404 cells.  Recombinant protein expression was assessed with small scale 
expression time trials and western blotting of crude leaf extracts harvested at 1-4 days 
post infiltration (dpi).  Recombinant protein expression of N-protein in leaves infiltrated 
at culture optical densities (OD600) of 0.25, 0.5 and 1 was determined by western blots 








Figure 6.3: Western blot analysis of transient expression time trial of N-protein in N. benthamiana via 
Agrobacterium mediated transfer.  A) infiltration at OD600 of 0.25, B) infiltration at OD600 of 0.5, C) 
infiltration at OD600 of 1.  Lanes 1-4 denote the number of days post infiltration (dpi).  Lane “-“, – negative 
control represented by extract from leaves infiltrated with an empty pEAQ-HT vector.  Lane M contains 
PageRuler™ Prestained protein ladder (Thermo Scientific, MA, USA).  The protein was detected with 
1:5000 anti-N primary antibody and 1:5000 anti-rabbit secondary antibody. 
 
The 28 kDa band representing N-protein could not be detected in crude extracts from 
leaves infiltrated with pEAQ-HT-N (i.e.: construct lacking the 6xhis tag) at an OD600 of 
0.25 and 0.5.  There was a very faint band visible from samples prepared from leaves 
infiltrated at OD600 of 1 from 2 to 4 dpi.  However, the expected band size of 28 kDa, 
as well as a dimer of 56 kDa, were detected from leaf samples infiltrated with pEAQ-
HT-his-N from 1 dpi.  These progressively increased in concentration with the 
incubation period until 4 dpi.  These bands were not present in the negative control.  
The highest protein expression levels, viewed as the darkest protein band, were 
visualised for conditions of Agrobacterium OD600 = 0.5 at 3 and duration of 4 dpi.  The 
optical density of 0.5 was thus selected for further experimentation.  Since speed or 
processing would be important when producing this antigen commercially, the shorter 
3 dpi period of incubation was selected for further analysis of the N-protein. 
 
6.3.3 Purification of recombinant protein 
In order to scale up the production of N-protein, 40 plants were vacuum-infiltrated at 
an OD600 of 0.5 and harvested at 3 dpi.  N-protein was enriched for by (NH4)2SO4 
precipitation and subsequent nickel affinity column chromatography.  The protein was 
detected in the 0 - 40% fraction, and was purified by 6xhis affinity chromatography.  
The protein was eluted from the column with an increase in imidazole concentration, 
corresponding to a protein peak visualised in fractions 33 - 38 (Figure 6.4 A).  The 
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recombinant protein was detected by western blot analysis as monomers (28 kDa) 
and dimers (56 kDa) (Figure 6.4 B and C).  No other plant-contaminating proteins were 
detected on Coomassie-stained gels (Figure 6.4 C).  Two further batches of protein 
were purified and eluted off the column at 30% (150 mM) imodazole concentration and 
peak fractions 23 – 26 were analysed.  The protein was mainly detected in fraction 24.  
The protein eluted off the column with other plant contaminating proteins.  Peak 
fractions 36 (Batch 1) and 24 (Batch 2 and 3) were used for further analysis. 
 
 
Figure 6.4: Purification of the N-protein using nickel affinity chromatography.  Chromatographic trace 
showing 6xhis-N elution from the HIS-chelating affinity column with increasing imidazole concentration 
(Yellow line).  B) western blot analysis of collected fractions.  Lane 1 contains crude plant extract, lane 
2 0 – 40% (NH4)2SO4 precipitate, lane 3 contained unbound wash fraction, lane 4-9 contained fractions 
33 – 38 and lane 10 contained PageRuler ™ Prestained protein ladder (Thermo Scientific, MA, USA).  
The protein was detected with 1:5000 anti-NP primary antibody and 1:5000 anti-rabbit secondary 
antibody.  C) coomassie gel staining of fractions 35, 36, and 38 containing the purified protein.  Lane M 




The maximum protein yield of RVF N-protein was calculated to be ~500-558 mg/kg of 
fresh weight leaf material.  An average total protein concentration of 0.450 mg/mL was 
obtained.  I also measured the OD260nm/OD280nm ratio for the fractions to determine the 
presence of bound nucleic acids.  Fractions 35 and 36 were pooled and had an 
OD260nm/OD280nm ratio of 1.9.  The identity of the protein was confirmed by LC-MS 
resulting in 87.35% coverage and 264 unique peptides (Figure 6.5 A).  
 
 
Figure 6.5: Recombinant protein confirmation and visualisation.  A) Mass spectrophotometry of N-
protein recovered from SDS-PAGE analysis of a nickel affinity chromatography purified protein from 
infiltrated plant leaf material.  Unique peptide sequences highlighted in red.  B) TEM of E. coli produced 
N-protein by Ferron et al 2011, (Ferron et al., 2011).  C) TEM of plant-produced N-protein (indicated by 
pink arrow), D) represents an empty pEAQ-HT infiltrated plant was used as the negative control.  Scale 
bar represents 100 nm 
 
Previously, purified N-protein expressed in a bacterial system (Ferron et al., 2011) , 
has been shown using TEM to form distinct ring-shaped particulate structures which 
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are approximately 10 nm in diameter (Figure 6.5 B).  Samples of affinity–purified plant-
produced N-protein were therefore subjected to TEM and shown to contain similar-
shaped particles of similar magnitude (Figure 6.5 C).  This particulate matter was not 
observed in the negative control (Figure 6.5 D). 
 
6.3.4 IgG capture ELISA  
To determine whether the purified plant-produced RVFV N antigen was functionally 
active and able to bind IgG antibody directed against RVFV, the antigen was reacted 
against known RVFV-positive and RVFV-negative sera from animals using ELISA.  
Plant-produced mock antigen was simultaneously tested as a negative control.  
Checkerboard titrations of the antigen were used to optimise the antigen dilution used 
for the ELISA protocol.  The optimal antigen dilution of 1:200 was used.  Two replicates 
of positive and negative RVF control sera as well as a conjugate control were tested.  
The mean OD values calculated for the 3 different batches of the positive control tested 
ranged from 0.146 to 1.8635, while the negative control values ranged from 0.0635 to 
0.143.  The cut-off value for the distinction between positive and negative results for a 
positive result in IgG capture ELISA was calculated as the percentage of high-positive 
control serum (PP) values greater than 7.0.  PP values less than 4.0 were regarded 








Figure 6.6:  Detection of anti-RVFV IgG antibodies in sheep sera by ELISA using plant produced N-
protein eluted off the HIS-chelating affinity column, A) batch 1, B) batch 2 and C) batch 3.  Sample 1 – 
20 represent PP values calculated for sera from RVFV negative sera and 21 – 40 represents PP values 
calculated for RVFV positive sera.  The error bars illustrate ± mean standard deviation calculated from 
each PP value.  PP values less than 4.0 regarded as negative, PP values between 4.0 and 7.0 regarded 




The mean PP values for the positive sera ranged from 53.05 to 186.883, while the 
negative sera ranged from -1.51513 to 37.7862 (Figure 6.6 A-C).  From the first 
purified protein batch (6.6 A), all positive sera tested positive with PP values ranging 
from 53.05 to 138.025; 19 negative sera tested negative with a PP value range of -
0.525 to 3.75 with 1 false positive having a PP value of 7.75.  For the ELISA using the 
second N-protein batch (Figure 6.6 B) all positive sera tested positive with PP values 
ranging from 49.49 to 189.88; six negative sera tested negative with PP values ranging 
from -0.917 to 3.36 with13 false positive samples with PP values ranging from 7.5 to 
27.32.  For the third N-protein batch tested (Figure 6.6 C), all positive sera tested 
positive with PP values ranging from 78.63 to 155.75; five negative samples tested 
negative with PP value ranges of -1.5 to 5.45 with 15 false positive samples with PP 
values ranging from 7.05 to 37.78.   
 
6.3.5 Protein stability 
The potential for use of the N-protein as a reagent in a diagnostic ELISA would call for 
antigen stability, particularly at temperatures close to ambient temperature which 
would make it easier for transportation and use in areas which do not have cold 
storage facilities.  I conducted a preliminary set of experiments to assess the stability 
of the N-protein stored at various temperatures over a fixed period (36 weeks).  SDS-
PAGE staining and western blot analysis of purified N-protein after 4 to 36 weeks 
showed the presence of the usual 2 bands representing the monomeric (28 kDa) and 
dimeric (56 kDa) forms of N-protein (Figure 6.5 A and B) when stored at RT, 4 ˚C, -20 
˚C and -80 ˚C.  However, in addition to these, a third band corresponding to a 
hexameric form of N-protein (140 kDa) became visible, over the fixed storage period 
at RT, 4 ˚C, -20 ˚C and -80 ˚C (Figure 6.5 A and B) (not visible on day 0, refer to Figure 
6.4 B and C).  This large protein aggregate became visible at RT within four weeks.  A 
similar pattern gradually occurred over time with storage at other temperatures.  
Hexamer formation at -20 ˚C and -80 ˚C occurred at a much slower rate (Figure 6.5 
B).  The protein was mainly stable at 4˚C and could still be detected at -80 ˚C after 8 





Figure 6.5: Coomassie blue staining presenting N-protein stability at varies storage temperatures over 
a period of time.  A) recombinant protein stored for 4 weeks, B) recombinant protein stored for 16 
weeks, C) recombinant protein stored for 34 weeks, lane 1, room temperature (RT), lane 2; 4 ˚C, lane 
3; - 20 ˚C, lane 4; - 80 ˚C and lane M contains PageRuler ™ Prestained protein ladder.  The arrows 
indicate protein, monomers (28 kDa) (purple arrow), dimers (56 kDa) (pink arrow) and hexamers (140 




Rift Valley fever virus is regarded as an emerging virus due to the increasing number 
of mosquito vectors that can spread the virus into non-endemic areas as a result of 
recent global warming (Paweska et al., 2008).  Monitoring of the spread of the disease 
is imperative in both endemic and non-endemic areas, and consequently requires 
reliable diagnostic tools.  The development of a safe and cost-effective diagnostic tool 
is important, especially for South Africa as well as other developing countries where 
RVFV disease is prevalent and also where high levels of surveillance/monitoring for 
the disease are conducted (Rybicki et al., 2012).   
 
This study looked at the possibility of using plants to express RVFV N-protein as a 
low-cost antigen for use in an ELISA which can be used to distinguish between animal 
serum containing and lacking anti-RVFV antibodies.  RVF N-protein is highly 
conserved amongst other RVFV strains (Pepin et al., 2010; Saijo et al., 2002; Zaki et 
al., 2006) and it is the main immunodominant viral protein in other members of the 
Bunyaviridae family (Schwarz et al., 1996; Swanepoel et al., 1986b).  Although N-
protein is highly immunogenic, antibodies against N-protein do not exhibit neutralising 
activity (Boshra et al., 2011; Faburay et al., 2014; Lagerqvist et al., 2009).  Since 
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recombinant N-protein lacks infectivity and is very stable, it is a suitable candidate for 
use as an antigen in an ELISA (Fafetine et al., 2007; Jansen van Vuren et al., 2007; 
Paweska et al., 2007). 
 
The RVFV gene encoding the N-protein of a South African RVFV strain (SA M35/74) 
was human-codon optimised and synthesised.  It was cloned into the pEAQ-HT plant 
expression vector, and I successfully expressed the recombinant RVF N-protein 
transiently in N. benthamiana by Agrobacterium-mediated infiltration.  An expression 
time trial revealed that the N-protein without the 6xhis tag was poorly expressed 
compared to the N-protein with the 6xhis tag.  The 6xhis-N was expressed well at ODs 
of 0.25, 0.5 and 1, with the OD of 0.5 giving the highest protein expression levels.  This 
could be due to the 6xhis tag having some kind of stabilising effect on the recombinant 
protein.  Reed et al (2005) have shown that N-terminus 6xhis tag fusions have been 
found to improve the stability of ricin B-chain in tobacco (Reed et al., 2005).  
 
The production of the 6xhis-tagged N-protein was scaled up by vacuum infiltration of 
plants and crude extracts treated for purification of N-protein by using ammonium 
sulphate precipitation and subsequent affinity chromatography.  The protein was 
detected as monomers (28 kDa), dimers (56 kDa) and (140 kDa) hexamers after being 
stored.  This correlates with work done by Le May et al (Le May et al., 2005) who 
showed similar results with RVF N-protein expressed in mammalian cells.  When Liu 
et al., (Liu et al., 2008) expressed it in recombinant baculovirus cells and Ferron et al., 
(Ferron et al., 2011) expressed the protein in E. coli, they also demonstrated that N-
protein interacts with itself forming dimers and hexamers.  The high protein 
concentration drives the small units of N-protein to assemble into larger stable 
oligomers (Ferron et al., 2011). 
 
Plant production resulted in protein yields ranging from 500 – 558 µg/g fresh leaf 
material.  These yields are much higher than those obtained in transgenic Arabidopsis 
3.8 µg/g of fresh weight (Kalbina et al., 2016).  An average soluble protein 
concentration of 0.450 mg/mL was obtained.  These yields are comparable to those 
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that have been achieved from recombinantly-produced in E. coli - 0.34 – 0.71 mg/mL 
(Fafetine et al., 2007; Jansen van Vuren et al., 2007).  Moreover, the plant-produced 
N-protein was soluble and stable, and apparently much more suitable than other 
products for use in the validated ELISA. 
 
Mass spectrometry confirmed the monomeric protein to be RVF N-protein.  The 
variability in oligomeric state of N-protein is consistent with previous studies of the 
protein expressed in E. coli, mammalian cells or baculovirus cells.  The 
OD260nm/OD280nm ratio of the protein fractions was 1.9, indicating that the protein co-
eluted with nucleic acids, presumably with RNA from the expression host.  TEM 
images revealed distinct 10 nm ring shaped structures similar to those visualised in an 
E. coli expression system; this phenomenon has not been previously demonstrated in 
plants.  The N-protein associates with RNA to form stable ring-shaped structures 
(Ferron et al., 2011). 
 
The ability of plant-produced N-protein to differentiate between infected and uninfected 
sera was assessed by testing samples of RVFV-infected or uninfected sheep (Williams 
et al., 2011).  The objective of the cut-off value is to be able to distinguish between 
serum from animals or individuals which are infected from those that are not infected 
with RVFV.  The plant-produced N-protein could detect 100% of the known positive 
sera with a rage of PP values from 53.05 – 186.88 and 40% of the known negative 
sera as negative with PP value rage of -1.5 – 3.36 and 60% were regarded as false 
positive with PP values range from 4.05 – 37.78.  The first protein batch which 
contained very few plant contaminating proteins showed 100% specificity for the 
positive sera and 95% of the negative sera.  The recombinant antigen bound readily 
to the ELISA plates and generated minimal background.  The second and the third 
batches of recombinant N-protein showed 100% specificity in detecting the positive 
sera and 30% and 20%, respectively, of the negative sera as negative, thus conferring 
low sensitivity on the assay.  False positives possibly arise from the background 
absorbance of the plant proteins, which may react with plant-specific antibodies in the 
sheep serum.  One of the limitations of the 6xhis tag is co-purification of the target 
protein with contaminating proteins which have an external His residue.  The presence 
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of co-purified contaminating plant proteins with batches 2 and 3 of N-protein could 
explain the false positives from the non-infected animal sera.  This phenomenon was 
shown to be a major obstacle in the purification of human SERCA2a cardiac isoform 
expressed in Saccharomyces cerevisiae (Antaloae et al., 2013), as well as the 
purification of Gn ectodomain in insect cells which resulted in co-purification of 
contaminating proteins (de Boer et al., 2010).  This was resolved by replacing the C-
terminal 6xhis tag with three Strep-tags (van der Wal et al., 2012). 
 
My preliminary data indicates that the antigen could differentiate clearly between most 
of the sera from infected and non-infected animals – see Figure 6.6 A.  This could be 
attributed to the purity of the N-protein preparation, as protein purity significantly 
reduced the sensitivity of plant-produced N-protein to the negative sera.  Similarly to 
other recombinantly produced N-protein in other expression systems, purity of the 
antigen affects sensitivity and specificity of the ELISA.  High protein purity is required 
for high specificity and sensitivity (Paweska et al., 2005a).  Results of ELISA from 
recombinant N-protein with high purity levels have been shown to display high 
sensitivity and specificity (Fafetine et al., 2007; Jansen van Vuren et al., 2007).  
However, this preliminary study indicated that the plant-produced N-protein is certainly 
able to detect RVFV-specific antibodies.  The problem of contaminating protein in this 
case can be resolved by eluting the protein off the column with increase in imidazole 
concentration (see Figure 6.6 A) instead of elution at 30% imidazole during batch 
purification.  The problem of raised PP values for negative sera could be potentially 
addressed by absorbing all serum samples with a standard clarified soluble plant 
extract prior to testing with plant-produced N-protein, as this has proved highly 
effective in (for example) detection of antibodies to plant viruses (Rybicki, 1984 – PhD 
Thesis). 
 
Recombinant proteins lack infectivity and are generally very stable (Wade-Evans et 
al., 1993), and are therefore good candidates for use as reagents.  With a view to the 
plant-produced N-protein being a potential candidate for use as a reagent in a routine 
ELISA, the stability of the protein over time was assessed at various temperatures by 
assessing the degree of degradation on a western blot.  Viewed as monomeric and 
124 
 
dimeric bands, the N-protein remained stable at various temperatures with 4˚C being 
the optimal storage temperature for 8 months.  Interestingly, hexamers were formed 
over time when stored at RT and 4˚C, viewed as a 140 kDa band.  The protein 
remained mainly as monomers and dimers when stored at -20˚C and -80˚C but 
formation of hexamers was detected at a later stage compared to samples stored at 
RT and 4°C.   
 
An advantage of a plant-produced antigen is that it does not have biosafety 
requirements for its production, which is important for diagnostic laboratories that are 
not equipped with high levels of biosafety containment facilities.  Other advantages of 
using the plant-produced N-protein as an antigen include stability, as the antigen could 
still accurately distinguish between infected and non-infected sera after one year of 
storage.  The ELISA technique is ideal for developing countries as they are low-cost, 
sensitive and not time consuming, thus suitable for general surveillance as well as 
monitoring during large RVFV outbreaks.  In addition, this ELISA is DIVA-compliant. 









Although RVFV is preventable by vaccination, there is currently no commercially 
available vaccine for use outside endemic areas, as these vaccines are comprised of 
inactivated or live-attenuated virus, and the possibility of live virus escaping remains 
a problem.  It is therefore imperative that we continue to search for safe and 
economically viable alternative vaccine candidates, especially in Africa.  An ideal 
vaccine candidate would be in line with the One Health approach; thus, it should be 
able to prevent the spread of the disease by protecting animals and humans, and must 
be DIVA compliant.  Various recombinant vaccines have been developed in different 
expression systems (Bird et al., 2008; Bird et al., 2011; Boshra et al., 2011; Dulal et 
al., 2016; Dungu et al., 2010; Kortekaas et al., 2014; Liu et al., 2013b).  However, even 
though these vaccine candidates have been developed and shown to be 
immunogenic, they are not commercially available.  The research conducted in this 
study was successful in achieving its primary aims, which was to identify recombinant 
RVFV gene/s suitable for the development of a transiently-produced candidate 
vaccine in plants.  The initial immunogenic candidate/s tested however, were wild type 
RVFV GnGc or Gn genes expressed in plants, which expression was not successful; 
further investigation showed that the expression of these particular genes required 
extensive modification in order to facilitate expression in N. benthamiana. 
 
The RVFV glycoproteins have proven to be extremely difficult proteins to work with.  
Initially, I was unable to express the wild type RVFV GnGc as the gene seemed to be 
toxic in bacterial host cells; this could possibly be attributed to low-level leaky 
transcription and translation of toxic protein products.   
 
New strategies were developed to encourage or facilitate protein expression, those 
included testing expression of codon optimised genes instead, as previously 
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demonstrated by de Boer et al., who showed that RVFV gene expression in insect 
cells was only achieved using insect cell codon optimised genes (de Boer et al., 2010) 
and by Mandell et al who showed that mammalian cell codon optimised genes 
expressed in mammalian cells (Mandell et al., 2010b).  Nonetheless, expression of the 
full-length GnGc in planta was unsuccessful, irrespective of codon optimisation and 
choice of plant expression vector, which are known to play a role in recombinant 
protein expression.  Even with the focus solely on the immunogenic Gn glycoprotein, 
recombinant protein expression with the native signal peptide and TMD/CT was also 
unsuccessful.  It was postulated that the TMD/CT might be interfering with the 
expression because of incompatibility with plant secretion machinery, and therefore 
expression of Gn with either a heterologous LPH or PDI signal peptide without its 
native TMD/CT (truncated) was tested.  Interestingly, the construct encoding truncated 
Gn with the plant-derived PDI signal peptide did not result in detectable expression, 
but the construct encoding truncated Gn with the mouse-derived LPH signal peptide 
was successful in directing expression of the protein.  This was probably due to a 
mouse-derived signal sequence allowing for sufficient ribosomal translocation during 
protein translation in plant host cells, thus being more compatible with accumulation 
of the protein.  Plant-codon optimisation was also favoured more than human-codon 
optimisation as far as enhancement of expression levels was concerned. 
 
Recombinant protein expression levels can be significantly increased by the choice of 
expression vector.  Thus, the recombinant A. tumefaciens with modified Gn constructs 
were transiently expressed in N. benthamiana and compared the pEAQ-HT vector 
which targets protein expression to the cytoplasm and with the pTRAc-ERH vector 
which targets expression ER.  Expression was further optimised by investigating 
longer expression times.  Highest expression was found to be at 5 dpi, the pEAQ-HT 
vector gave higher protein expression levels compared to pTRAc vector, and it was 
thus selected for further studies.  An affinity chromatography purification protocol was 
subsequently developed, which gave sufficient protein yields for testing in animals.  
Immunisation studies revealed that the subunit Gn-derived vaccine candidate was 




In order to investigate whether a chimaeric RVFV vaccine candidate could be made in 
plants, the H5N1 influenza virus HA TMD/CT was fused to the plant-codon optimised 
modified Gn.  Recombinant protein was transiently expressed by Agrobactrium-
mediated transfer in plants, expression was detectable using the pEAQ-HT vector and 
no expression was observed in the pTRAc suite vectors; this confirmed again that the 
native signal peptide and TMD/CT of Gn affects recombinant protein expression, since 
no protein expression was detectable in the constructs with the native signal peptide 
and TMD/CT.  The choice of vector played a significant role, allowing for successful 
expression of recombinant protein.  Discontinuous iodixanol gradients were 
investigated for the purification of putative chimaeric RVFV Gn particles.  Particle 
characterisation by TEM showed what appeared like capsomers, and consistent 
recovery of particles which were morphologically different to those produced in other 
expression systems.  The heterologous influenza TMD/CT apparently allowed for the 
formation of chimaeric RVFV particles.  Immunisation studies revealed that the 
chimaeric vaccine candidate was highly immunogenic compared to the soluble protein 
vaccine candidate.  Despite the immunogenicity of the candidate vaccines being 
observed, the yields of the vaccines were very low, which meant that doses were low 
(~5 µg).  It is possible that the immune response could be increased by higher doses 
and use of adjuvant.  
 
The RVFV N-protein intended for use as a diagnostic reagent was human-codon 
optimised and successfully transiently produced in N. benthamiana by Agrobacterium-
mediated transfer.  Optimal expression levels were at three dpi.  Recombinant protein 
was purified by affinity chromatography and characterised by TEM.  TEM 
demonstrated ring-shaped particles of ~10 nm range produced in planta.  Preliminary 
data from ELISAs indicates that the reagent is functional and it is highly successful at 
differentiating between infected and non-infected animal serum, and that this could be 
a viable product.  
 
To the best of our knowledge, this is the first study demonstrating the successful 
production by Agrobacterium-mediated transient heterologous expression in N. 
benthamiana of recombinant RVFV Gn and chimaeric Gn particles as vaccine 
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candidates, as well as of N-protein as a diagnostic reagent.  The vaccine candidates 
were tested in mice and were shown to be immunogenic.  The N-protein antigen was 
functional as it could distinguish between infected and non-infected animal sera.  
7.2 Future work 
 
Having successfully managed to produce recombinant plant-produced RVFV 
glycoprotein vaccine candidates, it is possible that protein yields could be significantly 
improved by fusing the modified Gn with histidine or strep tags to facilitate purification.  
A recombining E. coli plasmid can be made by cloning the modified Gn gene into a 
bacterial expression vector.  This would allow for further analysis of humoral antibody 
response from the mice sera. 
 
Now that I have shown that Gn can be expressed on its own, in order to produce a 
vaccine candidate with the full GnGc polyprotein, modified Gn and Gc could be cloned 
into pEAQ-HT and simultaneously expressed by co-expression.  Alternatively, these 
could be co-expressed using the pEAQ-HT dual expression system.  Expression could 
also potentially be enhanced by co-expression with chaperones.  
 
With the preliminary ELISAs using the plant-produced N-protein antigen showing 
functionality, the possibility of using this protein as a diagnostic reagent appears bright.  
The antigen needs to be validated further, however, by testing larger panels of positive 




Chapter 8: Appendix 
Appendix A: Gene alignment between wild type, plant- and human-codon 
optimised sequences 
 
CLUSTAL O(1.2.1) multiple sequence alignment 
 
 
GnGc Human      ATGG---------------CTGGAATCGCTATGACCGTGCTGCCTGCTCTGGCCGTGTTC 
GnGc WT         ATGGCTGGAATCGCTATGACTGTGCTTCCAGCTCTTGCTGTGTTTGCTCTTG-------- 
GnGc Plant      ATGGCTGGAATCGCAATGACTGTTCTCCCTGCTC------TCGCTGTTTTCG-------- 
                ****               ***   *  *           *   ** * * *         
 
GnGc Human      GCTCTGGCTCCTGTCGTGTTCGCTGAAGACCCCCACCTGCGGAACAGGCCAGGCAAAGGG 
GnGc WT         -CTCCAGTT------GTGTTCGCTGAGGATCCACATCTTAGGAACAGACCAGGTAAGGGC 
GnGc Plant      -CTCTCGCTCCTGTTGTTTTCGCTGAAGATCCTCACCTTAGGAATAGACCTGGAAAAGGT 
                 ***  * *      ** ******** ** ** ** **  **** ** ** ** ** **  
 
GnGc Human      CACAATTACATCGACGGCATGACACAGGAGGATGCCACTTGCAAGCCCGTCACCTATGCA 
GnGc WT         CACAACTACATCGATGGCATGACTCAAGAGGATGCTACTTGCAAGCCAGTGACTTACGCT 
GnGc Plant      CATAACTATATTGATGGAATGACTCAAGAGGATGCTACTTGTAAGCCAGTGACTTACGCT 
                ** ** ** ** ** ** ***** ** ******** ***** ***** ** ** ** **  
 
GnGc Human      GGGGCCTGTAGCTCCTTCGACGTGCTGCTGGAAAAGGGAAAATTCCCCCTGTTTCAGTCC 
GnGc WT         GGTGCTTGCTCCTCTTTCGATGTGCTTCTTGAGAAGGGCAAGTTCCCACTCTTCCAGTCT 
GnGc Plant      GGAGCATGCTCTTCATTTGATGTTCTTTTGGAGAAGGGTAAATTTCCTTTGTTCCAGTCT 
                ** ** **    ** ** ** ** **  * ** ***** ** ** **  * ** *****  
 
GnGc Human      TACGCCCACCATCGCACCCTGCTGGAGGCTGTGCACGATACAATCATTGCTAAGGCAGAC 
GnGc WT         TACGCTCATCACAGGACTTTGCTTGAGGCTGTGCACGATACAATTATCGCTAAGGCTGAT 
GnGc Plant      TATGCACATCACAGGACATTACTCGAAGCTGTTCATGATACTATTATCGCTAAAGCAGAT 
                ** ** ** **  * **  * ** ** ***** ** ***** ** ** ***** ** **  
 
GnGc Human      CCCCCTTCATGCGATCTGCAGAGCGCCCACGGCAACCCTTGTATGAAGGAGAAACTGGTC 
GnGc WT         CCACCATCCTGCGATCTTCAATCTGCTCATGGAAACCCATGCATGAAAGAAAAGCTCGTG 
GnGc Plant      CCACCTTCCTGTGATTTGCAATCTGCTCACGGAAATCCTTGCATGAAGGAAAAACTTGTG 
                ** ** ** ** *** * **    ** ** ** ** ** ** ***** ** ** ** **  
 
GnGc Human      ATGAAAACACACTGCCCAAATGACTACCAGTCCGCTCATTATCTGAACAATGATGGCAAG 
GnGc WT         ATGAAGACTCACTGCCCAAACGATTACCAGTCCGCTCACTACCTCAACAACGATGGCAAG 
GnGc Plant      ATGAAAACACATTGTCCAAACGATTATCAGAGCGCACACTACTTGAATAACGATGGAAAG 
                ***** ** ** ** ***** ** ** ***  *** ** **  * ** ** ***** *** 
 
GnGc Human      ATGGCATCTGTGAAATGTCCACCCAAGTACGAACTGACTGAGGACTGCAACTTTTGTCGG 
GnGc WT         ATGGCTTCTGTGAAGTGCCCACCAAAGTACGAGCTTACTGAGGATTGCAACTTCTGCAGG 
GnGc Plant      ATGGCTAGTGTTAAATGCCCACCTAAGTACGAGTTGACAGAAGATTGTAACTTCTGCAGA 
                *****   *** ** ** ***** ********  * ** ** ** ** ***** **  *  
 
GnGc Human      CAGATGACCGGCGCTTCCCTGAAGAAAGGGTCTTATCCTCTGCAGGATCTGTTCTGCCAG 
GnGc WT         CAGATGACTGGCGCTTCTCTTAAGAAGGGATCTTACCCTCTCCAGGATCTCTTCTGCCAG 
GnGc Plant      CAAATGACTGGAGCATCACTTAAGAAAGGTAGTTACCCATTGCAAGATTTGTTTTGTCAG 
                ** ***** ** ** ** ** ***** **   *** **  * ** *** * ** ** *** 
 
GnGc Human      TCTAGTGAAGACGATGGAAGCAAGCTGAAAACTAAGATGAAAGGAGTGTGCGAAGTGGGA 
GnGc WT         TCCTCTGAAGATGATGGCTCCAAGCTCAAGACTAAGATGAAGGGCGTTTGCGAGGTTGGA 
GnGc Plant      AGTAGCGAGGATGATGGATCAAAGCTTAAAACAAAGATGAAAGGAGTTTGTGAAGTTGGT 
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                      ** ** *****    ***** ** ** ******** ** ** ** ** ** **  
 
GnGc Human      GTCCAGGCCCTGAAGAAATGTGACGGCCAGCTGTCCACCGCACACGAGGTGGTCCCCTTC 
GnGc WT         GTGCAGGCTCTCAAGAAATGTGATGGCCAGCTTTCCACTGCTCACGAGGTTGTGCCATTC 
GnGc Plant      GTGCAAGCTTTGAAGAAATGCGATGGACAGTTATCTACTGCACATGAAGTTGTGCCTTTT 
                ** ** **  * ******** ** ** *** * ** ** ** ** ** ** ** ** **  
 
GnGc Human      GCCGTGTTTAAGAACTCTAAGAAAGTCTACCTGGACAAACTGGATCTGAAGACCGAGGAA 
GnGc WT         GCTGTGTTCAAGAACTCCAAGAAGGTGTACCTCGATAAGCTCGATCTCAAGACTGAGGAA 
GnGc Plant      GCTGTTTTCAAAAACTCTAAGAAAGTGTATTTGGATAAACTCGATCTTAAGACTGAAGAG 
                ** ** ** ** ***** ***** ** **  * ** ** ** ***** ***** ** **  
 
GnGc Human      AATCTGCTGCCTGATAGCTTCGTGTGCTTTGAACATAAAGGCCAGTATAAGGGGACTATG 
GnGc WT         AACCTCCTCCCAGATTCCTTCGTTTGCTTCGAGCATAAGGGACAGTACAAGGGCACTATG 
GnGc Plant      AACCTTTTGCCAGATTCATTTGTTTGTTTCGAGCACAAAGGACAATACAAGGGTACTATG 
                ** **  * ** ***   ** ** ** ** ** ** ** ** ** ** ***** ****** 
 
GnGc Human      GACAGCGGCCAGACCAAAAGAGAGCTGAAGTCCTTTGATATCTCTCAGTGCCCAAAGATT 
GnGc WT         GATTCCGGACAGACTAAGCGTGAGCTTAAGTCCTTCGATATCTCCCAGTGCCCAAAGATT 
GnGc Plant      GATAGTGGTCAGACTAAAAGGGAACTTAAGTCATTCGATATCAGTCAATGTCCTAAGATA 
                **    ** ***** **  * ** ** ***** ** ******   ** ** ** *****  
 
GnGc Human      GGCGGGCACGGATCAAAGAAATGTACTGGCGACGCCGCTTTCTGCAGCGCATACGAGTGT 
GnGc WT         GGAGGACACGGCTCTAAAAAGTGCACTGGTGATGCTGCTTTCTGCTCCGCTTATGAGTGC 
GnGc Plant      GGAGGTCATGGATCCAAGAAATGCACTGGAGATGCTGCATTTTGTTCTGCATATGAATGC 
                ** ** ** ** ** ** ** ** ***** ** ** ** ** **    ** ** ** **  
 
GnGc Human      ACCGCCCAGTACGCCAACGCTTATTGCAGTCATGCTAATGGATCAGGCGTGGTCCAGATC 
GnGc WT         ACTGCTCAGTACGCTAACGCTTACTGCTCTCACGCTAACGGATCTGGTGTGGTGCAGATT 
GnGc Plant      ACTGCTCAGTATGCTAATGCATACTGTAGCCACGCAAACGGATCCGGTGTTGTGCAAATT 
                ** ** ***** ** ** ** ** **    ** ** ** ***** ** ** ** ** **  
 
GnGc Human      CAGGTGTCCGGAGTCTGGAAGAAACCACTGTGCGTGGGCTATGAACGAGTGGTCGTGAAA 
GnGc WT         CAAGTTTCCGGCGTGTGGAAGAAGCCACTCTGCGTTGGATATGAGAGGGTTGTGGTGAAG 
GnGc Plant      CAGGTTTCTGGAGTGTGGAAGAAACCTTTGTGCGTGGGTTACGAGAGAGTTGTGGTTAAA 
                ** ** ** ** ** ******** **  * ***** ** ** **  * ** ** ** **  
 
GnGc Human      CGGGAGCTGTCTGCCAAGCCTATCCAGCGGGTGGAACCATGCACCACATGTATTACAAAA 
GnGc WT         AGGGAACTCTCCGCTAAGCCAATTCAAAGGGTTGAGCCATGCACTACTTGCATCACTAAG 
GnGc Plant      AGGGAACTTTCAGCTAAGCCTATTCAAAGAGTTGAGCCATGTACTACATGCATCACAAAA 
                 **** ** ** ** ***** ** **  * ** ** ***** ** ** ** ** ** **  
 
GnGc Human      TGCGAGCCCCACGGCCTGGTCGTGAGAAGTACTGGGTTCAAGATCTCAAGCGCAGTGGCA 
GnGc WT         TGCGAGCCACACGGACTTGTTGTGAGGTCTACTGGCTTCAAGATCTCCTCTGCTGTTGCT 
GnGc Plant      TGTGAACCACATGGATTGGTGGTTAGGTCTACTGGTTTTAAGATTTCCTCTGCTGTTGCA 
                ** ** ** ** **  * ** ** **   ****** ** ***** **    ** ** **  
 
GnGc Human      TGCGCTTCAGGCGTGTGCGTGACCGGAAGTCAGTCACCTAGCACCGAGATCACACTGAAA 
GnGc WT         TGCGCTTCTGGTGTTTGCGTTACAGGATCTCAGTCCCCATCCACTGAGATCACTCTTAAG 
GnGc Plant      TGTGCTTCTGGAGTTTGCGTGACTGGTAGCCAATCCCCTTCTACTGAAATAACACTTAAG 
                ** ***** ** ** ***** ** **    ** ** **    ** ** ** ** ** **  
 
GnGc Human      TACCCAGGAATTAGCCAGTCCTCTGGAGGCGACATTGGCGTGCACATGGCACATGACGAT 
GnGc WT         TACCCTGGCATCTCCCAGAGTTCCGGTGGTGATATTGGAGTTCACATGGCTCACGATGAT 
GnGc Plant      TATCCAGGAATCTCACAGTCAAGTGGAGGAGATATTGGTGTTCATATGGCACACGATGAT 
                ** ** ** **    ***      ** ** ** ***** ** ** ***** ** ** *** 
 
GnGc Human      CAGTCCGTGAGTTCAAAGATCGTCGCCCACTGCCCTCCACAGGATCCCTGTCTGGTGCAC 
GnGc WT         CAGTCCGTGTCCAGTAAGATTGTGGCTCATTGCCCACCACAGGATCCATGCCTTGTTCAT 
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GnGc Plant      CAAAGTGTTAGCTCCAAGATTGTGGCTCATTGTCCACCTCAGGATCCATGCCTTGTTCAT 
                **    **       ***** ** ** ** ** ** ** ******** ** ** ** **  
 
GnGc Human      GGATGCATCGTCTGTGCCCACGGCCTGATTAACTACCAGTGCCATACAGCACTGTCCGCC 
GnGc WT         GGATGTATTGTGTGCGCTCACGGCCTCATTAACTACCAGTGTCACACTGCACTCTCCGCA 
GnGc Plant      GGATGTATAGTGTGCGCTCACGGTCTCATTAATTATCAATGTCACACAGCACTTTCTGCT 
                ***** ** ** ** ** ***** ** ***** ** ** ** ** ** ***** ** **  
 
GnGc Human      TTTGTCGTGGTCTTCGTGTTTAGCTCCGTCGCTATCATTTGCCTGGCAATCCTGTATAAG 
GnGc WT         TTCGTTGTGGTGTTCGTGTTCTCCTCCGTGGCTATTATTTGCCTCGCTATCCTCTACAAG 
GnGc Plant      TTTGTGGTTGTGTTTGTTTTCTCTTCAGTGGCTATTATTTGTCTCGCTATCCTTTACAAG 
                ** ** ** ** ** ** **    ** ** ***** ***** ** ** ***** ** *** 
 
GnGc Human      GTCCTGAAATGTCTGAAGATTGCCCCCAGGAAGGTGCTGGACCCTCTGATGTGGATCACC 
GnGc WT         GTGCTCAAGTGCCTCAAGATCGCTCCTAGGAAGGTGCTCGATCCACTCATGTGGATCACT 
GnGc Plant      GTGTTGAAGTGCCTCAAGATTGCTCCTAGAAAAGTTCTCGATCCACTTATGTGGATCACT 
                **  * ** ** ** ***** ** ** ** ** ** ** ** ** ** ***********  
 
GnGc Human      GTGTTCATTCGCTGGGTCTACAAGAAAATGGTGGCCAGAGTGGCAGATAACATCAATCAG 
GnGc WT         GTGTTCATCCGTTGGGTGTACAAGAAAATGGTGGCTAGGGTGGCAGATAACATCAACCAG 
GnGc Plant      GTTTTTATTAGATGGGTGTATAAGAAAATGGTTGCAAGGGTGGCTGATAATATCAACCAA 
                ** ** **  * ***** ** *********** ** ** ***** ***** ***** **  
 
GnGc Human      GTGAACCGCGAAATTGGATGGATGGAGGGAGGACAGCTGGCCCTGGGAAATCCAGCTCCT 
GnGc WT         GTGAACCGTGAGATCGGATGGATGGAAGGTGGACAACTTGCTCTTGGAAATCCAGCTCCA 
GnGc Plant      GTTAATAGGGAGATAGGATGGATGGAAGGAGGACAGTTGGCATTAGGTAACCCAGCTCCT 
                ** **  * ** ** *********** ** *****  * **  * ** ** ********  
 
GnGc Human      ATCCCACGGCACGCTCCCATTCCTAGATACTCCACTTATCTGATGCTGCTGCTGATCGTG 
GnGc WT         ATTCCAAGGCACGCTCCTATCCCAAGGTACTCTACTTACCTCATGCTCCTTTTGATCGTG 
GnGc Plant      ATTCCAAGACATGCACCTATCCCAAGGTACTCTACATACTTGATGCTCCTCCTTATAGTT 
                ** *** * ** ** ** ** ** ** ***** ** **  * ***** **  * ** **  
 
GnGc Human      TCATATGCAAGCGCCTGCTCCGAACTGATCCAGGCCAGCAGCCGGATTACTACCTGCAGC 
GnGc WT         TCCTACGCTTCTGCTTGCTCTGAGCTTATCCAGGCTTCCTCCAGGATTACTACTTGCTCT 
GnGc Plant      TCCTACGCATCTGCTTGTTCAGAGCTTATACAAGCTAGTAGCAGAATTACTACATGTTCT 
                ** ** **    ** ** ** ** ** ** ** **      * * ******** **     
 
GnGc Human      ACAGAGGGGGTGAATACTAAGTGTCGACTGAGCGGAACCGCCCTGATTCGAGCTGGATCC 
GnGc WT         ACTGAGGGCGTGAACACAAAGTGCAGGTTGTCTGGAACTGCACTCATCAGGGCTGGATCT 
GnGc Plant      ACAGAAGGAGTTAATACTAAGTGCAGATTATCTGGTACTGCACTCATTAGGGCTGGATCA 
                ** ** ** ** ** ** *****  *  *    ** ** ** ** **  * ********  
 
GnGc Human      GTCGGAGCTGAAGCATGCCTGATGCTGAAAGGCGTGAAGGAGGACCAGACAAAATTTCTG 
GnGc WT         GTTGGAGCTGAAGCTTGCCTTATGCTTAAGGGTGTGAAAGAGGATCAGACTAAGTTCCTT 
GnGc Plant      GTGGGTGCAGAGGCTTGTCTCATGCTTAAGGGAGTTAAGGAAGATCAAACAAAGTTCTTG 
                ** ** ** ** ** ** ** ***** ** ** ** ** ** ** ** ** ** **  *  
 
GnGc Human      AAGATCAAAACCGTGAGCAGCGAACTGAGCTGTCGGGAGGGGCAGTCCTACTGGACCGGA 
GnGc WT         AAGATCAAGACTGTGTCCTCCGAGCTTTCTTGCAGAGAGGGACAGTCTTATTGGACTGGC 
GnGc Plant      AAGATTAAAACTGTTTCCTCTGAGTTATCTTGCAGAGAAGGACAGTCATATTGGACAGGT 
                ***** ** ** **   *   **  *    **  * ** ** ***** ** ***** **  
 
GnGc Human      TCCTTCTCTCCTAAGTGCCTGTCCTCTCGGAGATGTCACCTGGTGGGGGAATGCCATGTC 
GnGc WT         TCCTTCAGTCCAAAGTGCCTCTCATCTAGAAGGTGCCACCTTGTTGGAGAGTGCCACGTT 
GnGc Plant      TCTTTTTCTCCTAAGTGTCTCTCAAGTAGAAGGTGCCATCTTGTTGGAGAGTGTCACGTG 
                ** **   *** ***** ** **   * * ** ** ** ** ** ** ** ** ** **  
 
GnGc Human      AACAGATGTCTGTCCTGGAGGGATAATGAAACAAGTGCCGAGTTCTCATTTGTGGGCGAG 
132 
 
GnGc WT         AACAGATGCCTCAGTTGGAGGGATAACGAGACTTCCGCTGAGTTCTCATTCGTGGGCGAG 
GnGc Plant      AATAGATGCTTGTCTTGGAGGGATAACGAGACTAGCGCTGAATTTTCCTTCGTTGGTGAA 
                ** *****  *    *********** ** **    ** ** ** ** ** ** ** **  
 
GnGc Human      TCTACAACTATGAGAGAAAACAAGTGCTTTGAGCAGTGTGGCGGGTGGGGGTGCGGATGT 
GnGc WT         TCTACTACTATGCGTGAGAACAAGTGTTTCGAGCAGTGTGGTGGTTGGGGATGCGGATGC 
GnGc Plant      TCTACTACAATGAGGGAGAATAAGTGTTTTGAACAATGCGGAGGTTGGGGATGTGGTTGC 
                ***** ** *** * ** ** ***** ** ** ** ** ** ** ***** ** ** **  
 
GnGc Human      TTCAACGTGAATCCATCTTGCCTGTTTGTCCACACCTATCTGCAGAGTGTGCGCAAAGAA 
GnGc WT         TTCAATGTTAACCCTTCTTGCCTCTTCGTGCACACTTACCTTCAGTCTGTGAGGAAAGAG 
GnGc Plant      TTTAATGTTAACCCAAGTTGTTTGTTCGTGCATACTTACTTACAGAGCGTTAGAAAAGAG 
                ** ** ** ** **   ***  * ** ** ** ** **  * ***   **  * *****  
 
GnGc Human      GCCCTGCGAGTCTTCAATTGTATCGACTGGGTGCATAAGCTGACTCTGGAGATTACCGAC 
GnGc WT         GCTCTCAGGGTTTTCAACTGCATCGATTGGGTGCACAAGCTCACTCTCGAGATCACTGAT 
GnGc Plant      GCTTTGAGGGTGTTTAATTGCATCGATTGGGTTCACAAGTTGACTCTCGAAATCACAGAT 
                **  *  * ** ** ** ** ***** ***** ** *** * ***** ** ** ** **  
 
GnGc Human      TTTGATGGCAGCGTGAGCACCATCGACCTGGGGGCTAGTTCAAGCAGGTTCACAAACTGG 
GnGc WT         TTCGATGGCTCCGTGTCTACTATCGATCTCGGCGCTTCTTCCTCCCGTTTCACTAATTGG 
GnGc Plant      TTCGATGGAAGCGTGTCCACAATTGATCTTGGTGCAAGCTCCTCTAGGTTTACTAATTGG 
                ** *****   ****   ** ** ** ** ** **    **     * ** ** ** *** 
 
GnGc Human      GGCAGCGTGTCCCTGTCTCTGGATGCAGAAGGCATCAGTGGGTCAAATAGCTTCTCCTTT 
GnGc WT         GGATCCGTGTCCTTGTCTCTCGATGCTGAGGGAATCTCTGGCTCCAACTCCTTCTCCTTC 
GnGc Plant      GGATCTGTTTCACTCAGTCTTGATGCTGAGGGAATCAGCGGTTCCAACTCTTTTTCATTC 
                **    ** **  *   *** ***** ** ** ***   ** ** **    ** ** **  
 
GnGc Human      ATTGAGAGCCCTGGCAAAGGGTACGCCATCGTGGATGAACCATTCTCCGAGATTCCCAGA 
GnGc WT         ATCGAATCACCTGGAAAGGGCTACGCTATCGTGGATGAGCCATTCTCTGAGATTCCTAGG 
GnGc Plant      ATAGAATCACCTGGAAAAGGTTATGCTATAGTTGATGAGCCTTTTAGTGAAATTCCAAGA 
                ** **    ***** ** ** ** ** ** ** ***** ** **    ** ***** **  
 
GnGc Human      CAGGGATTTCTGGGCGAAATTAGGTGCAACTCTGAGTCCTCTGTGCTGAGCGCCCACGAG 
GnGc WT         CAGGGATTCCTCGGAGAGATTAGGTGCAACTCTGAGTCCTCTGTGTTGTCCGCTCATGAG 
GnGc Plant      CAAGGATTCTTAGGAGAGATTAGGTGTAATTCAGAATCAAGTGTTCTTTCTGCACATGAA 
                ** *****  * ** ** ******** ** ** ** **   ***  *    ** ** **  
 
GnGc Human      TCCTGTCTGCGAGCACCAAACCTGATCAGCTATAAGCCCATGATTGACCAGCTGGAATGC 
GnGc WT         TCTTGTCTTAGGGCTCCAAACCTCATCTCCTACAAGCCAATGATTGATCAGCTCGAGTGC 
GnGc Plant      TCATGCCTTAGAGCTCCTAATTTGATCTCTTACAAGCCAATGATAGATCAACTCGAGTGT 
                ** ** **  * ** ** **  * ***   ** ***** ***** ** ** ** ** **  
 
GnGc Human      ACCACAAATCTGATCGATCCCTTCGTGGTCTTTGAGAGGGGCTCTCTGCCTCAGACCCGC 
GnGc WT         ACTACTAACCTCATCGATCCATTCGTGGTTTTCGAGAGGGGATCTTTGCCACAGACTAGG 
GnGc Plant      ACTACAAACCTTATTGATCCTTTTGTTGTGTTCGAAAGAGGTTCTCTTCCACAGACAAGG 
                ** ** ** ** ** ***** ** ** ** ** ** ** ** *** * ** *****  *  
 
GnGc Human      AACGACAAAACATTCGCAGCCAGTAAGGGGAATAGAGGAGTCCAGGCATTTTCTAAGGGC 
GnGc WT         AACGATAAGACTTTCGCTGCTTCCAAGGGAAACAGGGGAGTTCAGGCTTTCTCTAAGGGA 
GnGc Plant      AATGATAAAACTTTTGCTGCATCTAAGGGAAACAGGGGTGTGCAAGCATTCAGTAAGGGA 
                ** ** ** ** ** ** **    ***** ** ** ** ** ** ** **   ******  
 
GnGc Human      AGTGTGCAGGCCGACCTGACACTGATGTTCGACAATTTTGAAGTGGATTTCGTCGGGGCT 
GnGc WT         TCTGTGCAGGCTGATCTCACTCTCATGTTCGATAATTTCGAAGTGGATTTCGTGGGAGCT 
GnGc Plant      AGCGTTCAGGCTGATTTGACACTCATGTTCGATAACTTCGAGGTTGATTTTGTGGGTGCT 




GnGc Human      GCAGTGTCATGCGATGCCGCTTTTCTGAACCTGACTGGGTGCTACAGCTGTAATGCCGGC 
GnGc WT         GCTGTGTCTTGTGATGCAGCATTCCTTAACCTCACTGGCTGCTACTCTTGCAATGCTGGT 
GnGc Plant      GCAGTGTCATGTGATGCTGCATTCCTCAATCTTACTGGATGTTATAGTTGCAACGCAGGT 
                ** ***** ** ***** ** ** ** ** ** ***** ** **    ** ** ** **  
 
GnGc Human      GCCAGAGTGTGCCTGTCAATCACTAGCACCGGAACAGGCACTCTGTCTGCCCACAACAAA 
GnGc WT         GCTAGGGTTTGCCTCTCCATCACTTCTACTGGAACTGGCACACTCTCTGCACACAACAAG 
GnGc Plant      GCTAGAGTTTGCCTCTCCATTACTTCTACAGGAACTGGTACATTGAGTGCTCATAATAAG 
                ** ** ** ***** ** ** ***   ** ***** ** **  *   *** ** ** **  
 
GnGc Human      GACGGAAGTCTGCATATTGTGCTGCCCTCAGAGAATGGCACAAAGGATCAGTGCCAGATC 
GnGc WT         GATGGTTCTCTCCACATCGTGCTCCCATCTGAGAACGGAACTAAGGATCAGTGCCAGATC 
GnGc Plant      GATGGAAGCTTGCACATCGTTTTACCTTCCGAAAACGGTACAAAGGATCAATGTCAGATT 
                ** **     * ** ** **  * ** ** ** ** ** ** ******** ** *****  
 
GnGc Human      CTGCATTTCACTGTGCCAGAAGTCGAGGAAGAGTTTATGTATTCCTGTGACGGCGATGAG 
GnGc WT         CTCCACTTCACTGTTCCAGAAGTGGAAGAGGAATTCATGTACTCATGTGATGGTGATGAA 
GnGc Plant      TTGCATTTTACTGTTCCAGAGGTGGAAGAGGAATTCATGTACTCATGCGATGGAGATGAA 
                 * ** ** ***** ***** ** ** ** ** ** ***** ** ** ** ** *****  
 
GnGc Human      CGCCCACTGCTGGTGAAGGGGACCCTGATCGCCATTGACCCCTTCGACGATAGGCGCGAA 
GnGc WT         CGTCCACTCCTCGTGAAGGGTACTCTCATTGCTATCGATCCTTTCGATGATAGGCGTGAG 
GnGc Plant      AGACCATTGTTAGTTAAAGGTACACTTATCGCAATAGATCCATTTGATGATAGAAGGGAG 
                 * *** *  * ** ** ** ** ** ** ** ** ** ** ** ** *****  * **  
 
GnGc Human      GCTGGAGGCGAGAGCACAGTGGTCAACCCTAAATCTGGCAGTTGGAATTTCTTTGATTGG 
GnGc WT         GCTGGTGGTGAGTCTACTGTTGTTAACCCAAAGTCCGGCTCCTGGAACTTCTTCGATTGG 
GnGc Plant      GCTGGTGGTGAATCTACTGTTGTGAATCCTAAAAGTGGAAGCTGGAACTTTTTCGATTGG 
                ***** ** **    ** ** ** ** ** **    **    ***** ** ** ****** 
 
GnGc Human      TTCTCTGGGCTGATGAGTTGGTTTGGGGGACCACTGAAGACCATCCTGCTGATTTGCCTG 
GnGc WT         TTCTCTGGACTTATGTCCTGGTTCGGAGGCCCTCTTAAGACTATTCTCCTCATTTGCCTC 
GnGc Plant      TTTAGTGGTTTGATGAGCTGGTTCGGAGGTCCATTAAAGACTATTCTCCTTATCTGTCTC 
                **   ***  * ***   ***** ** ** **  * ***** ** ** ** ** ** **  
 
GnGc Human      TACGTGGCCCTGAGCATCGGCCTGTTCTTTCTGCTGATCTACCTGGGGAGAACTGGGCTG 
GnGc WT         TATGTGGCTCTCTCTATCGGCCTCTTCTTCTTGCTTATCTACCTCGGAAGGACTGGCCTC 
GnGc Plant      TATGTTGCACTTTCTATTGGTTTGTTTTTCTTGCTCATCTACTTAGGAAGAACAGGTCTC 
                ** ** ** **    ** **  * ** **  **** ****** * ** ** ** ** **  
 
GnGc Human      TCCAAAATGTGGCTGGCCGCTACAAAAAAGGCTTCATGACCCGGGGAGCTCCTCGAG 
GnGc WT         TCCAAGATGTGGCTTGCTGCTACTAAGAAGGCTTCC--------------------- 
GnGc Plant      TCAAAGATGTGGCTTGCTGCAACTAAGAAAGCTAGTTAAAGGCCTCCCGGGAA---- 
                ** ** ******** ** ** ** ** ** ***                         
 
Figure 1: Alignment of nucleotide sequence between Human-codon optimised (upper), 
native (middle) and plant-codon optimised genes.  Mismatched nucleotides are 
marketed with …  
 
Percent Identity Matrix - created by Clustal2.1  
 
 
     1: GnGc Human  100.00   77.31   71.37 
     2: GnGc WT      77.31  100.00   79.50 






Appendix B:  Polymerase chain reaction primer sequences 
 
Table 1: Primer sequences for WT strain RVFV Gn and GnGc glycoprotein gene 




G1 Fw ATGGCAGGGATTGCAATGACA 50.9 21 - 
RVFV Rev TGATGCATATGAGACAATCAA 56 21 - 
G2 Rev ACATATTACTTTTACACGTAC 43.0 22 - 
G1 Fw979 GGGGTTCAAGCACACAAAAAG 50.9 21 - 
G1 Rev1023 CTTTGAGTTCTTAAACACTGC 47.0 21 - 
G2 Fw2693 ATCTCAGGCTCAATAGCTT 46.3 20 -- 
G2 Rev2749 GAACCCTTGCCGAGGAATTTC 52.8 21 - 
Gn SmaI Fw AAACCCGGGATGGCAGGGATT 54 22 SmaI 
Gn XmaI Rev AACCCCGGGTGATGCATATGA 50.4 22 Xmal 
GnGc XmaI Rev TTCCCGGGACATATTACTTTTACACGTAC 63.3 29 XmaI 
Gn XhoI Rev TTCTCGAGTGCTGATGCATATGAGACAATCAATA
ATAACAT 
59.3 41 XhoI 
Gc XhoI Rev TTCTCGAGACATATTACTTTTACACGTA 51.7 28 XhoI 
GnGc XhoI Rev TTCTCGAGACATATTACTTTTACACGTA 58.8 28 XhoI 
GnGc NruI Fw AATCGCGAATGGCAGGGATTGCAATGACA 59.4 29 NruI 
Gn NruI Fw AATCGCGAATGGCAGGGATTGCAATGACA 50.4 29 NruI 
Gn XmaI Rev TTCCCGGGTGCTGATGCATATGAGACAATCAATA
ATAACAT 
61.3 41 XmaI 
Gc XmaI Rev TTCCCGGGACATATTACTTTTACACGTAC 56.2 29 Xmal 
GnStuI Rev TTCCCGGGAGGCCTTTAAGATGCGTAGGAAA 64.3 31 StuI 
Gn NcoI Fw AACCATGGGCAGGGATTGCAATGACAGT 69.9 28 NcoI 
135 
 
Gc AgeI Fw TTTACCGGTGCCTAGGATGTCAGA 66.9 27 AgeI 
M13 Fw CGCCAGGGTTTTCCCAGTCACGAC  24  
M13 Rev GAGCGGATAACAATTTCACACAGG  24  
pEAQ Fw GACGAACTTGGAGAAAGATTGTTAAGC 61.2 27  
pEAQ Rev GACCGCTCACCAAACATAGAAATG 60.6 24  
pTRAc Fw AACCATGGCAGTGTGGCTGTCTACG 58.9 25  
pTRAc Rev AATCTAGACTCGAGTTAAGTACGTCTCTTGCGTTT
AGATG 
61.3 40  
 
 
Table 2: Primer sequence for plant- and human-codon optimised Gn and GnGc 
glycoproteins  





GnNcoI Fw TTTTTCCATGGCTGGAATCGCAATGACTGTT 57.7 31 NcoI 
Fw961  AAGTTTCCGGCGTGTGGAAG 60.2 21 - 
Fw2161  CTCTCAGGGTTTTCAACTGC 56.2 20 - 
Rev2221 AGTAGACACGGAGCCATCGA 59.5 20 - 
Rev1012 TGGCTTAGCGGAGAGTTCCC 60.6 20 - 
Gn Fw AACCATGGACCGGTGCCACCTAGGATGGCTGAA 66.6 33 NcoI & AgeI 
Gc Rev TTCCCGGGAGGCCTTAACTAGCTTTCTTA 59.0 30 XmaI & AgeI 
GnStuI Rev TTCCCGGGAGGCCTTTAAGATGCGTAGGAAA 61.7 31 XmaI & Agel 
 
Table 3: Primer sequences for removing the native signal peptide and PDI peptide 
fusion primers 






Gn∆SP NcoI Fw AAAACCATGGATCCTCACCTTAGGAATA (removing SP) 54.6 28 NcoI 
PDI Rev TAAGGTGAGGATCCTCAGCGAAGATCTGAGAAGGAACC 64.6 38 - 
Gn_PDI Fw GATCTTCGCTGAGGATCCTCACCTTAGGAATAGACCTGGA 65.4 40 - 
136 
 
Gn Rev CCCGGGAGGCCTTTAAGATGC 61 21 XmaI 
Gn-PDI.Rev TAAGGTGAGGATCCTCAGCGAAGATCTGAGAAGGAACC 67 38  
PDI_Gn Fw GATCTTCGCTGAGGATCCTCACCTTAGGAATAGACCTGGA 67 40  
∆hGn Fw TTACCGGTACCATGGACCCCCACCTGCGGAA 58 31 AgeI & 
NcoI 
htGn Rev AACTCGAGTTATGCTGTATGGCACTGGTAGTT 57 32 XhoI 
hGn Rev TAACTCGAGGCTTGCATATGACACGATCAGCAGC 62 34 XhoI 
tGn XmaI Fw AACCCGGGATGGCTGGAATCGCAATG 60.5 26 XmaI 
tGn XhoI Rev TTCTCGAGTTATGCTGTGTGACATTGATA 54.8 29 XhoI 
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